Materialise (MTLS) 20-F 30 Apr 20 2019 FY Annual report (foreign) Financial data

Document and entity information

Document and entity information	12 Months Ended
	Dec. 31, 2019shares
Document and entity information [abstract]
Document type	20-F
Amendment flag	false
Document period end date	Dec. 31, 2019
Document fiscal year focus	2019
Document fiscal period focus	FY
Trading symbol	MTLS
Entity registrant name	MATERIALISE NV
Entity central index key	0001091223
Current fiscal year end date	--12-31
Entity well known seasoned issuer	No
Entity current reporting status	Yes
Entity filer category	Accelerated Filer
Entity emerging growth company	false
Entity shell company	false
Entity common stock shares outstanding	53,172,513
Entity Voluntary Filers	No
Entity interactive data current	Yes
Document annual report	true
Document transition report	false
Document shell company report	false
Title of 12(b) security	Ordinary shares

Consolidated income statements

Consolidated income statements - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Consolidated income statements [line item]
Revenue	€ 196,679	€ 184,721	€ 142,573	[1]
Cost of sales	(86,972)	(82,299)	(62,952)	[1]
Gross profit	109,707	102,422	79,621	[1]
Research and development expenses	(23,348)	(22,416)	(19,959)	[1]
Sales and marketing expenses	(52,989)	(46,303)	(38,935)	[1]
General and administrative expenses	(31,786)	(32,310)	(24,876)	[1]
Net other operating income / (expenses)	5,432	3,771	4,541	[1]
Operating profit (loss)	7,016	5,164	392	[1]
Financial expenses	(3,682)	(4,864)	(4,728)
Financial income	1,377	3,627	3,210	[1]
Share in loss of joint venture	(392)	(475)	(469)	[1]
(Loss) profit before taxes	4,319	3,452	(1,595)	[1]
Income taxes	(2,595)	(425)	(522)	[1]
Net (loss) profit for the year	1,724	3,027	(2,117)	[1]
Net (loss) profit attributable to:
The owners of the parent	1,646	3,027	(2,117)	[1]
Non-controlling interest	€ 78	€ 0	€ 0	[1]
[1]	* The year 2017 has been restated to reflect certain reclassification adjustments and the final accounting of the ACTech business combination.

Consolidated income statements

Consolidated income statements (Parenthetical) - € / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	[1]
Earnings per share attributable to ordinary owners of the parent [line items]
Basic	€ 0.031106	€ 0.060776	€ (0.044733)
Diluted	€ 0.031415	€ 0.060694	€ (0.044733)
[1]	* The year 2017 has been restated to reflect certain reclassification adjustments and the final accounting of the ACTech business combination.

Consolidated statements of comp

Consolidated statements of comprehensive income - EUR (€) € in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	[1]
Consolidated statements of comprehensive income [line items]
Net (loss) profit for the year		€ 1,724	€ 3,027	€ (2,117)
Other comprehensive income (loss) [abstract]
Exchange differences on translation of foreign operations	[2]	245	(47)	(691)
Other comprehensive (loss) income, net of taxes		245	(47)	(691)
Total comprehensive income (loss)		1,969	2,980	(2,808)
Total comprehensive (loss) income attributable to:
The owners of the parent		2,102	2,980	(2,808)
Non-controlling interest		€ (133)	€ 0	€ 0
[1]	* The year 2017 has been restated to reflect certain reclassification adjustments and the final accounting of the ACTech business combination.
[2]	May be reclassified subsequently to profit& loss

Consolidated statement of finan

Consolidated statement of financial position - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	[1]
Non-current Assets [Abstract]
Goodwill	€ 20,174	€ 17,491	€ 17,552
Intangible assets	27,395	26,326	28,600
Property, plant and equipment	90,331	92,537	87,065
Right-of-use assets	10,586	0	0
Investments in joint ventures	39	0	31
Deferred tax assets	192	315	304
Other non-current assets	9,391	7,237	3,667
Total non-current assets	158,108	143,906	137,219
Current assets [Abstract]
Inventories and contracts in progress	12,696	9,986	11,027
Trade receivables	40,977	36,891	35,582
Other current assets	8,616	6,936	7,675
Cash and cash equivalents	128,897	115,506	43,175
Total current assets	191,186	169,319	97,459
Total assets	349,294	313,225	234,678
Equity [Abstract]
Share capital	3,066	3,050	2,729
Share premium	138,090	136,637	79,839
Consolidated reserves	(195)	(1,848)	(3,711)
Other comprehensive income (loss)	(1,394)	(1,850)	(1,803)
Equity attributable to the owners of the parent	139,567	135,989	77,054
Non-controlling interest	3,107	0	0
Total equity	142,675	135,989	77,054
Non-current liabilities [Abstract]
Loans and borrowings	104,673	92,440	81,788
Lease liabilities	6,427	0	0
Deferred tax liabilities	5,747	6,226	7,415
Deferred income	5,031	4,587	3,768
Other non-current liabilities	696	868	1,904
Total non-current liabilities	122,574	104,121	94,875
Current liabilities [Abstract]
Loans and borrowings	13,389	13,598	12,769
Lease liabilities	3,449	0	0
Trade payables	18,517	18,667	15,670
Tax payables	3,363	2,313	2,023
Deferred income	27,641	23,195	18,791
Other current liabilities	17,686	15,342	13,496
Total current liabilities	84,045	73,115	62,749
Total equity and liabilities	€ 349,294	€ 313,225	€ 234,678
[1]	* The year 2017 has been restated to reflect the final accounting of the business combination with ACTech.

Consolidated statement of chang

Consolidated statement of changes in equity - EUR (€) € in Thousands		Share capital [Member]	Share premium [Member]	Consolidated reserves [Member]	Other comprehensive income [Member]	Total equity attributable to the owners of the parents [member]	Non-controlling interest [Member]	Total equity [Member]
At beginnig of the period at Dec. 31, 2016		€ 2,729	€ 79,019	€ (1,603)	€ (1,112)	€ 79,033	€ 0	€ 79,033
Net profit (loss) for the year	[1]	0	0	(2,117)	0	(2,117)	0	(2,117)
Other comprehensive (loss) income		0	0	0	(691)	(691)	0	(691)
Total comprehensive income (loss)	[1]	0	0	(2,117)	(691)	(2,808)	0	(2,808)
Equity-settled share-based payment expense		0	820	9	0	829	0	829
At end of the period at Dec. 31, 2017		2,729	79,839	(3,711)	(1,803)	77,054	0	77,054
IFRS 15 - impact on operning reserves	[2]	0	0	(1,173)	0	(1,173)	0	(1,173)
Adjusted equity At January 1, 2018		2,729	79,839	(4,884)	(1,803)	75,881	0	75,881
Net profit (loss) for the year		0	0	3,027	0	3,027	0	3,027
Other comprehensive (loss) income		0	0	0	(47)	(47)	0	(47)
Total comprehensive income (loss)		0	0	3,027	(47)	2,980	0	2,980
Capital increase in cash		312	59,575	0	0	59,887	0	59,887
Capital increase through excercise of warrants		9	593	0	0	602	0	602
Capital increase Rapidfit+		0	(4,003)	0	0	(4,003)	0	(4,003)
Equity-settled share-based payment expense		0	633	9	0	642	0	642
At end of the period at Dec. 31, 2018		3,050	136,637	(1,848)	(1,850)	135,989	0	135,989
Net profit (loss) for the year		0	0	1,646	0	1,646	78	1,724
Other comprehensive (loss) income		0	0	0	456	456	(211)	245
Total comprehensive income (loss)		0	0	1,646	456	2,102	(133)	1,969
Capital increase through excercise of warrants		16	1,252	0	0	1,268	0	1,268
Acquisition NCI Engimplan		0	0	0	0	0	3,240	3,240
Equity-settled share-based payment expense		0	201	7	0	208	0	208
At end of the period at Dec. 31, 2019		€ 3,066	€ 138,090	€ (195)	€ (1,394)	€ 139,567	€ 3,107	€ 142,675
[1]	** The year 2017 has been restated to reflect the final accounting of the ACTech business combination.
[2]	* The Goup initially adopted IFRS 15 using the cumulative effect method. Under this method, the comparative information is not restated.

Consolidated cash flow statemen

Consolidated cash flow statements - Consolidated entity [member] - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017	[1]
Operating activities
Net (loss) profit for the year	€ 1,724	€ 3,027		€ (2,117)
Non-cash and operational adjustments
Depreciation of property, plant and equipment	14,339	12,223		8,754
Amortization of intangible assets	4,859	5,064		3,822
Share-based payment expense	302	1,075		1,033
Loss (gain) on disposal of property, plant and equipment	165	(83)		25
Movement in provisions	138	5		61
Movement reserve for bad debt and slow moving inventory	121	1,293		502
Financial income	(1,377)	(581)		(381)
Finance expense	3,682	2,172		1,597
Impact of foreign currencies	(176)	(299)		302
Share in loss of a joint venture (equity method)	392	475		469
Income taxes and deferred taxes	2,595	425		522
Fair value adjustment contingent consideration	0	(192)		0
Other	(245)	87		(22)
Working capital adjustment and income tax paid
Decrease (increase) in trade receivables and other receivables	216	(3,156)		(4,973)
Decrease (increase) in inventories and contracts in progress	(745)	812		(417)
Increase (decrease) in trade payables and other payables	4,196	7,341		2,343
Income tax paid	(2,139)	(1,368)		(1,569)
Interest received	355	0		0
Net cash flow from operating activities	28,402	28,320		9,951
Investing activities
Purchase of property, plant and equipment	(13,472)	(18,270)		(27,733)
Purchase of intangible assets	(2,193)	(1,836)		(4,345)
Proceeds from the sale of property, plant and equipment (net)	278	281		221
Acquisition of subsidiary (net of cash)	(6,331)	0		(27,173)
Investments in joint-ventures	(875)	0		(500)
Convertible loan granted	(2,743)	0		0
Other equity investments in non-listed entities	(281)	(2,671)		0
Interest received	0	363		281
Net cash flow used in investing activities	(25,617)	(22,133)		(59,249)
Financing activities
Proceeds from loans and borrowings	29,000	32,554		54,319
Repayment of loans and borrowings	(12,126)	(18,820)		(11,904)
Repayment leases	(5,283)	(3,102)		(2,947)
Capital increase in parent company	1,268	60,489		0
Direct attributable expense capital increase	0	(4,003)		0
Interest paid	(2,286)	(1,733)		(955)
Other financial income (expense), net	208	(150)		(472)
Net cash flow from (used in) financing activities	10,781	65,235		38,041
Net increase of cash and cash equivalents	13,566	71,422		(11,257)
Cash and cash equivalents at beginning of the year	115,506	43,175	[1]
Exchange rate differences on cash and cash equivalents	(175)	908		(1,480)
Cash and cash equivalents at end of the year	€ 128,897	€ 115,506		€ 43,175
[1]	* The year 2017 has been restated to reflect the final accounting of the ACTech business combination.

Corporate information

Corporate information	12 Months Ended
	Dec. 31, 2019
Corporate information [abstract]
Disclosure of notes and other explanatory information [text block]	Notes to the consolidated financial statements 1 Corporate information Materialise NV is a limited liability company with its registered office at Technologielaan 15, 3001 Leuven, Belgium. The consolidated financial statements comprise Materialise NV (the "Company" or "Parent") and its subsidiaries (collectively, the "Group"). See Note 28 for a list of subsidiaries of the Company. The Group is a leading provider of additive manufacturing (AM) software and of sophisticated 3D printing services. The products and services of the Group are organized in the three segments: Materialise Medical, Materialise Software and Materialise Manufacturing. The Group sells its products in Europe, the Americas, Africa and Asia-Pacific. The consolidated financial statements of the Group for the year ended December 31, 2019 were approved and authorized for issue on April 30 , 2020 in accordance with a resolution of the Parent’s Board of Directors.

Basis of preparation

Basis of preparation	12 Months Ended
	Dec. 31, 2019
Basis of preparation
Disclosure of basis of preparation of financial statements [text block]	2 Basis of preparation The consolidated financial statements of the Group for the three years ended December 31, 2019 , 2018 and 2017 were prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) (collectively "IFRS") and with International Financial Reporting Standards (IFRS) as adopted by the European Union ("EU-IFRS"). These consolidated financial statements have been prepared on a historical cost basis, except for the assets and liabilities that have been acquired as part of a business combination, which have been initially recognized at fair value, and certain financial assets such as the non-listed equity instruments and the convertible loan receivable which are both included in the other non-current assets, the share appreciation rights, and the written put option of Rapidfit which are measured at fair value. The financial statements are prepared on a going concern basis considering the COVID-19 impact as disclosed in note27. The consolidated financial statements are presented in thousands of euros (K€ or thousands of €) and all "currency" values are rounded to the nearest thousand (€000), except when otherwise indicated. The preparation of financial statements in compliance with adopted IFRS requires the use of certain critical accounting estimates. It also requires Group management to exercise judgment in applying the Group’s accounting policies. The areas where significant judgment and estimates have been made in preparing the financial statements and their effect are disclosed in Note 3. New standards, interpretations and amendments adopted by the Group The Group has adopted the following new and revised standards and interpretations issued by the IASB and IFRIC that are relevant to its operations and effective for accounting periods beginning on January 1, 2019 . IFRIC 23 Uncertainty over income tax treatments IFRS 16 Leases Several other amendments and interpretations apply for the first time in 201 9 , but do not have an impact on the consolidated financial statements of the Group. The Group has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective. The application of the above relevant new standards and interpretations are explained below. IFRIC 23 Uncertainty over income tax treatments Uncertainty over income tax treatments has been applied as from January 1, 2019. The adoption of this new interpretation did not have an impact. IFRS 16 Leases The Company has applied IFRS 16 as from January 1, 2019 by using the modified retrospective approach, not restating comparatives for the 2018 reporting period. The reclassifications and the adjustments arising from the new leasing standard are recognized in the opening balance sheet on January 1, 2019. On the adoption of IFRS 16, the Company recognized lease liabilities in relation to leases which had previously been classified as "operating leases" under the IAS 17 Leasing standard. These leases were measured at the present value of the remaining lease payments, using a discount rate based on the incremental borrowing rate as of January 1, 2019. The weighted average discount rate applied to the lease liabilities at January 1, 2019 was 2.99% . The Company had leases classified as finance leases under IAS 17 for an amount of K€5,886 net book value for which the carrying amount has not been reassessed consistent with the transition requirements. The table below shows the reconciliation of the IAS 17 operating lease commitments disclosed in the 2018 consolidated financial statements with the IFRS 16 lease liability at January 1, 2019: As at January 1, 2019 (in 000€) Non-cancellable operating lease commitments disclosed at December 31, 2018 5,442 Discounted using the company’s incremental borrowing rate (268) Add: finance lease liabilities recognized at December 31, 2018 6,809 (Less) short-term/low-value leases recognized on a straight-line basis as an expense (88) Add/(Less) adjustments related to different treatment extension and termination options (101) Lease liability recognized as at January 1, 2019 11,794 The right-of-use assets for all assets were measured at the amount equal to the lease liability and relate to the following assets: (in 000€) As at December 31, 2019 As at January 1, 2019 Buildings 3,843 3,255 Vehicles 882 849 Other materials 301 880 Total right-of-use assets 5,026 4,984 Total lease liabilities 5,026 4,984 The impact on the consolidated statement of profit and loss for the year ended December 31, 2019 and the basic and diluted loss per share is not significant. There was no impact on the retained earnings as per January 1, 2019. In applying IFRS 16 at January 1, 2019, the company has used the following practical expedients permitted by the standard: The use of a single discount rate to a portfolio of leases with similar characteristics; The accounting for operating leases with a remaining lease term of less than 12 months as at January 1, 2019 as short-term leases; The accounting for operating leases with a low value (less or equal to $5,000) as low-value leases; and The use of hindsight in determining the lease term where the contract contains options to extend or terminate the lease. The other new standards and interpretations effective as of January 1, 2019 did not have any impact on the statement of financial position and the statement of profit and loss.

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Dec. 31, 2019
Summary of significant accounting policies [abstract]
Disclosure of significant accounting policies [text block]	3 Summary of significant accounting policies Basis for consolidation The consolidated financial statements comprise the financial statements of the Group and its subsidiaries. Entities are fully consolidated from the date of acquisition, which is the date when the Group obtains control, and continue to be consolidated until the date when such control ceases. The financial statements of the entities are prepared for the same reporting period as the parent company, using consistent accounting policies. All intra-Group balances, transactions, unrealized gains and losses resulting from intra-Group transactions and dividends are fully eliminated. The Group attributes profit or loss and each component of other comprehensive income to the owners of the parent company and to the non-controlling interest based on present ownership interests, even if the results in the non-controlling interest have a negative balance. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over the subsidiary, it will derecognize the assets (including goodwill) and liabilities of the subsidiary, any non-controlling interest and the other components of equity related to the subsidiary. Any surplus or deficit arising from the loss of control is recognized in profit or loss. If the Group retains an interest in the previous subsidiary, then such interest is measured at fair value at the date the control is lost. The proportion allocated to the parent and non-controlling interests in preparing the consolidated financial statements is determined based solely on present ownership interests. In 2019, Engimplan entered into the consolidated scope - see note 28. Non-controlling interests The Group has the choice, on a transaction by transaction basis, to initially recognize any non-controlling interest in the acquiree which is a present ownership interest and entitles its holders to a proportionate share of the entity’s net assets in the event of liquidation at either acquisition date fair value or, at the present ownership instruments’ proportionate share in the recognized amounts of the acquiree’s identifiable net assets. Other components of non-controlling interest such as outstanding share options are generally measured at fair value. The Group has not elected to take the option to use fair value in acquisitions completed to date. Currently the only non-controlling interest resulting from business combinations coming from Engimplan. Foreign currency translation The Group’s consolidated financial statements are presented in euros, which is also the parent company’s functional currency. For each entity, the Group determines the functional currency, and items included in the financial statements of each entity are measured using the functional currency. Financial statements of foreign subsidiaries Foreign subsidiaries use the local currencies of the country where they operate. The statement of financial position is translated into euro at the closing rate on the reporting date and their income statement is translated at the average exchange rate at each month-end. Differences resulting from the translation of the financial statements of said subsidiaries are recognized in other comprehensive income as "exchange differences on translation of foreign operations". Foreign currency transactions Transactions denominated in foreign currencies are translated into euro at the exchange rate at the end of the previous month-end. Monetary items in the statement of financial position are translated at the closing rate at each reporting date and the relevant translation adjustments are recognized in financial or operating result depending on its nature. Business combinations and goodwill Business combinations are accounted for using the acquisition method at the acquisition date, which is the date at which the Group obtains control over the entity. The cost of an acquisition is measured as the amount of the consideration transferred to the seller, measured at the acquisition date fair value, and the amount of any non-controlling interest in the acquiree. The Group measures goodwill initially at cost at the acquisition date, being: the fair value of the consideration transferred to the seller, plus the amount of any non-controlling interest in the acquiree, plus if the business combination is achieved in stages, the fair value of the existing equity interest in the acquiree re-measured at the acquisition date, less the fair value of the net identifiable assets acquired and assumed liabilities Goodwill is recognized as an intangible asset with any impairment in carrying value being charged to the consolidated income statement. Where the fair value of identifiable assets, liabilities and contingent liabilities exceed the fair value of consideration paid, the excess is credited in full to the consolidated income statement on acquisition date. Acquisition costs incurred are expensed and included in general and administrative expenses. Any contingent consideration to be transferred by the acquirer will be recognized at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration, which is deemed to be an asset or liability, will be recognized either as a profit or loss or as a change to other comprehensive income. If the contingent consideration is classified as equity, it should not be re-measured until it is finally settled within equity. Acquisition of non-controlling interests are accounted for as an equity transaction. Investments in joint ventures The Group carries investment in a joint venture (RS Print NV). The Group’s investments in its joint venture is accounted for using the equity method. Under the equity method, the investment in the joint venture was initially recognized at cost. The carrying amount of the investment is adjusted to recognize changes in the Group’s share of net assets of the joint venture since the acquisition date. Goodwill relating to the joint venture is included in the carrying amount of the investment and is not tested for impairment individually. The income statement reflects the Group’s share of the results of operations of the joint venture. Any change in other comprehensive income of the joint venture is presented as part of the Group’s other comprehensive income. In addition, when there has been a change recognized directly in the equity of the joint venture, the Group recognizes its share of the change in the statement of changes in equity. Unrealized gains and losses resulting from transactions between the Group and the joint venture are eliminated to the extent of the interest in the joint venture. After application of the equity method, the Group determines whether it is necessary to recognize an impairment loss on its investment in its joint venture. At each reporting date, the Group determines whether there is objective evidence that the investment in the joint venture is impaired. If there is such evidence, the Group calculates the amount of impairment as the difference between the recoverable amount of the Group’s interest in the joint venture (higher of value in use and fair value less costs to sell), and then recognizes the loss as ‘Share of profit or loss of joint ventures’ in the income statement. Property, plant & equipment Property, plant and equipment is stated at cost, net of accumulated depreciation and/or accumulated impairment losses, if any. Such cost includes borrowing costs directly attributable to construction projects if the asset necessarily takes a substantial period of time to get ready for its intended use, it is probable that they will result in future economic benefits to the group and the cost can be measured reliably. When significant parts of property, plant and equipment are required to be replaced at intervals, the Group recognizes such parts as individual assets with specific useful lives and depreciates them accordingly. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the property, plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognized in the income statement as incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows: Buildings: 20-30 years Machinery: 5-12 years IT assets: 3-5 years Fixtures & Furniture: 10-15 years Vehicles: 2-4 years Leasehold Building Improvements: 10 years Land is not depreciated. An item of property, plant and equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement when the asset is derecognized. The assets’ residual values, useful lives and methods of depreciation are reviewed at each financial year-end and adjusted prospectively, if appropriate. Right-of-use assets and related liabilities Right-of-use assets: The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the short er of its estimated useful life and the lease term: Property leased Assets: Lease terms up to 10 years or useful life of 10 - 15 years when reasonable certain ownership will be obtained at the end of the lease Leased machines: Lease terms up to 10 years or useful life of 5 - 10 years when reasonable certain ownership will be obtained at the end of the lease Leased vehicles: Lease terms up to 4 years or useful life of 4 years when reasonable certain ownership will be obtained at the end of the lease Right-of-use assets are subject to impairment. Lease liabilities: At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Short-term leases and leases of low-value assets: The Company applies the short-term lease recognition exemption to its short-term leases of machinery and equipment (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option) however this exemption is not applied for property leases . It also applies the lease of low-value assets recognition exemption to leases of office equipment that are consid ered of low value (i.e., below k€ 5). Lease payments on short-term leases and low-value assets are recognized in the income statement when incurred. Borrowing costs Borrowing costs directly attributable to the acquisition, construction or production of a qualified asset that necessarily takes a substantial period of time to prepare for its intended use or sale are capitalized as part of the cost of the respective assets. All other borrowing costs are expensed in the period they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Research and development Research and development includes the costs incurred by activities related to the development of software solutions (new products, updates and enhancements), guides and other products. Development activities involve the application of research findings or other knowledge to a plan or a design of new or substantially improved (software) products before the start of the commercial use. Development expenditures on an individual project are recognized as an intangible asset when the Group can demonstrate: the technical feasibility of completing the intangible asset so that the asset will be available for use or sale; its intention to complete and its ability to use or sell the asset; how the asset will generate future economic benefits; the availability of resources to complete the asset; and the ability to measure reliably the expenditure during development. The Group has determined that the conditions for recognizing internally generated intangible assets from proprietary software, guide and other product development activities are not met until shortly before the products are available for sale, unless either (i) the Group has strong evidence that the above criteria are met and a detailed business plan is available showing the asset will on a reasonable basis generate future economic benefits or (ii) the development is done based upon specific request of the customer, it is highly likely that the Group will be able to market the product also to other parties than the customer, the development is subject to an agreement and the substance of the agreement is that the customer reimburses the Group for a significant portion , but not all, of the development expenses incurred. As such, development expenditures not satisfying the above criteria and expenditures on the research phase of internal projects are recognized in the consolidated income statement as incurred. Internally generated intangible assets from proprietary software are amortized over their useful l ives, starting from the moment they are ready for use/available for sale . Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete and the asset is available for use. It is amortised over the period of expected future benefit , which is determined on a project-by-project basis . Amortisat ion is recorded in cost of sales. During the period of development, the asset is tested for impairment at least annually or whenever there is an indication of impairment. Intangible assets other than goodwill and capitalized development expenditures Intangible assets comprise acquired technology and customer portfolio, patents and licenses and technology and customers acquired in connection with business combinations. Those intangible assets are measured on initial recognition at cost, except for the acquired technology and customers arising from business combinations, which are measured initially at fair value. Following initial recognition, intangible assets other than goodwill are carried at cost less any accumulated amortization and accumulated impairment losses, if any. The useful life of the intangible assets is as follows: Software: 3 years; Patents and licenses: 10 years; Acquired customers and Technology: 5-20 years; Order Backlog: Period over which orders will be completed. The intangible assets with finite lives are amortized over their useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. The amortization expense on intangible assets with finite lives acquired through business combination is recognized in the consolidated income statement in the line " net other operating income ". Impairment of goodwill and other non-financial assets (excluding inventories and deferred tax assets) Impairment tests on goodwill and other intangible assets with indefinite useful economic lives, assets under construction or capitalized development expenses which are not amortized yet, are undertaken annually at the financial year end. Other non-financial assets and goodwill are subject to impairment tests whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Where the carrying value of an asset exceeds its recoverable amount (i.e. the higher of value in use and fair value less costs to sell), the asset is written down accordingly. Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the smallest Group of assets to which it belongs for which there are separately identifiable cash flows: its cash generating units (CGUs). Goodwill is allocated on initial recognition to each of the Group’s CGUs that are expected to benefit from the synergies of the combination giving rise to the goodwill. The Group bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Group’s CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. For longer periods, a long-term growth rate is calculated and applied to future cash flows projected after the fifth year. Impairment charges are included in profit or loss, except, where applicable, to the extent they reverse gains previously recognized in other comprehensive income. An impairment loss recognized for goodwill is not reversed. Where goodwill forms part of a cash-generating unit and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal of the operation. Goodwill disposed of in this circumstance is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained. Inventories and Contracts in progress Inventories are valued at the lower of cost and net realizable value. Costs incurred in bringing each product to its present location and condition are accounted for as follows: Raw materials: purchase cost on a first in, first out basis; and Finished goods and work in progress: cost of direct materials and labor and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs . Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. A write-off of inventories is estimated based on an ageing or rotation analysis. Work in progress relates to production of inventory for which a customer has not yet been secured, while contracts in progress are contract assets that relate to production for specific customers in performance of a signed contract. We refer also to the accounting policy on revenue recognition. Financial assets Financial assets are classified at initial recognition, and subsequently measured at amortised cost, fair value through other comprehensive income (OCI), and fair value through profit or loss. The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Group’s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient, the Group initially measures a financial asset at its fair value plus transaction costs, i n the case of a financial asset not at fair value through profit or loss or OCI . Trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient are measured at the transaction price. For purposes of subsequent measurement, fin ancial assets are classified in four categories: Financial assets at amortise d cost; Financial assets at fair value through OCI with recycling of cumulative gains and losses (debt instruments) ; Financial assets designated at fair value through OCI with no recycling of cumulative gains and losses upon derecognition (equity instruments) ; and Financial assets at fair value through profit or loss . Financial assets measured at amortized cost This category is the most relevant to the Group. The Group measures financial assets at amortised cost if both of the following conditions are met: The financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows ; and The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding . Financial assets , trade and other receivables, cash and cash equivalents at amortised cost are subsequently measured using the effective interest rate (EIR) method and are subject to impairment. Gains and losses are recognised in profit or loss when the asset is derecognised, modified or impaired. Financial assets at fair value through OCI with recycling of cumulative gains and losses (debt instruments) The Group currently does not have financial assets at fair value through OCI with recycling of cumulative gains and losses. Financial assets designated at fair value through OCI with no recycling of cumulative gains and losses upon derecognition (equity instruments) The Group has irrevocably elected at initial recognition to classify the minority interest in the non-listed equity investment Essentium Inc, as disclosed in Note 10 and Note 20, as a financial asset designated at fair value through OCI as this measurement is most representative of the business model for this asset. Gain and losses on these financial assets are never recycled to profit and loss. Dividends are recognised as other operational income in the consolidated income statement when the right of payment has been established, except when the Group benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment. Financial assets measured at fair value through profit or loss The Group does have the following financial assets classified as financial assets at fair value through profit or loss : a call option on non -controlling interests in RapidF it+ as disclosed in Note 13; derivatives, a convertible loan granted to a company as disclosed in Note 10;. Those financial assets are carried in the statement of financial position at fair value with changes recognized in the income statement in the lines financial income/expense. Derecognition A financial asset is derecognized when: The rights to receive cash flows from the asset have expired, or The Group has transferred its rights to receive cash flows from the assets. Impairment of financial assets Further disclosures relating to impairment of financial assets are also provided in Note 3 Significant accounting judgments, estimates and assumptions. The Group recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. A loss allowance is recognized at each reporting date based on lifetime ECLs. The Group established a provision matrix that is based on its historical loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. For all other receivables, ECLs are based on the differ ence between the contractual cas h flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms. ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). Financial liabilities All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Group’s financial liabilities include trade and other payables, loans and borro wings including bank overdrafts and derivative financial instruments including written put options over non-controlling interests. Financial liabilities at amortized cost The trade and other payables, and loans and borrowings are classified as financial liabilities at amortized cost. Those financial liabilities are measured at amortized cost using the effective interest rate method. Gains and losses are recognized in the income statement when the liabilities are derecognized as well as through the effective interest rate method amortization process. Financial liabilities at fair value through profit and loss The derivative financial instruments are classified as financial liabilities at fair value through profit and loss except for the written put options on non-controlling interests which is disclosed below. Written put options on non-controlling interest The Group recognizes a financial liability for the written put options on non-controlling interest. The written put options have a variable redemption price based on a formula as specified in the contract (see Note 13 ). The financial liability is initially recognized at fair value and the fair value is reclassified from non-controlling interest and, for any amount higher than the non-controlling interest, from consolidated reserves. The fair value is determined as the present value of the redemption amount. Any change in the fair value as a result of a change in the estimated redemption price is recognized directly in consolidated reserves. Any unwinding effect of the present value of the redemption price is recognized directly in profit and loss (financial cost). No share of profit is allocated to the non-controlling interest. Upon exercise of the written put option, the carrying value will be offset with the cash payment received. When the written put option is not exercised, the carrying value of the financial liability is derecognized against non-controlling interest with the difference going to consolidated reserves. Compound financial instruments The Group has issued convertible debt which is accounted for as a compound financial instrument. For those instruments, the Group determines the carrying amount of the liability component by measuring the fair value of a similar liability (including any embedded non-equity derivative features) that does not have an associated equity component. The carrying amount of the equity instrument is then determined by deducting the fair value of the financial liability from the fair value of the compound financial instrument as a whole. Derecognition A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. Offsetting Financial assets and financial liabilities are offset and the net amount is reported in the consolidated statement of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the assets and settle the liabilities simultaneously. Share capital Financial instruments issued by the Group are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Group’s ordinary shares are classified as equity instruments. Provisions Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Pensions benefits The Group has a defined contribution obligation where the Group pays contributions based on salaries to an insurance company, in accordance with the laws and agreements in each country. The Belgian defined contribution pension plans are by law with variable minimum returns based on the Belgian government bonds, with a minimum of 1.75% and a maximum of 3.75% , effective for contributions paid as from 2016. For contribution paid until 2015, the minimum guaranteed return is 3.25% on employer contributions and 3.75% on employee contributions. These plans qualify as defined benefit plans. Contributions are recognized as expenses for the period in which employees perform the corresponding services. Outstanding payments at the end of the period are shown as other current liabilities. Those plans are accounted for as a defined benefit plan however are considered not material. Share based payments Directors and employees (including senior executives) of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments (equity-settled transactions). The Group currently has only warrants and share-appreciation rights as share-based payments. Equity-settled transactions Equity-settled share-based payments to employees and others providing similar services are measured, indirectly, at the fair value of the equity instruments granted. The cost of equity-settled transactions is recognized, together with a corresponding increase in other capital reserves in equity, over the period in which the performance and/or service conditions are fulfilled. The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group’s best estimate of the number of equity instruments that will ultimately vest. The income statement expense or credit for a period represents the movement in cumulative expense recognized at the beginning and end of that period and is recognized as employee benefits expense. The Group does currently only have equity-settled share-based payments that have service-based vesting conditions and no instruments with market vesting conditions. No expense is recognized for awards that do not ultimately vest. When the terms of an equity-settled award are modified, the minimum expense recognized is the expense as if the terms had not been modified, if the original terms of the award are met. An additional expense is recognized for any modification that increases the total fair value of the share-based payment transaction, or is otherwise beneficial to the employee as measured at the date of modification. When an equity-settled award is cancelled, it is treated as if it vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This
Disclosure of accounting judgements and estimates [text block]	, the Group determined that the fair value is not significantly different than its carrying value. Changes in the significant assumptions may lead to a significant increase/decrease in the fair value of the convertible loan. A increase/decrease in the applied discount rate by 2.0% would lead to a change in fair value by K€ -267 / K€298 . Changes in useful life for certain assets We review the useful life of our definite lived intangible assets and property, plant and equipment on an annual basis considering the current facts and circumstances available. This review has resulted in in a re-assessement of the useful life for certain specific assets in the categories buildings, fixtures, vehicles and machinery. We refer to Note 7 for the impact of the change in useful lifes during the year 2019. Leases IFRS 16 - estimating the discount rate and probability of exercisting extension options/termination options and purchase options The Group can not always determine the interest rate implicit in the lease contract and therefore, the Group has to estimate the incremental borrowing rate to measure certain lease liabilities such as buildings. The Group uses for buildings the property yield as reference to determine the incremental borrowing rate. For other assets, the Group generally uses the interest rate implicit in the lease contract or applies the incremental borrowing rate for a portfolio of similar assets. The incremental borrowing rate reflects what the Group "would have to pay", which requires estimation when no observable rates are available or when they need to be adjusted to reflect the terms and conditions of the lease. In addition, certain lease contracts may have extension options, termination options in case of property leases and/or purchase options in case of leases. The Group estimates whether it is reasonable certain or not, whether those options will be exercised or not, which impact the lease term in case of extension options and termination options and the period over which the lease assets are depreciated in case of purchase options." id="sjs-B5">Significant accounting judgments, estimates and assumptions The preparation of the Group’s consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities, and the accompanying disclosures. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities for future periods. On an ongoing basis, the Group evaluates its estimates, assumptions and judgments, including those related to revenue recognition, development expenses, share-based payment transactions, income taxes, impairment of goodwill, intangible assets and property, plant & equipment and business combinations, provisions for expected credit losses, convertible loans, useful lifes of certain assets and IFRS 16. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the Group. Such changes are reflected in the assumptions when they occur. Revenue recognition Our revenue recognition policies require management to make significant estimates. Management analyzes various factors, including a review of specific transactions, historical experience, creditworthiness of customers and current market and economic conditions. Changes in judgments based upon these factors could impact the timing and amount of revenue and cost recognized and thus affects our results of operations and financial condition. T he significant estimates and judgments relate to : The assessment w hether a performance obligation is distinct in a bundled sales transactions ; E stimates of the variable consideration s and the assessment of the revenue constraint limitation; Estimates of the stand-alone selling prices for each distinct performance obligation; and The stage of completion of our customized development of software components for customers when revenue is satisfied over time. The Group is making significant judgments when performing the assessment of whether a performance obligation is distinct from the other performance obligations in a contract, i.e. whether the good or service has a benefit for the customer in its own or together with readily available resource and/or whether the good or service is highly interrelated or a significant input with another good or service delivered, or whether it significantly modifies or customizes another good or service. The relevant judgments include the following: Whether the software license is distinct from the 3D printed guides - in most cases with contracts with collabroration partners in the Materialise Medical segment, the software licenses is combined with the manufacturing of the 3D printed guides as the software license has no benefit for the customer without the manufacturing services. Note that the Group is implementing a new feature " Plan Only " which where the collaboration partners could benefit from the software license on its own. Whether the development services are distinct from other performance obligations - in most cases, those performance obligations are distinct however for one contract with a collaboration partner in the Materialise Medical segment, the software license is combined with the license and the 3D printed guides as one " distinct " performance obligation For the stand-alone selling prices, the Group is using prices from price list or historical prices for similar transactions. However, in certain cases, such information is not immediately available and in such cases, the Group estimates the stand-alone selling price by using a cost-plus or another estimate. In addition, for certain performance obligations such as development services, stand-alone selling prices also require an estimate of the time to complete the development. Certain contracts include estimates of variable considerations within the transaction price and assessing the revenue constraint, such as: Quantities/volume sold for fixed prices in relation to, but not limited to, manufacturing of 3D printed products, software licenses sold, maintenance renewals; Contractual prices may be different based on volume purchased during a certain period; FTE spend for development or other services billed on a time and material basis; and Volume rebates. The method applied to estimate the variable consideration is dependent on the number of possible scenarios and the probability of each scenario. In case there are many possible scenarios with a wide range of probabilities (each less than 50%), the Group will use the expected value method while the most likely method is used when there is a scenario with a higher probability (more than 50%). Variable consideration is not constrainted when, based on historical experience, high reliable business forecast and/or the timeframe of the estimates, the Group determines that there is a high probability that this will not result in a future revenue reversal. W e determine the stage of comple tion for development contracts satisfied over time by comparing labor hours incurred to-date to the estimated total labor hours required to complete the project. We consider labor hours to be the most reliable, available measure of progress on these projects. Adjustments to estimates to complete are made in the periods in which facts resulting in a change become known. When the estimate indicates that a loss will be incurred, such loss is recorded in the period identified. Significant judgments and estimates are involved in determining the percent complete of each contract. Different assumptions could yield materially different results. Development expenses Under IAS 38, internally generated intangible assets from the development phase are recognized if certain conditions are met. These conditions include the technical feasibility, intention to complete, the ability to use or sell the asset under development, and the demonstration of how the asset will generate probable future economic benefits. The cost of a recognized internally generated intangible asset comprises all directly attributable cost necessary to make the asset capable of being used as intended by management. In contrast, all expenditures arising from the research phase are expensed as incurred. Determining whether internally generated intangible assets from development are to be recognized as intangible assets requires significant judgment, particularly in determining whether the activities are considered research activities or development activities, whether the product enhancement is substantial, whether the completion of the asset is technical feasible considering a company-specific approach, the probability of future economic benefits from the sale or use including an assessment whether FDA approval will be obtained. The Group has determined that the conditions for recognizing internally generated intangible assets from proprietary software, guide and other product development activities are not met until shortly before the products are available for sale, unless either (i) the Group has strong evidence that the above criteria are met and a detailed business plan is available showing the asset will on a reasonable basis generate future economic benefits or (ii) the development is done based upon specific request of the customer, the Group has the intention to market the product also to other parties than the customer, the development is subject to an agreement and the substance of the agreement is that the customer reimburses the Group for a significant portion of the development expenses incurred. As such, development expenditures not satisfying the above criteria and expenditures on the research phase of internal projects are recognized in the consolidated income statement as incurred. This assessment is monitored by the Group on a regular basis. We have determined that the criteria for internally generated intangible assets were met for two projects in 2018: (1) the software development of a new planner for hospitals within the cardiovascular field and (2) the process to obtain FDA and E.U. approval for a 3D printed tracheal splint within the Materialise Medical segment. The first development is finished and amortization has started in 2019. For the latter, we determined that there is a low risk that FDA approval will not be obtained although clinical trials have to be started and commercialization is not expected before 2022. This assessment was made by management based on several factors including the developed product itself, the exclusive patent rights obtained on the developed product, the successful application of the product on a number of patients as part of the emergency exception use obtained from the FDA and the continued discussions to speed up the trial duration and commercialization. The product is also expected to receive E.U. approval for commercialization by the end of 2020. The amount capitalized for the tracheal splint amounted to K€1,376 a s of December 31, 2019 the amount capitalized for the software development of a new planner for hospitals amounted to K€461 as per December 31, 2019. Share-based payment transactions The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted and measured the cost of cash-settled transactions by reference to the fair value of the equity instrument at the date of reporting. The Group has applied the Black-Scholes valuation model to estimate fair value. Using this model requires management to make assumptions with regards to volatility and expected life of the equity instruments. The assumptions used for estimating fair value for share-based payment transactions are disclosed in Note 14 and are estimated as follows: Volatility is estimated based on the average annualized volatility of the Group; Estimated life of the warrant is estimated to be until the first exercise period which is typically the month after their vesting; Fair value of the shares is determined based on the share price of the Group on Nasdaq at the date of issuance. For the grants prior to the initial public offering , the fair value of the shares was estimated based on a discounted cash flow model with 3-year cash flow projections and a multiple of EBITDA determined based on a number quoted pee rs in the 3D printing industry; and The dividend return is estimated by reference to the historical dividend payment of the Group. Currently, this is estimated to be zero as no dividends have been paid since inception. Income taxes Deferred tax assets are recognized for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies. As at December 31, 2019 , the Group had K€37,440 ( 2018 : K€25,285 ; 2017 : K€11,948 ) of tax losses carry forward and other tax credits such as investment tax credits and notional interest deduction, of which K€25,172 related to Materialise NV ( 2018 : K€15,592 ; 2017 : K€4,581 ). These losses relate to the parent and subsidiaries that have a history of losses, in countries where these losses do not expire ( except for the notional interest deduction 2019 : K€0 ; 2018 : K€0 ; 2017 : K€315 ) and may not be used to offset taxable income elsewhere in the Group. With respect to the unused tax losses of Materialise NV, no deferred tax assets have been recognized in 2019 , 2018 and 2017 , given that in view of the Belgian Patent Income Deduction and Innovation Income Deduction there is an uncertainty to which extent these tax losses will be used in future years. As from July 1, 2016, the new In novation Income Deduction replaces the form er Patent Income Deduction . Under the grandfathering rule the Patent Income Deduction system can still be applied until June 30, 2021. The Belgian Patent Income Deduction allows companies to deduct 80% of the qualifying gross patent income from the taxable basis. Under the Innovation Income Deduction system, companies can deduct up to 85% of their net innovation income from the taxable basis. Based on its analysis in 2019 the Company has assessed that no deferred tax asset should be accounted for with respect to its unused tax losses in Belgium. With respect to the unused tax losses of the other entities, no deferred tax assets have been recognized in 2019 ( 2018 : K€0 ; 2017 : K€0 ). The Group has not recognized deferred tax as sets on unused tax losses total ing K€10,737 in 2019 ( 2018 : K€11,906 ; 2017 : K€7,904 ) given that it is not probable that sufficient positive taxable base will be available in the foreseeable future against which these tax losses can be utilized. If the Group was able to recognize all unrecognized deferred tax assets, net profit would have increased by K€6,855 in 2019 during which K€23,141 of tax losses were utilized. Further details on taxes are disclosed in Note 22 .10. Impairment of goodwill, intangible assets and property, plant & equipment and determination of the cash-generating-unit. The Group has goodwill for a total amount of K€20,174 as at December 31, 2019 ( 2018 : K€17,491 ; 2017 : K€17,552 ) which has been subject to an impairment test. The goodwill is tested for impairment based on a discounted cash flow model with cash flows for the next five years derived from the budget and a residual value considering a perpetual growth rate. The value in use is sensitive to the discount rate used for the DCF model as well as the expected future cash-inflows and the growth rate used for extrapolation purposes . Also, as part of the impairment analysis, the Group need to determine the different CGUs at the lowest non-aggregated level which include judgments about application of the criteria to determine the CGUs based on the facts and circumstances how the entities and business units within the CGU and within the Group operate and are monitored. The level of CGU may also have an impact on certain assumptions to make with regard to transfer pricing. The key assumptions used to determine the value in use for the different CGUs are disclosed and further explained in Note 5. The Group capitalized development expenses in 2019 for a total amount of K€1,328 which are not in the condition as intended by management and as such not amortized. Those development expenses have been subject to an impairment test based on a discounted cash flow model with cash flows derived from the latest business plan. The value in use is sensitive to the discount rate used for the DCF model as well as the expected commercialization date for the products and the expected future cash inflows after commercialization. We refer to the section on development expenses above for further explanations. The Group is in progress of building or refurbishing a number of machines that allow to use recycled powder and reduce the scrap rate, which will bring significant benefits in the production for the Group. The project aims a completion date in 2020. The total carrying value of these assets under construction is K€1,804 as at December 31, 2019 . Those assets under construction have been subject to an impairment test based on a discounted cash flow model using five years of projected cash flows. The present value is sensitive to the discount rate ( 10.0% applied) used for the 10.0% model, when the assets are in the state intended by management to use in the production as well as the expected future net cash inflows (revenue minus production costs). We refer to Note 7. When events or changes in circumstances indicate that the carrying amount of the intangible assets and property, plant and equipment may not be recoverable, we estimate the value in use for the individual assets, or when not possible, at the level of CGUs to which the individual assets belong. No impairment charges have been recorded during 2019 ( 2018 : K€0 ; 2017 : K€0 ). Business combinations We determine and allocate the purchase price of an acquired business to the assets acquired and liabilities assumed as of the business combination date. Business combinations are discussed further in Note 4. The purchase price allocation process requires us to use significant estimates and assumptions, including estimated fair value of the acquired intangible assets; estimated fair value of property, plant and equipment ; and estimated fair value of the contingent consideration. The contingent consideration as included in the financial statements is recorded at fair value at the date of acquisition and is reviewed on a regular basis. The fair value of the contingent consideration is based on risk-adjusted future cash flows of different scenarios discounted using appropriate interest rates. The structure of the possible scenarios and the probability assigned to each one of them is reassessed by management at every reporting peri od and requires judgement from m anagement about the outcome and probability of the different scenarios as well as the evolution of the variables . While we are using our best estimates and assumptions as part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the date of acquisition, our estimates and assumptions are inherently uncertain and subject to refinement. Examples of critical estimates in valuing certain of the intangible assets we have acquired or may acquire in the future include but are not limited to: future expected cash flows from customer contracts and relationships, software license sales and maintenance agreements; the fair value of the plant and equipment the fair value of the deferred revenue; and discount rates . Provision for expected credit losses of trade receivables and contract assets The Group uses a provision matrix to calculate ECLs for trade receivables and contract assets. The provision rates are based on days past due for groupings of various customer segments that have similar loss patterns (i.e., by legal entity). The provision matrix is initially based on the Group’s historical observed default rates. The Group will calibrate the matrix to adjust the historical credit loss experience with forward-looking information. For instance, if forecast economic conditions (i.e., gross domestic product) are expected to deteriorate over the next year which can lead to an increased number of defaults, the historical default rates are adjusted. At every reporting date, the historical observed default rates are updated and changes in the forw ard-looking estimates are analyz ed. The assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate. The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. The Group’s historical credit loss experience and forecast of economic conditions may also not be representative of customer’s actual default in the future. Convertible loan granted to Fluidda The Group accounts for the convertible loan granted to Fluidda in January 2019, with a notional amount of K€2,500 , at fair value. The carrying value of the convertible loan amounts to K€2,750 at December 31, 2019 . Fluidda is a private start-up company which delivers CRO services for drug development and develops medical devices which require EMA/FDA approvals . Fluidda is currently loss-making. In determining the fair value, the Group consider different contractual parameters such as the repayment and conversion scenario’s and dates. In addition, the Group needs to make significant estimates such as (i) the discount rate, (ii) the probabilities for each repayment and conversion scenario, (iii) the amount of a qualified capital increase that will determine the conversion factor and (iv) the timing for each repayment and conversion scenario. The convertible loan has a duration of 7 years with a 10.0% annual interest rate which are capitalized. The Group has applied a discount factor of 13.88% that is based on the estimated WACC of Fluidda reflecting the uncertainty in relation to the success of the company and the applied estimates by the Group. At December 31, <replace copy-paste-field from ' DOCVARIABLE REPORTVARIABLE-39bbc1a1-39d1-401f-b670-18639e8597ff \* CHARFORMAT '> , the Group determined that the fair value is not significantly different than its carrying value. Changes in the significant assumptions may lead to a significant increase/decrease in the fair value of the convertible loan. A increase/decrease in the applied discount rate by 2.0% would lead to a change in fair value by K€ -267 / K€298 . Changes in useful life for certain assets We review the useful life of our definite lived intangible assets and property, plant and equipment on an annual basis considering the current facts and circumstances available. This review has resulted in <replace copy-paste-field from ' DOCVARIABLE REPORTVARIABLE-39bbc1a1-39d1-401f-b670-18639e8597ff \* CHARFORMAT '> in a re-assessement of the useful life for certain specific assets in the categories buildings, fixtures, vehicles and machinery. We refer to Note 7 for the impact of the change in useful lifes during the year 2019. Leases IFRS 16 - estimating the discount rate and probability of exercisting extension options/termination options and purchase options The Group can not always determine the interest rate implicit in the lease contract and therefore, the Group has to estimate the incremental borrowing rate to measure certain lease liabilities such as buildings. The Group uses for buildings the property yield as reference to determine the incremental borrowing rate. For other assets, the Group generally uses the interest rate implicit in the lease contract or applies the incremental borrowing rate for a portfolio of similar assets. The incremental borrowing rate reflects what the Group "would have to pay", which requires estimation when no observable rates are available or when they need to be adjusted to reflect the terms and conditions of the lease. In addition, certain lease contracts may have extension options, termination options in case of property leases and/or purchase options in case of leases. The Group estimates whether it is reasonable certain or not, whether those options will be exercised or not, which impact the lease term in case of extension options and termination options and the period over which the lease assets are depreciated in case of purchase options.

Business combinations

Business combinations	12 Months Ended
	Dec. 31, 2019
Disclosure of detailed information about business combination [abstract]
Disclosure of business combinations [text block]	4 Business Combinations Acquisitions in 2019 Engimplan The Group executed a share purchase agreement dated August 6, 2019 and acquired 40% of the shares and voting interest of Engimplan Engenharia de Implante Indústria e Comércio Ltda (referred to as "Engimplan") for a total purchase consideration in cash of K€6,647 . As p a rt of this transaction, the Group increased its shareholding in Engimplan to 75% with a capital increase of K€5,750 in cash in Engimplan. The Brazilian-based company is specialist in manufacturing of orthopaedic and cranio- maxillofacial (CMF) implants and instruments. Engimplan w ill be part of the Medical segment. The preliminary fair value of the identifiable assets and liabilities at the date of acquisition were: in 000€ Carrying value at acquisition date Fair value adjust- ments Fair value at acquisi- tion date Assets Software 214 − 214 Customer relations − 2,530 2,530 Trademarks − 556 556 Other intangible assets 9 − 9 Property, plant & equipment 2,268 101 2,369 Right-of-use assets 633 − 633 Deferred tax assets − − − Other non-current financial assets 3 − 3 Inventory 2,084 96 2,180 Trade receivables 1,802 − 1,802 Other current assets 391 − 391 Cash from capital increase 5,750 − 5,750 Cash & cash equivalents 316 − 316 Total Assets 13,470 3,283 16,753 Liabilities Deferred tax liabilities − − − Deferred income (83) − (83) Loans & borrowings (1,443) − (1,443) Lease liabilities (633) − (633) Trade payables (271) − (271) Tax payables (100) − (100) Payroll related payables (298) − (298) Other liabilities (914) − (914) Total Liabilities (3,742) − (3,742) Total identified assets and liabilities 9,728 3,283 13,011 Goodwill − − 2,639 Non-controlling interest − − (3,253) Acquisition price − − 12,397 The cash flow from the business combination is as follows: Cash & cash equivalents acquired (316) Cash from capital increase (5,750) Acquisition price in cash 12,397 Total cash flow 6,331 The preliminary fair value of the identifiable assets and liabilities are included in our consolidated financial statements per December 31, 2019. We have performed a preliminary fair value analysis of the Engimplan business combination, with corresponding adjustments to the intangible assets, property, plant and equipment and inventories. The full fair value exercise for plant, property & equipment is not yet finalised. The accounting for the business combination resulted in fair values at date of acquisition of K€2,530 for customer relationships, K€556 for trademarks . Fair value analysis with respect to property, plant and equipment led to a preliminary fair value of K€2,369 . A fair value adjustment was identified of K€96 for the inventory. There are no contingent considerations payable. The goodwill recognized is primarily attributable to the trained and knowledgable workforce and to the expected synergies that will be realized at level of manufacturing and existing customer base. The goodwill is not deductible for income tax purposes. The total acquisition-related costs recognized as an expense in the general & administration costs are K€140 . The contribution of the acquired business to the revenue and net profit of the Group for the year ended December 31, 2019 were, respectively, K€2,437 and K€315 . The pro forma revenue and the pro forma net profit of the acquired business would have been K€2,437 and K€ (1,258) , respectively, if the business would have been acquired on January 1, 2019. Acquisitions in 2018 The Group has not completed any Business Combinations during the year 2018 . Acquisitions in 2017 ACTech The Group has signed a share and purchase agreement on October 4, 2017 to acquire all of the shares and voting interest of ACTech Holding Gmbh, an entity incorporated in Germany, and its subsidiaries ACTech Gmbh and ACTech North America Inc. (together referred to as "ACTech Group") for a total purchase consideration in cash of K€28,907 (net of indemnification asset). The German-based ACTech Group is specialist in producing limited runs of highly complex cast metal parts in a short timeframe . ACTech Group will be part of the Manufacturing segment. The fair value of the identifiable assets and liabilities at the date of acquisition were: in 000€ Carrying value at acquisition date Fair value adjust- ments Fair value at acquisi- tion date Assets Technology − 515 515 Customer relations − 17,092 17,092 Other intangible assets 6,330 (5,345) 985 Property, plant & equipment 19,986 243 20,229 Deferred tax assets 503 (415) 88 Other non-current financial assets 56 − 56 Inventory 2,356 433 2,789 Trade receivables 5,176 − 5,176 Cash & cash equivalents 2,244 − 2,244 Other assets 542 − 542 Total Assets 37,193 12,523 49,716 Liabilities Deferred tax liabilities (47) (5,977) (6,024) Deferred income (1,298) 1,298 − Loans & borrowings (11,308) − (11,308) Trade payables (777) − (777) Tax payables (3,664) 1,214 (2,450) Other liabilities (9,062) − (9,062) Total Liabilities (26,156) (3,465) (29,621) Total identified assets and liabilities 11,037 9,058 20,095 Goodwill − − 8,812 Acquisition price − − 28,907 The cash flow from the business combination is as follows: Cash & cash equivalents acquired (2,244) Acquisition price in cash including escrow 29,417 Total cash flow 27,173 The fair value of the identifiable assets and liabilities as included in our consolidated financial statements per December 31, 2017 were provisional as the final valuation had not been completed by the date these consolidated financial statements were approved for issue by the board of directors. As of October 4, 2018, we have completed the fair value analysis of the ACTech business combination, which corresponding adjustments to the intangible assets, property, plant and equipment, inventories and contracts in progress, other current assets, investment grants and tax payables. The fair value of the identified assets and liabilities were K€2,432 higher than the provisional valu e at date of acquisition, with a corresponding reduction in goodwill. The accounting for the business combination resulted in fair values at date of acquisition of K€17,092 for customer relationships, K€515 for patented technology, K€826 for order backlog, and K€222 for tax contingencies subject to an indemnification asset. The fair value of the receivables is K€5,176 which equals the gross contractual amounts receivable. Fair value analysis with respect to property, plant and equipment led to a fair value of K€20,229 . A fair value adjustment was identified of K€433 for the inventory. The deferred tax liabilities comprise the tax effect of the fair value adjustment s for the above described items . The purchase price paid at the acquisition date amounted to K€29,417 . The share and purchase agreement foresees that the Sellers will indemnify the Group for certain tax payables and contingencies that may occur in the period between 2018 and 2021. An amount of K€3,788 has been paid in an escrow account which can be applied against the indemnification asset. The Group has estimated that the fair value of the indemnification asset is K€222 which has been applied against the acquisition price. The indemnification asset will be paid out of the escrow account when the related tax payables and contingencies are paid. There are no contingent considerations payable. The goodwill recognized is primarily attributable to the trained and knowledgable workforce and to the expected synergies that will be realized at level of software platforms, manufacturing and existing customer base. The goodwill is not deductible for income tax purposes. The total acquisition-related costs recognized as an expense in the general & administration costs were K€609 in 2017. The contribution of the acquired business to the revenue and net profit of the Group for the year ended December 31, 2017 were , respectively , K€9,965 and K€275 . The pro forma revenue and the pro forma net profit of the acquired business would have been K€37,096 and K€2,060 , respectively, if the business would have been acquired on January 1, 2017. Changes in the measurement of the contingent consideration for previous acquisitions Cenat The Group has settled it contingent consideration in relation to the sale and purchase agreement of Cenat BVBA, signed on March 10, 2015, on January 21, 2019 for a total amount of K€450 . No remeasurement gain or loss has been recorded during 2019 ( 2018 : gain of K€192 ). No remeasurement has been recorded at December 31, 2017 .

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2019
Disclosure of goodwill [abstract]
Disclosure of goodwill [text block]	5 Goodwill The goodwill has been allocated to the cash generating units ("CGU") as follows: As of December 31, in 000€ 2019 2018 2017 CGU: MAT NV SAM BE 3,241 3,241 3,241 CGU: e-Prototypy 800 794 818 CGU: ACTech 8,812 8,812 8,812 CGU: OrthoView 4,683 4,467 4,504 CGU: MAT NV Manufacturing (Metal) 177 177 177 CGU: Engimplan 2,461 − − Total 20,174 17,491 17,552 The changes in the carrying value of the goodwill can be presented as follows for the years 2019 , 2018 and 2017 : in 000€ Gross Impair- ment Total At January 1, 2017 8,964 (104) 8,860 Additions 8,812 − 8,812 Impairment − − − Currency translation (120) − (120) At December 31, 2017 17,656 (104) 17,552 Additions − − − Currency translation (61) − (61) At December 31, 2018 17,595 (104) 17,491 Additions 2,639 − 2,639 Currency translation 44 − 44 At December 31, 2019 20,278 (104) 20,174 The goodwill of Orthoview (UK), e-Prototypy (PL) and Engimplan (BR) include respectively K€216 , K€6 and K€ (178) impact of currency translation in 2019 . The Group has performed an impairment test based on a discounted cash flow model with cash flows for the next five years derived from the budget and a residual value considering a perpetual growth rate. The MAT N V SAM BE and Cenat are included in the reportable segment " Materialis e Software". The CGU ACTech , e- Prototypy (PL) and MAT NV Manufacturing (Metal) are included in the reportable segment "Materialise Manufacturing". The CGU Orthoview (UK) and Eng implan (BR) are included in the reportable segment "Materialise Medical". CGU: MAT NV SAM (BE) The goodwill allocated to the CGU MAT NV SAM (BE) relates to the goodwill f rom the acquisition of CENAT in 2015 and the goodwill related to the acquisition of Marcam in 2011 (DE-3D Printing Software). The impairment test is based on the projected discounted cash flows resulting from the CGU MAT NV SAM BE , considering a period of five years. The main assumptions for goodwill impai rment testing include a discount rate (based on WACC ) of 10.96% a nd a perpetual growth rate of 5.00% . Other assumptions include the year-on-year growth rate of the revenue, gross margin and the operating costs which has been determined by management based on past experience. It was concluded that the value in use is higher than the carrying value of the cash generating unit of K€39,132 There are no reasonable changes in assumptions that would reduce the value in use below its carrying value of the cash generating unit. CGU e-Prototypy The goodwill relates to the acquisition of the Polish entity e-Prototypy . The impairment test on the CG U e-Prototypy is based on the projected d iscounted cash flows considering a period of five years. The mai n assumptions include a discount rate (based on WACC) of 14.52% a nd a perpetual growth rate of 2.0% . Other assumptions include the year-on-year growth rate of the revenue, gross margin and the operating costs which has been determined by management based on past experience and continued investments in capex in new 3D printing equipment. It was concluded that the value in use is significantly higher than the carrying value of the cash generating unit K€3,940 . Based on the sensitivity analysis where discount rate would increase with 1.0% , the value in use would still be significantly higher than the carrying value of the cash generating units . CGU Orthoview The goodwill relates to the acquisition of Orthoview. The impairment test on the CG U Orthoview is based on the projected d iscounted cash flows considering a period of 5 years .The mai n assumptions include a discoun t rate (based on WACC) of 11.97% and a perpetual growth rate of 1.00% . Other assumptions include the year-on-year growth rate of the revenue, gross margin and the operating costs which have been determined by management based on past experience. It was concluded that the value in use is higher than the carrying value of the cash generating unit of K€9,269 . Based on the sensitivity analysis where discount rate would increase with 1% , the value in use would still be higher than the carrying value of the cash generating unit. A perpetual growth of 0.0% still result in a value in use that is higher than the carrying value of the cash generating unit. The Orthoview business is being integrated further in the existing software business within our Materialise Medical segment. Synergies that are expected from joined product lines are not taken into account in the current impairment review as management believes that Orthoview can still be considered a separate cash generating unit in 2019 . CGU ACTECH The impairment test on the CGU ACTech is based on the projected discounted cash flows, considering a period of 5 years. The main assumptions include a discount rate (based on WACC) of 9.4% and a perpetual growth rate of 1.0% . Other assumptions include the year-on-year growth rate of the revenue, gross margin and the operating costs which have been determined by management based on past experience. It was concluded that the value in use is higher than the carrying value of the cash generating unit of K€26,284 . Based on the sensitivity analysis where discount rate would increase with 1.0% or other reasonable changes in the 5-year projected cash flows (such as lower EBITDA) and perpetual growth rate , the value in use would be higher than the carrying value of the cash generating unit. CGU ENGIMPLAN The impairment test on the CGU Engimplan is based on the projected discounted cash flows, considering a period of 5 years. The main assumptions include a discount rate (based on WACC) of 17.05% and a perpetual growth rate of 3.0% . Other assumptions include the year-on-year growth rate of the revenue, gross margin and the operating costs which have been determined by local & new management based on past experience. It was concluded that the value in use is higher than the carrying value of the cash generating unit of K€15,710 . Based on the sensitivity analysis where discount rate would increase with 1.0% or other reasonable changes in the 5-year projected cash flows (such as lower EBITDA) and perpetual growth rate , the value in use would be higher than the carrying value of the cash generating unit.

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2019
Disclosure of detailed information about intangible assets [abstract]
Disclosure of intangible assets [text block]	6 Intangible assets The changes in the carrying value of the intangible assets can be presented as follows for the years 2019 , 2018 and 2017 : in 000€ Patents and licenses Software Acquired customers, technology and backlogs Developed technology and software under construction Total Acquisition value At January 1, 2017 3,788 3,769 7,596 − 15,153 Additions 749 3,718 − − 4,467 Acquisition of a subsidiary 115 242 18,433 − 18,790 Disposals (159) (143) − − (302) Transfer between accounts − (98) − − (98) Currency translation − (5) (183) − (188) Other 4 155 (251) − (92) At December 31, 2017 4,497 7,638 25,595 − 37,730 Additions 554 807 32 951 2,344 Acquisition of a subsidiary − − − − − Disposals (759) (221) − − (980) Transfer between accounts 2 − − 364 366 Currency translation − − (48) − (48) Other − 17 − − 17 At December 31, 2018 4,294 8,241 25,579 1,315 39,429 Additions 209 656 − 1,328 2,193 Acquisition of a subsidiary 38 214 3,048 9 3,309 Disposals − (45) (32) − (77) Transfer between accounts (109) 1,601 − (988) 504 Currency translation 1 (10) 86 20 97 Other 3 10 − (32) (19) At December 31, 2019 4,436 10,667 28,681 1,652 45,436 in 000€ Patents and licenses Software Acquired customers, technology and backlogs Developed technology and software under construction Total Amortization At January 1, 2017 (2,042) (1,251) (2,095) − (5,388) Amortization charge for the year (609) (1,634) (1,579) − (3,822) Disposals 2 77 − − 79 Transfer between accounts − 98 − − 98 Currency translation − 4 45 − 49 Other (117) (279) 250 − (146) At December 31, 2017 (2,766) (2,985) (3,379) − (9,130) Amortization charge for the year (749) (2,310) (2,005) − (5,064) Disposals 854 206 − − 1,060 Transfer between accounts − − − − − Currency translation − 1 22 − 23 Other − 8 − − 8 At December 31, 2018 (2,661) (5,080) (5,362) − (13,103) Amortization charge for the year (246) (2,582) (2,031) − (4,859) Disposals − 23 − − 23 Transfer between accounts 109 (96) − − 13 Currency translation − (25) (126) − (151) Other − 20 16 − 36 At December 31, 2019 (2,798) (7,740) (7,503) − (18,041) Net carrying value At December, 31 2019 1,638 2,927 21,178 1,652 27,395 At December, 31 2018 1,633 3,161 20,217 1,315 26,326 At December 31, 2017 1,731 4,653 22,216 − 28,600 At January, 1 2017 1,746 2,518 5,501 − 9,765 Patent and licenses include only the direct attributable external costs incurred in registering the patent and obtaining the license. Software relates to purchased software for internal use only except for software development on certain application interfaces that were almost fully funded by a third party. Apart from the d eveloped technology and software under construction that was capitalized per end of 201 9 for the amount of K€1,652 , no other software development was capitalized in 2019 ( 2018 : K€1,315 , 2017 : K€86 ). The remaining amortization period is 1.5 years for the main software purchases and 7.7 years for the main patents and licenses. The ‘Acquired customers and technology’ have been recognized as part of the acquisition of Engimplan, ACTech, E -Prototypy, OrthoView, and Cenat (see Note 4). At December 31, 2019 , the remaining amortization period for the acquired customers is 9.58 years for Engimplan, 17.75 years for ACTech, 4.75 years for OrthoView, fully amortized for E-Prototypy and 5.25 years for Cenat ( 2018 : 18.75 years for ACTech, 5.75 years for OrthoView and 6.25 years for Cenat). The developed technology and software relate to one project (Tracheal Splint Project) that meet the criteria for recognition as internally developed intangible asset (see also Note 3: significant accounting judgments, estimates and assumptions). This asset is still being developed and consequently is not amortized. The Group has performed an impairment analysis on this asset which resulted in no impairment. The key assumptions used are: Discount rate of 1 1.38 %; Periods of cash flows: 6 No perpetuity The total amortization charge for 2019 is K€4,859 ( 2018 : K€5,064 ; 2017 : K€3,822 ). As from 2017 the amortization of intangible assets from business combinations is mainly included in the line net operating income of the consolidated income statement.

Property, plant & equipment

Property, plant & equipment	12 Months Ended
	Dec. 31, 2019
Disclosure of detailed information about property, plant and equipment [abstract]
Disclosure of property, plant and equipment [text block]	7 Property, plant & equipment The changes in the carrying value of the property, plant & equipment can be presented as follows for the year 2019 and 2018 : in 000€ Land and buildings Plant and equipment Right-of-use assets Construc- tion in progress Total Acquisition value At January 1, 2018 40,184 67,117 14,303 3,754 125,358 Additions 3,079 9,476 792 5,210 18,557 Disposals (99) (1,882) (17) (387) (2,385) Transfers 2,728 2,953 (732) (5,547) (598) Currency Translation (119) (25) (19) (26) (189) Other 4 (82) − (2) (80) At December 31, 2018 45,777 77,557 14,327 3,002 140,663 Impact of adoption of IFRS 16 − − 4,984 − 4,984 Additions 302 7,363 3,429 5,807 16,901 Acquired from business combinations 61 2,291 633 17 3,002 Disposals (37) (6,091) (753) − (6,881) Transfers (3,360) 7,077 117 (4,338) (504) Currency Translation 150 199 8 6 363 Other* − (73) (1,099) (80) (1,252) At December 31, 2019 42,893 88,323 21,646 4,414 157,276 Depreciation At January 1, 2018 (4,504) (27,166) (6,623) − (38,293) Depreciation charge for the year (1,560) (8,010) (2,346) (307) (12,223) Disposals 26 2,102 6 − 2,134 Transfers (18) (253) 514 − 243 Currency Translation (15) (53) 8 − (60) Other − 73 − − 73 At December 31, 2018 (6,071) (33,307) (8,441) (307) (48,126) Depreciation charge for the year (1,199) (9,082) (4,058) − (14,339) Disposals 36 5,704 359 − 6,099 Transfers 200 (1,551) 1,031 307 (13) Currency Translation (25) (190) (2) − (217) Other 220 (34) 51 − 237 At December 31, 2019 (6,839) (38,460) (11,060) − (56,359) Net book value At December 31, 2019 36,054 49,863 10,586 4,414 100,917 At December 31, 2018 39,706 44,250 5,886 2,695 92,537 At January 1, 2018 35,680 39,951 7,680 3,754 87,065 * "Other" includes modification of Right-of-use assets for an amount of K€ (554) as disclosed in the Right-of-use assets table below. The changes in the carrying value of the property, plant and equipment can be presented as follows for the year 2017 : in 000€ Land and buildings Plant and equipment Right-of-use assets Construc- tion in progress Total Acquisition value At January 1, 2017 19,797 40,199 11,241 4,652 75,889 Additions 377 10,560 2,246 17,334 30,517 Acquired from business combinations 9,362 10,318 136 414 20,230 Disposals (31) (1,046) (39) 218 (898) Transfers 11,527 7,439 (425) (18,914) (373) Currency Translation (185) (118) 5 88 (210) Other (663) (235) 1,139 (38) 203 At December 31, 2017 40,184 67,117 14,303 3,754 125,358 Depreciation At January 1, 2017 (5,093) (22,263) (3,470) − (30,826) Depreciation charge for the year (831) (5,531) (2,327) − (8,689) Disposals 15 842 18 − 875 Transfers 521 (444) 296 − 373 Currency Translation 31 166 (1) − 196 Other 853 64 (1,139) − (222) At December 31, 2017* (4,504) (27,166) (6,623) − (38,293) Net book value At December 31, 2017 35,680 39,951 7,680 3,754 87,065 At January 1, 2017 14,704 17,936 7,771 4,652 45,063 Certain prior year amounts have been reclassified to conform to the current year presentation with no impact on previously reported net loss, financial position or cash flows. The investments in property, plant & equipment and right-of-use assets in 2019 amounted to K€16,901 ( 2018 : K€18,557 ; 2017 : K€30,517 ). They are mainly related to new machines and installations ( K€7,757 ), land and buildings ( K€4,865 ), IT equipment ( K€1,268 ) and leased vehicles ( K€1,118 ). The investments in 2018 related to new machines and installations in Belgium and Germany ( K€10,747 ), land and buildings in Germany ( K€2,491 ), IT equipment ( K€1,781 ) and lease vehicles ( K€792 ) . The investments in 2017 related to the building constructions in Leuven and Poland ( K€12,762 ) , the investments into new machines and installations ( acquired and leased - K€11,947 ) and the investment in motor vehicles ( K€1,444 ). The Group realized a net loss on disposal of property, plant and equipment of K€165 in 2019 ( 2018 : a net loss of K€83 ; 2017 : a net loss of K€25 ). No impairment of property, plant and equipment was recorded. The transfers in 2019 within property, plant and equipment are mainly related to the transfers from assets under construction towards plant and equipment of K€4,031 , mainly the finalization of the cleanroom and self-constructed built machines; the gross up of the net amount of the PPA of ACTech of K€2,050 ; the transfer from R ight-of- U se of assets to P lant and E quipment due to the exercise of purchase options at the end of the lease agreement for a net book value of K€362 ; a transfer from Plant and Equipment to Right-of-Use assets for leases with a net book value of K€1,510 which were incorrectly classified in prior year. Assets under construction Per end of 2019 the main assets under construction are related to our "Green Machine" p roject for an amount of K€1,870 located in Belgium and buildings located in G ermany for an amount of K€1,464 . Changes in useful life for certain assets The Group reviews the useful life for the intangible assets and property, plant and equipment on an annual basis considering the current facts and circumstances available. This review has resulted in 2019 in a re-assessment of the useful life for certain specific assets in the categories buildings, fixtures, vehicles and machinery. The impact of the change in useful life during the year 2019 resulted in a decrease of the depre ciation charges by K€1,147 . In 2020 and 2021 the depreciation charge will be less for respectively K€478 and K€276 . The effect will be neutralized in 2028 for machines, in 2033 for fixtures and in 2048 for buildings. The right of use assets can be presented as follows: The carrying value of Right-of-Use assets at December 31, 2019 was K€10,586 ( 2018 : K€5,886 ; 2017 : K€7,680 ). Right-of-Use assets are mainly relate d to 3D printing machines with a carrying value of K€3,048 at December 31, 2019 ( 2018 : K€4,608 ; 2017 : K€6,613 ) and for which depreciation of K€1,045 was recorded in 2019 ( 2018 : K€1,745 ; 2017 : K€1,864 ). New leases in 2019 amount to K€4,062 of which K€1,119 relate to leased motor vehicles ( 2018 : K€792 ; 2017 : K€1,596 ). in 000€ Buildings Vehicles Equipment Total Acquisition value At January 1, 2019 before adoption IFRS 16 935 2,542 10,850 14,327 Impact of adoption of IFRS 16 3,255 849 880 4,984 At January 1, 2019 after adoption IFRS 16 4,190 3,391 11,730 19,311 Additions 2,222 1,118 89 3,429 Acquired from business combinations 633 − − 633 Modifications (9) (40) (496) (545) Disposals (550) (147) (56) (753) Currency Translation 4 − 4 8 Transfers − (47) 164 117 Other (2) − (552) (554) At December 31, 2019 6,488 4,275 10,883 21,646 Depreciation At January 1, 2019 (1,011) (1,189) (6,241) (8,441) Depreciation charge for the year (1,953) (1,060) (1,045) (4,058) Acquired from business combinations − − − − Modifications − − − − Disposals 257 147 56 460 Currency Translation (1) − (1) (2) Transfers − 41 990 1,031 Other 3 31 (84) (50) At December 31, 2019 (2,705) (2,030) (6,325) (11,060) Net book value At December 31, 2019 3,783 2,245 4,558 10,586 At January 1, 2019 before adoption IFRS 16 (76) 1,353 4,609 5,886 At January 1, 2019 after adoption IFRS 16 3,179 2,202 5,489 10,870 The following amounts related to leases are recognized in profit & loss (in 000€) 2019 Depreciation expense (4,058) Interest expense on lease liabilities (204) Expenses related to short-term leases/ low-value assets/ variable lease payments (725) The Group has negotiated several contracts with extension and termination options because of common practice in the country or for the asset . Management has exercised significant judgments in determining whether these extension and termination options are reasonable certain to be exercised. The potential future cash flows beyond the period following the exercise of the extension and termination option that are not included in the lease term are presented in the following table: (in 000€) 2019 Potential cash flows for extension options that are not reasonably certain to be exercised: 843 Potential cash flows for termination options that are reasonably certain to be exercised 174 Pledges Land and buildings (including buildings under construction) wi th a carrying amount of K€26,270 ( 2018 : K€27,319 ; 2017 : K€28,526 ) are subject to pledges to secure several of the Group’s bank loans. In addition , pledges have been given o n machines with a total carrying amount of K€2,884 ( 2018 : K€3,533 ; 2017 : K€13,340 ) (Note 24).

Investments in joint ventures

Investments in joint ventures	12 Months Ended
	Dec. 31, 2019
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [text block]	8 Investments in joint ventures The Group has one investment in the joint venture RSPrint NV (Belgium). The summarized financial information of RSPrint NV can be presented as follows: in 000€ 2019 2018 2017 Joint venture’s statement of financial position Current assets 1546 850 1,256 Non-current assets 93 114 212 Goodwill − − − Current liabilities (1,114) (756) (692) Non-current liabilities (448) (1,096) (788) Shareholders’ deficit (surplus) (77) 888 12 The joint venture income (loss) Revenue 1,736 1,186 817 Profit (loss) (785) (876) (723) Total current assets include cash and cash equivalents for a total amount of K€247 per December 31, 2019 ( 2018 : K€175 ; 2017 : K€128 ). Profit (loss) include total deprecations and amortization for a total amount of K€25 in 2019 ( 2018 : K€30 ; 2017 : K€50 ). The movement of the carrying value of the joint venture is as follows: in 000€ Carrying value as of January 1, 2017 − Additional investment 500 Transfer from receivables − Share in loss (469) Carrying value as of December 31, 2017 31 Additional investment − Transfer from receivables 444 Share in loss (475) Carrying value as of December 31, 2018 − Additional investment 875 Transfer to receivables (444) Share in loss (392) Carrying value as of December 31, 2019 39

Inventory and contracts in prog

Inventory and contracts in progress	12 Months Ended
	Dec. 31, 2019
Inventory and contract in progress [abstract]
Disclosure of Inventories and contracts in progress [text block]	9 Inventories and contracts in progress Inventories and contracts in progress include the following: As of December 31, in 000€ 2019 2018 2017* Raw materials 7,400 5,616 4,970 Work in progress 2,805 2,151 3,377 Finished goods 1,996 1,390 1,414 Contracts in progress 495 829 1,266 Total inventories and contracts in progress 12,696 9,986 11,027 The amount of the inventory written-off as an expense is K€526 ( 2018 : K€229 ; 2017 : K€48 ). The expenses are booked in Cost of Sales. The group has contracts in progress and advances from customers. The total costs incurred is K€366 and the profit recognized is K€129 as per December 31, 2019 . Advances were received for the amount of K€22 wit h respect to contracts in progress per end of 2019 ( 2018 : K€370 ; 2017 : K€0 ) .

Other assets

Other assets	12 Months Ended
	Dec. 31, 2019
Other assets [abstract]
Disclosure of other non-current assets [text block]	Other non-current assets Other non-current assets include the following: As of December 31, in 000€ 2019 2018 2017 Tax credits 3,015 3,006 2,446 Guarantees and deposits 415 405 362 Non-current receivable on joint venture 138 1,096 804 Non-listed equity investments 3,046 2,701 − Convertible loan 2,750 − − Other 27 29 55 Total non-current assets 9,391 7,237 3,667 The non-current tax credits relate to tax credits that will be realized over more than one year. The non-listed equity investments mainly consist of the investment in equity shares of the non-listed company Essentium Inc. The Group holds a non-controlling interest of 5% in this company. The increase is primarily to an additional investment in Essentium Inc at the same conditions as the initial investment. This investment was irrevocably designated at fair value through OCI as the Group considers these investments to be strategic in nature. We refer to Note 3 and Note 20. The Group has granted a convertible loan to Fluidda in January 2019, with a notional amount of K€2,500 . The converible loan is accounted for as a financial asset measured at fair value with changed in fair value through the income statement. The carrying value of the convertible loan amounts to K€2,750 at 31 December 2019 . The convertible loan has a duration of 7 years with a 10.0% annual interest rate which is capitalized. We refer to Note 3 and Note 20.
Disclosure of other current assets [text block]	Other current assets Other current assets include the following: As of December 31, in 000€ 2019 2018 2017 Deferred charges 2,632 2,046 2,021 Tax credits 695 185 219 Accrued income 486 958 524 Other tax receivables 3,127 2,286 2,910 Other non-trade receivables 1,676 1,461 2,001 Total current assets 8,616 6,936 7,675 The other tax receivables include Value Added Tax (VAT) receivables and corporate tax receivables . The non-trade receivables for the year ending December 31, 2019 include the indemnification asset for the amount of K€222 as referred to in Note 4 . Business Combinations related to ACTech. Also please note that a receivable related to factoring was accounted for under the non-trade receivables in the year ending December 31, 2017 ( K€646 ). In the year ending December 31, 2019 this receivable related to factoring has been recorded under the trade receivables for the amount of K€362 ( 2018 : K€445 ) .

Trade receivables

Trade receivables	12 Months Ended
	Dec. 31, 2019
Trade and other receivables [abstract]
Disclosure of trade and other receivables [text block]	11 Trade receivables The trade receivables include the following: As of December 31, in 000€ 2019 2018 2017 Trade receivables 42,509 38,764 36,572 Write off receivables (1,532) (1,873) (990) Total 40,977 36,891 35,582 Trade receivables are non-interest bearing and are generally on payment terms of 30 to 90 days. As at December 31, 2019 , trade receivables of an initial value of K€1,532 (2018: K€1,873 ; 2017: K€990 ) were impaired as part of the expected credit losses analysis. Impairment is accounted for under the other operating expenses. See below for changes in the impairment of receivables. in 000€ At January 1, 2017 (511) Addition (620) Usage 12 Reversal 129 At December 31, 2017 (990) At January 1, 2018 (990) Addition (1,284) Usage 182 Reversal 219 At December 31, 2018 (1,873) Addition (141) Usage 131 Reversal 351 At December 31, 2019 (1,532)

Cash and cash equivalents

Cash and cash equivalents	12 Months Ended
	Dec. 31, 2019
Cash and cash equivalents [abstract]
Disclosure of cash and cash equivalents [text block]	12 Cash and cash equivalents Cash and cash equivalents include the following: As of December 31, in 000€ 2019 2018 2017 Cash at bank 123,337 105,846 33,611 Cash equivalents 5,560 9,660 9,564 Total 128,897 115,506 43,175 Cash at banks earns interest at floating rates based on daily bank deposit rates. Short-term deposits are made for varying periods between one day and three months, depending on the immediate cash requirements of the Group, and earn interest at the respective short-term deposit rates. In connection with the exercise of warrants payments have been received in 2018 from employees for a total amount of K€209 , not converted into shares before year-end. In line with regulations the amount of K€209 was posted on a restricted bank account per December 31, 2018 . There were no restrictions on cash at December 31, 2019 or 2017 .

Equity

Equity	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Disclosure of share capital, reserves and other equity interest [text block]	13 Equity Share capital The share capital of the parent company Materialise NV consists of 53,172,513 ordinary nominative shares at December 31, 2019 ( 2018 : 52,890,761 ; 2017 : 47,325,438 ) with no nominal but par value of €0.058 in 2019 ( 2018 : €0.058 ; 2017 : €0.058 ) for a total amount of K€3,066 at December 31, 2019 ( 2018 : K€3,050 ; 2017 : K€2,729 ). in 000€, except share data Total number of ordinary shares Total share- holders' capital Total share- premium Outstanding at January 1, 2017 47,325,438 2,729 79,019 Equity settled share-based payments expense − − 820 Outstanding at January 1, 2018 47,325,438 2,729 79,839 Transfer share capital to share premium − − − Capital increase in cash - public offering 5,403,125 312 59,575 Expenses directly attributable to public offering − − (4,003) Capital increase via exercise of warrants 162,198 9 593 Equity settled share-based payments expense − − 633 Outstanding at January 1, 2019 52,890,761 3,050 136,637 Capital increase in cash - public offering and private placement − − − Expenses directly attributable to public offering − − − Capital increase via exercise of warrants 281,752 16 1,252 Equity settled share-based payments expense − − 201 Outstanding on December 31, 2019 53,172,513 3,066 138,090 The shareholders’ capital increased by K€16 in 2019 as a result of the exercise of warrants outstanding and fully vested. The number of new shares issued was 281,752 at an average price of €4.5 per share , including share premium. Share premium In Belgium, the portion of the capital increase in excess of par value is typically allocated to share premium. The carrying value of the share premium is K€138,090 at December 31, 2019 ( 2018 : K€136,637 ; 2017 : K€79,839 ). The change in 2019 is the result of: The capital increase via exercise of warrants of K€1,252 ; and th e share-based payment expense of K€201 . The change in 2018 is the result of the share-based payment K€633 , the capital increase via exercise of warrants of K€593 and the capital increase in cash-public offering and private placement of K€55,572 . The change in 2017 is the result of the share-based payment expense of and K€820 . Reserves The nature and purpose of the reserves is as follows: As of December 31, in 000€ 2019 2018 2017* Legal reserve 279 279 279 (Accumulated deficit) (474) (2,127) (3,990) Reserves (195) (1,848) (3,711) Based on the statutory result and after final result allocation approved by the annual shareholders meeting the legal reserve is increased by reserving 5% of the yearly statutory profit until the legal reserve reaches at least 10% of the shareholders’ capital. The legal reserve cannot be distributed to the shareholders. The Group did not pay any dividend during 2019 , 2018 and 2017 . Non-controlling interest The non-controlling interest has been recognized for 25% held by third party in Engimplan for an amount of K€3,107 per end of 2019 . In 2018 and 2017 there were no non-controlling interest. No non-controlling interest is recognized for the 17% held by a third party in RapidFit+ as the amount is presented as a financial liability. RapidFit+ The Group has purchased a call option and written a put-option on the non-controlling interest in Rapidfit+. The call option is accounted for in accordance with IFRS 9 and has an exercise price which is calculated according to a specified contractual formula based on the following parameters: invested capital, multiple of EBITDA minus net financial debt. Based on our analysis the call option remains out of the money and as such the fair value is estimated at zero at December 31, 2019 . The call option is exercisable between June 30, 2015 and June 27, 2020. The written put option has been recognized as a financial liability and measured at the fair value of the redemption amount and amounts to K€875 at December 31, 2019 ( 2018 : K€845 ; 2017 K€788 ). The undiscounted estimated redemption amount totals K€875 at December 31, 2019 ( 2018 : K€875 ; 2017 : K€875 ). The redemption price has an exercise price according to a specified contractual formula based on the following parameters: invested capital, multiple of EBITDA minus net financial debt. The initial recognition resulted in a reclassification of K€264 from non-controlling interest and K€64 from consolidated reserves. The parameter "invested capital" of the contractual formula has been adjusted in December 2014 to reflect the impact of the capital increase and the exercise period has been extended with one year. As a result, the estimated redemption amount of the written put option has increased by K€273 which has been recorded in diminution of the consolidated reserves. The written put option is exercisable between June 27, 2019 and June 27, 2021 and it is management’s estimate that the put option will be exercised within 12 months. As such, the written put option is presented as an other current liability. In addition, RapidFit+ has issued 10 dilution warrants to the non-controlling interest which are exercisable upon occurrence of certain specified events. The fair value of the dilution warrants is zero per end of 2019 ( 2018 : zero; 2017 : zero).

Share-based payment plans

Share-based payment plans	12 Months Ended
	Dec. 31, 2019
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Disclosure of share-based payment arrangements [text block]	14 Share-based payment plans Share-based payment plans of the parent The changes of the year for the warrant plans are as follows: 2019 2018 2017 Outstanding at January 1* 1,318,049 1,458,360 1,681,000 Granted − 2,000 − Forfeited / Cancelled (42,952) (69,104) (119,784) Exercised (310,045) (73,207) (102,856) Outstanding at December 31* 965,052 1,318,049 1,458,360 Exercisable at December 31 296,859 252,793 − *The Group’s share-based payment plans are all equity-settled except for the IPO warrants that have been granted to certain employees in certain countries due to legal requirements which are cash-settled. The outstanding amount includes number of stock appreciation rights (“SARs”) issued under cash-settled share-based payment plans. The number of outstanding warrants has been adjusted to reflect the 1-to-4 stock split decided in June 2014. The 2013 warrant plan gives a right to four shares for each warrant, whereas under all other warrant plans one warrant gives a right to one share. For presentation purposes the tables reflect the number of shares the warrants give right to across all plans. Equity-settled share-based payment plans The Group has several plans in place (2013 warrant plan, IPO warrant plan and 2015 warrant plan) which have similar terms except for the exercise price, except for the 2015 warrant plan. 2013 warrant plan Each warrant gives the right to the holder to four ordinary shares of the parent Company. The warrants have a contractual term of ten years and vest for 25% in the fourth year; 25% in the fifth year; 25% in the sixth year; and 25% in the seventh year. Warrants are exercisable as from the month after they have vested and in the subsequent exercise periods. There are no cash settlement alternatives and the Group does not have a practice of cash settlement for these warrants. The warrants have a contractual term of ten years. Under the 2013 warrant plan 301,096 warrants were effectively granted in October 2013 and 166,800 warrants were granted to certain employees and to certain members of our board of directors and senior management on November 28, 2013 with an exercise price ranging from €7.86 to €8.54. The status of the 2013 warrant plan at December 31 is as follows: 2019 2018 2017 Outstanding at January 1 300,040 320,640 435,096 Granted − − − Forfeited / Cancelled (3,500) (1,500) (11,600) Exercised (178,164) (19,100) (102,856) Outstanding at December 31 118,376 300,040 320,640 Exercisable at December 31 15,300 89,892 − With respect to the warrants exercised in 2019, a total of 44,541 warrants representing 178,164 shares were exercised in the last quarter . The average share price during that quarter was $18.40. Since the 2013 warrant plan prescribes that each warrant gives right to four shares and our table above presents the impact on the number of shares, the actual remaining number of warrants as per December 31, 2019 equals 29,594. IPO warrant plan Each warrant gives the right to the holder to one ordinary share of the parent Company. The warrants have a contractual term of 10 years and vest for 25% in the fourth year; 25% in the fifth year; 25% in the sixth year and 25% in the seventh year. Warrants are exercisable as from the month after they have vested and in the subsequent exercise periods. There are no cash settlement alternatives and the Group does not have a practice of cash settlement for these warrants. The warrants have a contractual term of 10 years. The Group granted 979,898 warrants in July 2014 and 36,151 warrants in November 2014 in the context of the initial public offering to the employees of the Group with an exercise price of €8.81 (“IPO warrant plan”). The Group granted an additional 18,180 warrants to employees in July 2015 under the IPO warrant plan. The status of the IPO warrant plan at December 31 is as follows: 2019 2018 2017 Outstanding at January 1 589,052 671,503 727,599 Granted − − − Forfeited / Cancelled (20,252) (42,209) (56,096) Exercised (103,588) (40,242) − Outstanding at December 31 465,212 589,052 671,503 Exercisable at December 31 169,071 114,012 − With respect to the warrants exercised in 2019, a total of 103,588 warrants representing 103,588 shares were exercised in the last quarter . The average share price during that quarter was $ 18.40. Warrant plan 2015 The board of directors decided on December 18, 2015 on a new plan (“2015 warrant plan”) by which it can grant up to 1,400,000 warrants to employees. Each warrant gives the right to the holder to one ordinary share of the parent Company. The warrants vest for 10% on the second anniversary of the granting; 20% on the third anniversary of the granting; 30% on the fourth anniversary of the granting; and 40% on the fifth anniversary of the granting, unless otherwise decided by the board of directors or one or more of its representatives granted powers thereto. Warrants are exercisable only after they have vested and only during a period of (i) four weeks following the publication of the results of the parent Company of the second and fourth quarter, or (ii) if no quarterly results are published, during the month March and the month September of every year. There are no cash settlement alternatives and the Group does not have a practice of cash settlement for these warrants. The warrants have a term of ten years. The Group granted 350,000 warrants in July 2016 to the employees of the Group with an exercise price of €6.45. The Group granted 2,000 warrants to an employee in May 2018 with an exercise price of €10.08. The status of the 2015 warrant plan at December 31 is as follows: 2019 2018 2017 Outstanding at January 1 325,200 329,000 350,000 Granted − 2,000 − Forfeited / Cancelled (14,800) (5,800) (21,000) Exercised − − − Outstanding at December 31 310,400 325,200 329,000 Exercisable at December 31 96,500 32,700 − Fair value The fair value of the warrants is estimated at the grant date using the Black-Scholes option pricing model, taking into account the terms and conditions upon which the warrants were granted. The following table provides the input to the Black-Scholes model for the 2013 warrant plan, IPO warrant plan and 2015 warrant plan: 2015 (Sept 16) 2015 (Nov) IPO 2014 (Nov) IPO 2014 (June) 2013(Dec) * 2013(Oct) * Return dividend 0% 0% 0% 0% 0% 0% Expected volatility 47% 47% 50% 46% 50% 53% Risk-free interest rate 0.24% 1.17% 1.12% 1.70% 2.56% 2.43% Expected life 4.30 5.50 5.50 5.50 5.50 5.50 Exercise price (in €) 6.45 8.81 8.81 8.81 8.54 7.86 Stock price (in €) 6.42 8.08 8.67 8.81 18.09 18.09 Fair value SAR (in €) 2.41 3.30 3.94 3.83 12.23 12.77 (*) Exercise price, stock price and fair value are not adjusted for the 1 to 4 stock-split completed in June 2014. The above input for the Black-Scholes model have been determined based on the following: The dividend return is estimated by reference to the historical dividend payment of the Group. Currently, this is estimated to be zero as no dividend have been paid since inception; Expected volatility is estimated based on the average annualized volatility of the volatility of the Group’s stock (until September 2016: of a number of quoted peers in the 3D printing industry and the volatility of the Group’s stock); Risk-free interest rate is based on the interest rate applicable for the 10Y Belgian government bond at the grant date; Estimated life of the warrant is determined to be until the first exercise period which is typically the month after vesting; and Fair value of the shares is determined based on the share price of the Group on Nasdaq at the date of valuation. For the grants prior to the initial public offering, the fair value of the shares was estimated based on a discounted cash flow model with 3-year cash flow projections and a multiple of EBITDA determined based on a number of quoted peers in the 3D printing industry. The expense arising from share-based payment transactions for the warrants plans mentioned above was K€401 (2018: K€640; 2017: K€819) The weighted average remaining estimated life of the warrants outstanding as of December 31, 2019 is 5.20 years (2018: 5.95 years; 2017: 5.62 years). The weighted average fair value for the warrants outstanding at the end of 2019 was €4.48 (2018: €5.62; 2017: €5.60). The weighted average exercise price for the warrants outstanding at the end of 2019 was €7.88 (2018: €7.99; 2017: €8.05). Cash-settled share-based payment plans The Group has issued 215,688 SARs in July 2014 towards certain employees in certain countries due to legal requirements with similar terms and conditions as the IPO warrant plan except that the SAR will be settled in cash. The exercise price of the SAR is €8.81. The status of this plan is as follows: 2019 2018 2017 Outstanding at January 1 103,757 137,217 168,305 Granted − − − Forfeited / Cancelled (4,400) (19,595) (31,088) Exercised (28,293) (13,865) − Outstanding at December 31 71,064 103,757 137,217 Exercisable at December 31 15,988 16,189 − The SAR plan grants the bearer the right to a cash payment equal to the difference between the exercise price and the stock price at the exercise date. This plan is considered a cash settled shared based payment and is as such recorded as liability (see Note 16). The SAR’s have a contractual term of ten years and vest for 25% in the fourth year; 25% in the fifth year; 25% in the sixth year and 25% in the seventh year. SAR’s are exercisable as from the month after they have vested and in the subsequent exercise periods. The fair value of the SAR is estimated at each reporting date using the Black-Scholes option pricing model, taking into account the terms and conditions upon which the warrants were granted. The following table lists the input used for the Black-Scholes model: 2019 2018 2017 Return dividend 0% 0% 0% Expected volatility 49% 49% 49% Risk-free interest rate 0.10% 0.77% 0.73% Expected life 0.25 1.25 2.25 Exercise price (in €) 8.81 8.81 8.81 Stock price (in €) 16.32 17.49 10.61 Fair value SAR (in €) 7.52 9.09 3.85 The expense arising from share-based payment transactions for the SAR’s plan was K€ (11) in 2019 (2018: K€435; 2017: K€204). The carrying value of the liability at December 31, 2019 amounts to K€574 (2018: K€786; 2017: K€351). The total intrinsic value of the liability for warrants currently exercisable at December 31, 2019 amounts K€120 (2018: K€141; 2017: K€0). Share-based payment plans of RapidFit+ The subsidiary RapidFit+ has issued a warrant plan on August 23, 2013 where a maximum of 300 warrants can be offered to management with an exercise price of €553.92. In January 2014, a total of 199 warrants were granted and accepted. The changes for the year for the RapidFit+ warrant plan are as follows: 2019 2018 2017 Outstanding at January 1 199 199 199 Granted − − − Forfeited / Cancelled (13) − − Exercised − − − Outstanding at December 31 186 199 199 Exercisable at December 31 184 − − The following table lists the input to the Black-Scholes model for the RapidFit+ warrant plan: 2014 Return dividend 0% Expected volatility 50% Risk-free interest rate 2.29% Expected life 5.5 Exercise price 553.9 Fair value option 262.7 The expense arising from share-based payment transactions for RapidFit+ warrant plan was K€2 in 2019 (2018: K€7; 2017: K€10)

Loans and borrowings

Loans and borrowings	12 Months Ended
	Dec. 31, 2019
Debt instruments held [abstract]
Disclosure of loans and advances to banks [text block]	15 Loans and borrowings The loans and borrowings include the following: As of December 31 in 000€ 2019 2018 2017 K€35,000 EIB bank loan 35,000 10,000 − K€28,000 acquisition bank loan 21,612 24,576 27,513 K€18,000 secured bank loans 17,429 17,739 17,575 K€12,300 bank loans ACTech 11,850 12,300 9,247 K€8,750 other facility loans 3,599 4,299 4,982 Bank investment loans - top 20 outstanding 22,132 23,801 21,441 Bank investment loans - other 4,429 3,808 2,289 Lease liabilities (2018 and 2017: Finance leases) 9,876 6,809 9,164 Institutional loan 824 1,492 1,105 Convertible bonds 1,000 1,000 1,000 Related party loan 187 214 241 Total loans and borrowings 127,938 106,038 94,557 Current 16,838 13,598 12,769 Non-Current 111,100 92,440 81,788 K€35,000 0 EIB bank loan On December 20, 2017 the Group entered into a finance contract with the European Investment Bank, or EIB, to finance future research and development programs. As part of a first tranche, an amount of K€10,000 was drawn in the course of 2018. The agreement foresees a first two-years period without loan reimbursements. Loans under the contract are made at a fixed rate, based on the Euribor rate at the time of the borrowing, plus a variable margin. The int e rest rate for this loan is 2.40% . The contract contains customary security, covenants and undertakings. A second tranche of K€25,000 was drawn in the course of 2019 with an interest rate of 2.72% . K€28,000 Acquisition loan This bank loan has been concluded in October 2017 to finance the acquisition of ACTech. The loan includes a portion of K€18,000 reimbursable monthly during seven years, and a bullet portion of K€10,000 , reimbursable at once in October 2024. The interest rate is fixed for the duration of the loan, and amounts to 1.1% on average for both portions. The bank loans are secured with a business pledge mandate, a share pledge on Materialise Germany GMBH, and debt covenants. K€18,000 secured bank loans The K€18,000 loan has been concluded in 2016 in two agreements to finance the construction of new facilities in Leuven (Belgium) and in Poland, both maturing in 2032. The agreement for the Belgian facility financing amounts to K€12,000 (drawn per end 2018 : K€11,739 ; per end 2017 K€11,739 ), and with reimbursements only starting in December 2022. The agreement for the Polish facility financing amounts to K€6,000 (fully drawn per end of 2017 ), and reimbursements have started in June 2019. The average interest rate of both agreements amounts to 1.2% . The bank loan is secured with a mortgage mandate on the Belgian facility buildings. K€12,300 bank loans In March 2018, three bank loans originating from the acquired ACTech Group were refinanced entirely for the amount of K€9,300 , with adjusted maturity to May 2025 and first reimbursements in August 2020. The interest rate has been fixed at a pproximately 1.6% , and pledges including a K€4,650 mortgage on ACTech’s facilities and a guarantee of Materialise NV. In addition, a new investment credit of K€3,000 was obtained in June 2018, repayable as from January 2019 and wi th a fixed interest rate of 1.5% . K€8,750 - Other facility loans Three facility loans were contracted in 2005, 2006 and 2012 for the construction of Leuven office and production facilities ( K€2,000 , K€300 and K€5,000 , respectively) and another loan for the Czech Republic offices in 2008 ( K€1,750 ). The balance of the four loans amounts to K€3,599 per December 31, 2019 . All loans have a repayment schedule of 15 years and interest rates are fixed between 4.3% and 5.4% for the four loans. Miscellaneous investment loans The 20 largest of these loans outstanding as at December 31, 2019 amount to a balance of K€22,132 . They have been agreed in 2019 and in the years before to finance various investments in machinery, printers, equipment, and software tools. The vast majority of the loans have a reimbursement period over seven years, and are at fixed interest rates with weighted average below 1% . K€9,876 Lease liabilities included lease with related party The Group has several lease obligations mainly with financial institutions and related to the financing of buildings and various other items of plant and equipment such as 3D printers. As at December 31, 2019 the balance of these lease agreements amounts to K€9,876 , and are mostly at fixed interest rates with weighted average below 2% . The subsidiary Engimplan rents the office and production building from its non-controlling shareholders for a initial term of 10 years , with an extension option for an additional 10 years (assessed not to be reasonable certain to be exercised).. The lease has been accounted for under IFRS 16 resulting in a lease liability at December 31, 2019 of K€617 . K€2,000 institutional loan This loan was contracted with a governmental institution in Germany to finance the production operations of Materialise Germany for a maximum amount of K€2,000 . The loan is repayable over a four year period, starting as of September 2017 with a fixed interest rate of 0.25% payable per quarter. As at December 31, 2019 K€2,000 has been drawn with an outstanding balance of K€824 . K€1,000 convertible bond with related party We issued, on October 28, 2013, 1,000 convertible bonds with a related party for a total amount of K€1,000 . The bonds have been fully subscribed by a member of our senior management. The conditions of the convertible bond can be summarized as follows: Number of convertible bonds: 1,000 Nominal value per bond: €1,000 Contractual life: 7 years Interest: 3.7% per year Conversion period: from January 1, 2017 until maturity Conversion price: €1.97 per share The maximum number of ordinary shares that can be issued upon conversion is 508,904 . The Group has estimated the fair value of a similar liability however without any conversion option by reference to a number of quoted peers in Belgium. The fair value was estimated at K€907 . Upon initial recognition, an amount of K€93 was recognized in consolidated reserves reflecting the fair value of the conversion option. Related party loan Ailanthus NV has granted us one other loan at fixed interest rate of 4.23% that matures in 2025. The purpose of the loan is to finance the purchase of a building in France. The amounts outstanding as of December 31, 2019 is K€187 ( 2018 : K€214 ; 2017 : K€241 ). The interest expense for the year ended December 31, 2019 is K€9 ( 2018 : K€10 ; 2017 : K€11 ). Changes of liabilities for financing activities: The following table presents the changes of the liabilities for financing activities: For the year ended December 31 in 000€ 2019 2018 2017 At January 1, 106,038 94,557 33,806 Proceeds from loans & borrowings 29,000 32,554 54,319 Repayment of loans & borrowings (12,126) (18,820) (11,904) New leases 8,326 792 2,906 Repayment of leases (5,283) (3,102) (2,947) Loans acquired from business combination 2,076 − 18,205 Net foreign exchange movements (92) 57 172 At December 31, 127,938 106,038 94,557

Other non-current liabilities

Other non-current liabilities	12 Months Ended
	Dec. 31, 2019
Miscellaneous non-current liabilities [abstract]
Disclosure of other non-current liabilities [text block]	16 Other non-current liabilities The other non-current liabilities consist of the following: As of December 31, in 000€ 2019 2018 2017 Written-put option RapidFit+ − − 788 Contingent consideration − − 648 Provisions 122 82 109 Other 574 786 359 Total 696 868 1,904 We refer to Note 13 for a description of the written-put options RapidFit+. With respect to the contingent consideration, related to the CENAT acquisition, we refer to Note 4 on business combinations. At December 31, 2018 only a consideration of K€450 remains, recorded under the other current liabilities (see Note 19). Per end of 2018 and 2017 the non-current part of the CENAT contingent consideration amounted to K€0 and K€648 , respectively. The other items in the above table include a liability of K€574 per December 31, 2019 related to the cash settled shared based payment plan as referred to in Note 14 ( 2018 : K€786 ; 2017 : K€351 ). The impact of the accounting treatment of the Belgian contribution plans with a minimal guarantee is not material as only a limited number of people can benefit. No provisions have been recognized as of December 31, 2019 , 2018 and 2017 . As such, no further disclosures have been provided.

Tax payables

Tax payables	12 Months Ended
	Dec. 31, 2019
Tax payables [abstract]
Disclosure of tax payables [text block]	17 Tax payables The tax payables amount to K€3,363 as per December 31, 2019 ( 2018 : K€2,313 ; 2017 : K€2,023 ) and is mainly related to the tax payable s of the entities located in Germany. In Germany a tax unity was set-up in 2018 between Materialise Germany and ACTech.

Deferred income

Deferred income	12 Months Ended
	Dec. 31, 2019
Accruals and deferred income [abstract]
Disclosure of deferred income [text block]	18 Deferred income Deferred income consists of the following: As of December 31 in 000€ 2019 2018 2017 Deferred maintenance & license 27,667 22,606 18,723 Deferred (project) fees 4,647 4,838 3,765 Deferred government grants 359 338 71 Total 32,672 27,782 22,559 current 27,641 23,195 18,791 non-current 5,031 4,587 3,768 The deferred maintenance and license consist of maintenance fees paid up-front which are deferred and amortized over the maintenance period. The deferred (project) fees consist of one-time and advance payments received which are deferred in accordance with the revenue accounting policies. The deferred government grants are recognized as income under "other operating income". We refer to Note 22.1.2 for more detail on the contract liabilities.

Other current liabilities

Other current liabilities	12 Months Ended
	Dec. 31, 2019
Miscellaneous current liabilities [abstract]
Disclosure of other current liabilities [text block]	19 Other current liabilities Other current liabilities include the following: As of December 31 in 000€ 2019 2018 2017 Payroll-related liabilities 10,281 10,111 9,274 Non-income tax payables 2,262 2,175 2,063 Accrued charges 1,080 789 769 Advances received 715 713 870 Other current liabilities 3,348 1,554 520 Total 17,686 15,342 13,496 The other current liabilities as per December 31, 2019 include an amount of K€0 ( 2018 : K€450 ; 2017 : K€257 ) payable in connection with the CENAT business combination (see also Note 4 and Note 16), and a payable for the amount of K€875 ( 2018 : K€845 ; 2017 : K€0 ) in connection with the written-put options RapidFit+ (see also Note 13 and Note 16), various accruals for K€1,110 and financial liabilities at fair value in respect of the foreign exchange hedges on GBP and JPY and interest rate swaps for K€478 . The non-income tax payables mainly relate to VAT payables and payroll taxes.

Fair value

Fair value	12 Months Ended
	Dec. 31, 2019
Disclosure of fair value of financial assets and liabilities [abstract]
Disclosure of fair value of financial instruments [text block]	20 Fair value Financial assets The carrying value and fair value of the financial assets as of December 31, 2019 , 2018 and 2017 can be presented as of : Carrying value Fair value in 000€ 2019 2018 2017 2019 2018 2017 Financial assets Debt instruments measured at amortized cost Trade receivables (current) 40,977 36,891 35,582 40,977 36,891 35,582 Other financial assets (non-current) 580 1,530 1,221 580 1,530 1,221 Other current non-trade receivables 1,676 1,461 2,001 1,676 1,461 2,001 Cash & cash equivalents 128,897 115,506 43,175 128,897 115,506 43,175 Total debt instruments 172,130 155,388 81,979 172,130 155,388 81,979 Financial assets at fair value through profit or loss Derivatives 9 117 218 9 117 218 Convertible loan 2,750 − − 2,794 − − Total financial assets measured at fair value 2,759 117 218 2,803 117 218 Equity instruments designated at fair value through OCI Non-listed equity investments 3,046 2,701 − 3,047 2,701 − Total Equity instruments designated at fair value through OCI 3,046 2,701 − 3,047 2,701 − The fair value of the financial assets has been determined on the basis of the following methods and assumptions: The carrying value of the cash and cash equivalents and the current receivables approximate their fair value due to their short term character; The fair value of the derivatives has been determined based on a mark-to-market analysis prepared by the bank based on observable market inputs (level 2 inputs); Other current non-trade receivables are being evaluated on the basis of their credit risk and interest rate. Their fair value is not different from their carrying value on December 31, 2019 , 2018 and 2017 The non-listed equity investments, mainly representing the investment in Essentium I nc, are measured at fair value. As of December 31, 2019 , management considers that currently the cost is an appropriate estimate of fair value (level 2 input) because a recent capital increase indicated that the market valuation of Essentium Inc. has not changed and because of the followings reasons: Essentium Inc is a non-listed entity; The Group only has an insignificant interest in Essentium Inc (5% of the shares); The Group has no representatives in the Board of Directors of Essentium Inc; and Insufficient more recent information is available to measure fair value; The convertible loan granted to Fluidda is measured at fair value. As of December 31, 2019 , management considers that the fair value is close to the carrying value (level 3 input). In assessing the fair value, the Group has made significant estimates with regard to the discount rate, the probability of each repayment and conversion scenario and related timing, the amount of the qualified capital increase. Changes in the significant assumptions may lead to a significant increase/decrease in the fair value of the convertible loan. A increase/decrease in the applied discount rate by 2% would lead to a change in fair value by K€ (267) / K€298 . Financial liabilities: The carrying value and fair value of the financial liabilities as of December 31, 2019 , 2018 and 2017 can be presented as follows : Carrying value Fair value in 000€ 2019 2018 2017 2019 2018 2017 Financial liabilities measured at amortized cost Loans & Borrowings including lease liabilities 127,939 106,037 94,557 128,930 105,026 95,351 Trade payables 18,517 18,667 15,670 18,517 18,667 15,670 Other liabilities excl. written put option on NCI 3,187 778 1,133 3,187 778 1,133 Total financial liabilities measured at amortized cost 149,643 125,482 111,360 150,634 124,471 112,154 Financial liabilities measured at fair value Contingent consideration − 450 905 − 450 905 Cash settled share based payments − 786 351 − 786 351 Written put option on NCI 875 845 788 875 845 788 Derivatives 478 194 8 478 194 8 Total financial liability measured at fair value 1,353 2,275 2,052 1,353 2,275 2,052 Total non-current 112,549 94,521 85,276 112,288 93,289 85,890 Total current 38,447 33,236 28,136 39,699 33,457 28,316 The fair value of the financial liabilities has been determined on the basis of the following methods and assumptions: The carrying value of current liabilities approximates their fair value due to the short term character of these instruments; Loans and borrowings are evaluated based on their interest rates and maturity date. Most interest bearing debts have fixed interest rates and their fair value is subject to changes in interest rates and individual creditworthiness. Their carrying value approximates their fair value; The fair value of the derivatives has been determined based on a markt-to-market analysis prepared by the bank based on observatab le marketinputs (level 2 inputs); The fair value of the written put option on non-controlling interest has been determined based on the present value of the red emption amount (level 3 inputs); The fair value of the cash-settled sharebased payments has been determined based on a black-scholes model using inputs that are level 1 (stock-price and risk-free interest rate) as well as level 2 (e.g. volatility). We refer to Note 14. The fair value of the ( contingent ) consideration has been determined based on the latest long-term business plans of the Cenat business (level 3 inputs). Note that the consideration is no longer contingent as per end 2018. Fair value hierarchy The Group uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique: Level 1: quoted (unadjusted) prices in active markets for identical assets and liabilities; Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly; and Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data. The Group has the following financial instruments carried at fair value in the statement of financial position on December 31, 2019 , 2018 and 2017 : the derivatives related to int e rest rate and foreign currency swaps as included in the above tables, a call option and written put option on non-controlling interest, the ( contingent ) consideration for the acquisition of Cenat and the non-listed equity investments.

Segment information

Segment information	12 Months Ended
	Dec. 31, 2019
Disclosure of operating segments [abstract]
Disclosure of operating segments [text block]	2 1 Segment information For management purposes, the Group is organized into segments based on their products, services and industry and has the following three reportable segments: The Materialise Medical segment, which develops and delivers medical software solutions, medical devices and other related products and services; The Materialise Manufacturing segment, which delivers 3D printe d products and related services; and The Materialise Software segment, which develops and delivers additive manufacturing software sol utions and related services. The measurement principles used by the Group in preparing this segment reporting are also the basis for segment performance assessment and are in conformity with IFRS. The Chief Executive Officer of the Group acts as the chief operating decision maker. As a performance indicator, the chief operating decision maker controls the performance by the Group’s revenue and adjusted EBITDA. The following table summarizes the segment reporting for each of the reportable periods ending December 31 . Corporate research and development, headquarters’ function, financing and income taxes are managed on a Group basis and are not allocated to operating segments. As management’s controlling instrument is mainly revenue-based, the reporting information does not include assets and liabilities by segment and is as such not available per segment. in 000€ Materialise Software Materialise Medical Materialise Manufacturing Total segments Unallocated Consolidated For the year ended December 31, 2019 Revenues 41,654 60,808 94,156 196,618 61 196,679 Segment Adjusted EBITDA 13,812 10,774 12,154 36,740 (10,084) 26,656 Segment Adjusted EBITDA % 33.2% 17.7% 12.9% 18.7% − 13.6% For the year ended December 31, 2018 Revenues 37,374 52,252 94,956 184,582 139 184,721 Segment Adjusted EBITDA 11,536 10,252 10,785 32,573 (9,047) 23,526 Segment Adjusted EBITDA % 30.9% 19.6% 11.4% 17.6% − 12.7% For the year ended December 31, 2017 Revenues 35,770 42,841 63,712 142,323 250 142,573 Segment Adjusted EBITDA 13,926 4,400 4,439 22,765 (8,155) 14,610 Segment Adjusted EBITDA % 38.9% 10.3% 7.0% 16.0% − 10.2% The segment Adjusted EBITDA is reconciled with the consolidated net profit (loss) for the year as follows: For the year ended December 31, in 000€ 2019 2018 2017 Segment Adjusted EBITDA 36,740 32,573 22,765 Depreciation, amortization and impairment (19,198) (17,287) (12,576) Corporate research and development (1,859) (1,913) (2,017) Corporate headquarter costs (11,077) (10,358) (9,690) Other operating income (expense) 2,410 2,149 1,910 Operating profit 7,016 5,164 392 Financial expenses (3,682) (4,864) (4,728) Financial income 1,377 3,627 3,210 Income taxes (2,595) (425) (522) Share in loss of joint venture (392) (475) (469) Net (loss) profit 1,724 3,027 (2,117) The Group has no customers with individual sales larger than 10% of the total revenue in 2019 ( 2018 : none; 2017 : none). Entity-wide disclosures T he revenue by geographical area is as follows: As of December 31, in 000€ 2019 2018 2017 United States of America 56,235 42,217 32,926 Americas other than USA 3,395 1,700 2,194 Belgium 7,917 9,350 8,145 Germany 31,185 30,436 27,011 France 20,110 22,282 18,737 Switzerland 14,907 13,135 7,782 United Kingdom 13,804 11,946 10,911 Italy 6,707 4,392 4,224 Netherlands 5,825 7,382 7,986 Other Europe 17,329 21,455 3,144 Asia Pacific 19,265 20,426 19,513 Total 196,679 184,721 142,573 The total revenue realized in the country of domicile (Belgium) in 2019 amounts to K€7,917 ( 2018 : K€9,350 ; 2017 : K€8,145 ) . The total non-current assets , other than financial instruments, deferred tax assets, by geographical area is as follows: As of December 31, in 000€ 2019 2018 2017 United States of America (USA) 4,194 3,953 3,880 Americas other than USA 8,374 62 29 Belgium 49,426 48,873 46,573 Germany 57,918 56,096 56,410 Poland 15,506 16,206 15,441 Rest of Europe 10,410 10,125 10,140 Asia-Pacific 2,658 1,039 744 Total 148,486 136,354 133,217 The totals of the above table includes goodwill, intangible assets and property, plant & equipment and Right-of-Use Assets as disclosed in the consolidated statements of financial position.

Income and expenses

Income and expenses	12 Months Ended
	Dec. 31, 2019
Disclosure of income and expenses [abstract]
Disclosure of income and expenses [text block]	2 2 Income and expenses 2 2 .1 Revenue 2 2.1.1 Disaggregated revenue information For the year ended December 31, 2019 in 000€ Materialise Software Materialise Medical Materialise Manufacturing Total segments Unallocated Consolidated Geographical markets United States of America (USA) 11,188 29,100 15,947 56,235 − 56,235 Americas other than USA 487 2,071 837 3,395 − 3,395 Europe (without Belgium) & Africa 18,767 21,356 69,744 109,867 − 109,867 Belgium 183 2,101 5,572 7,856 61 7,917 Asia Pacific 11,029 6,180 2,056 19,265 − 19,265 Total revenue from contracts with customers 41,654 60,808 94,156 196,618 61 196,679 Type of goods or service Software revenue (non-medical) 41,654 − − 41,654 − 41,654 Software revenue (medical) − 19,407 − 19,407 − 19,407 Medical devices and services − 41,401 − 41,401 − 41,401 Manufacturing − − 94,156 94,156 − 94,156 Other − − − − 61 61 Total revenue from contracts with customers 41,654 60,808 94,156 196,618 61 196,679 Timing of revenue recognition Goods/Services transferred at a point in time 21,190 45,730 88,988 155,908 61 155,969 Goods/Services transferred over time 20,464 15,078 5,168 40,710 − 40,710 Total revenue from contracts with customers 41,654 60,808 94,156 196,618 61 196,679 For the year ended December 31, 2018 in 000€ Materialise Software Materialise Medical Materialise Manufacturing Total segments Unallocated Consolidated Geographical markets United States of America (USA) 8,804 23,940 9,439 42,183 34 42,217 Americas other than USA 193 1,404 101 1,698 2 1,700 Europe (without Belgium) & Africa 17,026 19,073 74,852 110,951 77 111,028 Belgium 155 1,824 7,364 9,343 7 9,350 Asia Pacific 11,196 6,011 3,200 20,407 19 20,426 Total revenue from contracts with customers 37,374 52,252 94,956 184,582 139 184,721 Type of goods or service Software revenue (non-medical) 37,374 − − 37,374 − 37,374 Software revenue (medical) − 17,045 − 17,045 − 17,045 Medical devices and services − 35,207 − 35,207 − 35,207 Complex metal parts production (ACTech) − − 43,438 43,438 − 43,438 Other − − − − 139 139 Total revenue from contracts with customers 37,374 52,252 94,956 184,582 139 184,721 Timing of revenue recognition Goods/Services transferred at a point in time 20,326 39,682 90,614 150,622 139 150,761 Goods/Services transferred over time 17,048 12,570 4,342 33,960 − 33,960 Total revenue from contracts with customers 37,374 52,252 94,956 184,582 139 184,721 The revenue per type of good or service including the previous years is as follows: For the year ended December 31 in 000€ 2019 2018 2017 Software revenue (non-medical) 41,654 37,374 35,770 Software revenue (medical) 19,407 17,045 15,619 Medical devices and services 41,401 35,207 27,222 Manufacturing 94,156 94,956 63,712 Other 61 139 250 Total 196,679 184,721 142,573 2 2.1.2 Contract balances The following table provides information about receivables, contracts in progress (contract assets) and deferred income (contract liabilities) from contracts with customers. As of December 31, in 000€ 2019 2018 Trade receivables, included in 'trade and other receivables' 42,509 38,764 Contract assets / contracts in progress 495 829 Contract liabilities / deferred income 32,314 27,444 Total 75,318 67,037 We refer to note 18 for a detail of the deferred income. Note 18 include split of the deferred income in current and non-current. Non-current deferred income, representing mainly maintenance contracts with terms more than one year and certain contracts with up-front fees which are allocated to performance obligations that will be satisfied over more than one year, may be recognized as revenue between one to three years. Total revenue recognized during 2019 that was included in the contract liability at the beginning of the year amounts to K€27,444 . There is no revenue recognized during 2019 from performance obligations that were satisfied in the previous years. The relation between the timing of satisfaction of the performance obligations and the timing of billing resulting in contract assets and liabilities is as follows: Maintenance services: maintenance services are typically billed at the beginning of the maintenance period resulting in deferred income that is recognized on a straightline basis over the maintenance period. Software licenses: certain software licenses may have been billed prior to the delivery of the software key resulting in a deferred income balance. Certain agreements in the medical segment include up-front fees such as step-in fees or milestone payments which are billed at inception of the contract but which are allocated to performance obligations which are satisfied at a later time in the contract term or which have not been recognized considering the revenue contraint (i.e. may have to be credited when customer achieves certain volume targets). In addition, certain contracts include prepaid fees for volume "Plan Only" purchases for which the purchased services are only delivered during a one year period. Those fees result in deferred income which are recognized as revenue when services/products are delivered and revenue is not constrainted. Certain development services are satisfied while the services can only billed at certain pre-defined points in time or when the services are fully satisfied resulting in contracts in progress / contract assets. 2 2 .2 Cost of sales Cost of sales include the following selected information: For the year ended December 31 in 000€ 2019 2018 2017 Purchase of goods and services (37,870) (39,114) (34,480) Amortization and depreciation (10,837) (9,910) (7,560) Payroll expenses (37,715) (33,036) (20,806) Other expenses (550) (239) (106) Total (86,972) (82,299) (62,952) 2 2 .3 Research and development expenses Research and development expenses include the following selected information: For the year ended December 31 in 000€ 2019 2018 2017 Purchase of goods and services (2,583) (3,590) (3,140) Amortization and depreciation (1,483) (830) (686) Payroll expenses (19,219) (17,935) (16,054) Other (63) (61) (79) Total (23,348) (22,416) (19,959) 2 2 .4 Sales and marketing expenses Sales and marketing expenses include the following selected information: For the year ended December 31 in 000€ 2019 2018 2017 Purchase of goods and services (9,228) (9,775) (8,035) Amortization and depreciation (1,346) (725) (505) Payroll expenses (42,055) (35,585) (30,175) Other (360) (218) (220) Total (52,989) (46,303) (38,935) 2 2 .5 General and administrative expenses G eneral and administrative expenses include the following selected information: For the year ended December 31 in 000€ 2019 2018 2017 Purchase of goods and services (9,856) (9,892) (7,053) Amortization and depreciation (3,630) (3,828) (2,761) Payroll expenses (18,078) (18,442) (14,858) Other (222) (148) (204) Total (31,786) (32,310) (24,876) 2 2 .6 Net other operating income The net other operating income can be detailed as follows: For the year ended December 31 in 000€ 2019 2018 2017 Government grants 5,263 4,658 4,342 Amortization intangibles purchase price allocation (2,013) (1,994) (1,064) Allowance for doubtful debtors 210 (1,065) (454) Capitalized expenses (asset construction) 166 16 123 Net foreign currency exchange gains / (losses) − 246 (235) Tax Credits 665 706 899 Fair value adjustment Cenat liability − 192 − Personnel related income 37 168 − Other 1,104 844 930 Total 5,432 3,771 4,541 The Company has received government grants from the Belgian federal and regional governments and from the European Community in the forms of grants linked to certain of its research and development programs and reduced payroll taxes. 2 2 .7 Payroll expenses The following table shows the breakdown of payroll expenses for 2019 , 2018 and 2017 : For the year ended December 31 in 000€ 2019 2018 2017 Short-term employee benefits (87,775) (76,023) (60,195) Social security expenses (15,647) (14,139) (11,200) Expenses defined contribution plans (1,033) (936) (926) Other employee expenses (12,612) (13,900) (9,572) Total (117,067) (104,998) (81,893) 2,177 2,009 1,862 2 2 .8 Financial expenses Financial expenses includes the following selected information: For the year ended December 31 in 000€ 2019 2018 2017 Interest expense (2,146) (1,747) (1,026) Foreign currency losses (832) (2,748) (3,131) Other financial expenses (704) (369) (571) Total (3,682) (4,864) (4,728) 2 2 .9 Financial income Fi nancial income includes the following selected information: For the year ended December 31 in 000€ 2019 2018 2017 Foreign currency exchange gains 955 3,047 2,830 Amortization discount interest free loans − − 6 Other finance income 422 580 374 Total 1,377 3,627 3,210
Disclosure of income tax and deferred tax [text block]	2 2 .10 Income taxes and deferred taxes Current income tax The following table shows the breakdown of the tax expense for 2019 , 2018 and 2017 : As of December 31, in 000€ 2019 2018 2017 Estimated tax liability for the year (2,926) (1,216) (1,530) Tax adjustments to the previous year − − 412 Deferred income taxes 331 791 596 Total income taxes for the period (2,595) (425) (522) The current tax expense is equal to the amount of income tax owed to the tax authorities for the year, under the applicable tax laws and rates in effect in the various countries. The estimated tax liability is mainly due in Germany. Deferred tax Deferred tax is presented in the statement of financial position under non-current assets and non-current liabilities, as applicable. The following table shows the breakdown of the deferred tax a ssets, deferred tax liability and the deferred tax expense for 2019 , 2018 and 2017 : Asset/(liability) Income/(expense) in 000€ 2019 2018 2017 2019 2018 2017 Tax losses, notional interest deduction and other tax benefits − 26 − − − − Amortization development assets and other intangible assets 38 224 304 − − − Depreciation property, plant & equipment 70 30 − − − − Other items 84 35 − − − − Total deferred tax assets 192 315 304 (124) 11 (32) Property, plant & equipment (403) (694) (698) − − − Intangible assets (4,937) (5,370) (6,656) − − − Investment grants (301) (312) − − − − Inventory valuation (89) 141 − − − − Other items (17) 9 (61) − − − Total deferred tax liabilities (5,747) (6,226) (7,415) 455 780 628 Total deferred tax income (loss) − − − 331 791 596 The Group has unused tax losses, tax credits and notional interest deduction available in an amount of K€37,440 for 2019 ( 2018 : K€25,285 ; 2017 : K€11,948 ) of which K€25,172 for 2019 ( 2018 : K€15,592 ; 2017 : K€4,581 ) relating to Materialise NV. As at December 31, 2019 no unused notional interest deduction remains ( 2018 : K€0 ; 2017 : K€315 ), the amount remaing from previous periods has expired . With respect to the unused tax losses of Materialise NV, no deferred tax assets ha ve been recognized given that in view of the Belgian Patent Income Deduction and Innovation Income Deduction there is an uncertaint y to which extent these tax losses will be used in future years. As from July 1, 2016, the new Innovation Income Deduction replaces the former Patent Income Deduction. Under the grandfathering rule the Patent Income Deduction system can still be applied until June 30, 2021. The Belgian Patent Income Deduction allows companies to deduct 80% of the qualifying gross patent income from the taxable basis. Under the Innovation Income Deduction system, companies can deduct up to 85% of their net innovation income from the taxable b asis. Based on its analysis, in 2019 the Compan y has assessed that no deferred tax asset should be accounted for with respect to its unused tax losses in Belgium. With respect to the net tax losses of the other entities in the Group no deferred taxes have been recognized in 2019 ( 2018 : K€26 ; 2017 : K€0 ). The deferred tax liability of K€5,747 in the year ending December 31, 2019 mainly relate s to the intangibles that have been recognized as part of the purchase price allocation (ACTech). Relationship between Tax Expense and Accounting Profit For the year ended December 31 in 000€ 2019 2018 2017 Profit (loss) before taxes 4,319 3,452 (1,595) Income tax at statutory rate of 29.58% (2017: 33.99%) (1,278) (1,021) 542 Effect of different local tax rate 63 166 433 Tax adjustments to the previous period (367) 80 412 Non-deductible expenses (554) (1,141) (818) Capitalized initial public offering transaction costs − − − Research and development tax credits & patent income deduction 179 337 44 Notional interest deduction Belgium − − − Non recognition of deferred tax asset (1,579) (546) (1,505) Recognition of deferred tax assets on previous years tax losses 119 653 − Non-taxable income 925 606 556 Use of previous years tax losses and tax credits for which no − − 12 Taxes on other basis − 280 (117) Other (103) 161 (81) Income tax expense as reported in the consolidated income statement (2,595) (425) (522)

Earnings per share

Earnings per share	12 Months Ended
	Dec. 31, 2019
Earnings per share [abstract]
Disclosure of earnings per share [text block]	2 3 Earnings per share Basic earnings per share amounts are calculated by dividing the net profit (loss) for the year attributable to ordinary equity holders of the parent company by the weighted average number of ordinary shares outstanding during the year. Diluted earnings per share amounts are calculated by dividing the net profit (loss) attributable to ordinary equity holder of the parent company by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all warrants. The net profit (loss) for the year used for the basic and diluted earnings per share are reconciled as follows: For the year ended December 31 in 000€ 2019 2018 2017* Net profit attributable to ordinary equity holders of the parent for basic earnings 1,646 3,027 (2,117) Interest on convertible bonds 50 50 − Net profit attributable to ordinary equity holders of the parent adjusted for the effect of dilution 1,696 3,077 (2,117) The convertible bond and the warrants are dilutive as per December 31, 2019 and 2018 but are anti-dilutive as per December 31, 2017 . We refer to Notes 14 and 15 for information on the number of instruments that could potentially be dilutive but which were not considered in the calculation above. The following reflects the share data used in the basic and diluted earnings per share computations: For the year ended December 31 in 000 2019 2018 2017 Weighted average number of ordinary shares for basic earnings per share 52,915 49,806 47,325 Effect of dilution: Share options 563 382 − Convertible loan 509 509 − Weighted average number of ordinary shares adjusted for effect of dilution 53,987 50,697 47,325 The earnings per share are as follows: For the year ended December 31 2019 2018 2017* Earnings per share attributable to the owners of the parent Basic 0.03 0.06 (0.04) Diluted 0.03 0.06 (0.04)

Commitments and contingent liab

Commitments and contingent liabilities	12 Months Ended
	Dec. 31, 2019
Capital commitments [abstract]
Disclosure of commitments [text block]	24 Commitments and contingent liabilities Operating lease commitments The Group has operating lease commitments mainly related to cars and equipment as follows: As of December 31, in 000€ 2019 2018 2017 Within one year 28 2,053 1,721 Between one and three years 49 2,302 1,504 Between four and five years − 785 406 More than five years − 302 77 Total 77 5,442 3,708 The total lease payments recognized in the consolidated income statement are K€725 in 2019 ( 2018 : K€2,956 ; 2017 : K€2,909 ). Finance lease commitments (only valid for 2017 and 2018) The Group has finance leases for the building and various other items of plant and equipment. Future minimum lease payments under finance lease with the present value of the net minimum lease payments are as follows: December 31, 2019 December 31, 2018 December 31, 2017 in 000€ Minimum lease payments Present value of payments Minimum lease payments Present value of payments Minimum lease payments Present value of payments Within one year − − 2,876 2,829 3,179 3,034 Between two and three years − − 3,398 3,236 5,017 4,643 Between four and five years − − 655 604 1,361 1,269 More than five years − − 149 140 285 218 Total − − 7,078 6,809 9,842 9,164 Less finance charges − − (269) − (678) − Present value of minimum lease payments − − 6,809 6,809 9,164 9,164 Mortgages and pledges The Group has several loans secured by a mortgage on the building. The carrying value of related property, plant & equipment (including buildings under construction) is K€29,154 ( 2018 : K€30,853 ; 2017 : K€28,526 ). The total outstanding mortgages and pledges are K€77,849 in 2019 ( 2018 : K€124,428 ; 2017 : K€85,186 ). Included in the above, the Group also has pledges on the business goodwill ("fonds de commerce") of the Company for a total amount of K€36,992 in 2019 ( 2018 : K€70,300 ; 2017 : K€29,000 ) and pledges on other fixed assets for a total amount of K€3,301 ( 2018 : K€21,142 ; 2017 : K€6,383 ). Other commitments The Group has outstanding non-cancellable contracts with a future commitment of K€11,640 at December 31, 2019 ( 2018 : K€6,383 ; 2017 : K€7,638 ), mainly related to purchase commitment for raw materials. For property, plant & equipment, we have no committed expenditures as per December 31, 2019 ( 2018 : K€0 ; 2017 : K€672 ). Contingent liabilities The Group is currently involved in a legal proceeding with Dentsply Implants NV regarding the alleged wrongful termination of a supply agreement between the Company and Dentsply Implants NV entered into in 2010. Th e court of first instance ruled in favor of Dentsply Implants NV, that we have wrongfully terminated the relationship. We have appealed this decision before the court has pronounced itself on the monetary damages. The amount of damages which Dentsply Implants NV is claiming is K€2,700 . While we are confident that the first instance decision will be overruled, we believe that, in the event that the first instance decision would be confirmed, the amount of monetary dama ges that we would be exposed to w ill not have a material impact o n our business, financial conditions or result of operations. We are currently not a party to, and we are not aware of any threat of, any other legal proceedings, which, in the opinion of our management, is likely to have or could reasonably possibly have a material adverse effect on our business, financial condition or results of operations. As a result management concluded that no provision is required.

Risks

Risks	12 Months Ended
	Dec. 31, 2019
Risks [abstract]
Disclosure of financial risk management [text block]	2 5 Risks The Group is mainly exposed to liquidity risk, interest rate risk and credit risk . Foreign exchange risk The Group transact business globally and are subject to risks associated with fluctuating foreign exchange rates. The geographic areas outside of the Eurozone to which it sells their products and services are generally not considered to be highly inflationary. In the years ended December 31, 2019 , 2018 and 2017 , 29% , 30% and 31% of our revenue, respectively, were derived from sales in a currency different from the euro. Receivables denominated in a foreign currency are initially recorded at the exchange rate at the transaction date and subsequently re-measured in euro based on period-end exchange rates. Transaction gains and losses that arise from exchange rate fluctuations are charged to income. The Group has primarily exposure to the USD, GBP , BRL and JPY as foreign currency. During 2019 the impact of changes in foreign currency rates on the cash and term accounts held in USD funded through the initial public offering proceeds was positive for an amount of K€553 . If the USD (rate for 1 EUR) would have appreciated by 10% , the net result would have been K€895 higher, excluding the effect of the cash and term accounts held in USD. If the USD (rate for 1 EUR) would have depreciated by 10% , the net result would have been K€780 lower, excluding the effect of the cash and term accounts held in USD. To limit the exposure to foreign currency rate fluctuations on GBP and JPY, the Group has entered int o currency rate swaps as of 2017 . We refer to note 20. Liquidity risk The liquidity risk is that the Group may not have sufficient cash to meet its payment obligations. This risk is countered by day-by-day liquidity management at the corporate level. The Group has historically entered into financing and lease agreements with financial institutions to finance significant projects and certain working capital requirements. Th e Group has no longer undrawn lines of credit at December 31, 2019 ( 2018 : K€26,040 ; 2017 : K€4,473 ). On September 29, 2017 KBC Bank and Materialise agreed on a credit facility, mainly related to the financing of the ACTech acquisition, in which debt covenants were determined based on the ratio of the Group’s total net financial debt over EBITDA. On December 20, 2017, the European Investment Bank (EIB) and Materialise entered into a finance contract to support Materialise’s ongoing research and development programs for growth from 2017 to 2020. The contract provides a credit of up to €35.0 million drawable in two tranches. The first tranche could not exceed €25.0 million and could be drawn during the first year of the contract. The Group actually has drawn €10.0 million of this first tranche in the course of 2018. The second tranche of €25.0 million was drawn in July 2019. The duration of the loan will be between six to eight years starting from the disbursement of the respective tranches, and includes a two-year loan reimbursement grace period. Loans under the contract will be made at a fixed rate, based on the Euribor rate at the time of the borrowing , plus a variable margin. The interest rate for the first tranche is initially equal to 2.4% . The interest rate for the second tranche is initially 2.72% and varies in function of certain EBITDA levels and debt ratios. The contract contains customary security, covenants and undertakings. The range of contracted obligations are as follows: in 000€ Less than 1 year 2 to 3 years 4-5 years More than 5 years Total At December 31, 2019 Loan & borrowings 14,300 33,034 41,672 34,447 123,453 Lease liabilities 3,685 4,907 1,040 720 10,352 Trade payables 18,517 − − − 18,517 Other current liabilities and advances received 4,063 − − − 4,063 Total 40,565 37,941 42,712 35,167 156,385 Less than 1 year 2 to 3 years 4-5 years More than 5 years Total At December 31, 2018 Loan & borrowings 14,491 42,100 33,636 23,870 114,097 Trade payables 18,667 − − − 18,667 Other current liabilities 2,267 − − − 2,267 Total 35,425 42,100 33,636 23,870 135,031 Less than 1 year 2 to 3 years 4-5 years More than 5 years Total At December 31, 2017* Loan & borrowings 14,331 37,933 22,286 32,699 107,249 Trade payables 15,670 − − − 15,670 Other current liabilities 1,390 − − − 1,390 Total 31,391 37,933 22,286 32,699 124,309 Interest rate risk Although the Group mainly has loans outstanding with a fixed interest rate, some of the loans have been contracted with variable interest rates. The most significant loans with variable interest rates have been secured by means of a variable to fixed interest rate swap. We therefore believe that the Group is not subject to immediate changes in interest rates. With respect to the interest rate swaps, we refer to note 20. Credit risk Credit risk is the risk that third parties may not meet their contractual obligations resulting in a loss for the Group. The Group is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, which are mainly deposits with financial institutions. The Group limits this exposure by contracting with credit-worthy business partners or with financial institutions which meet high credit rating requirements. In addition, the portfolio of receivables is monitored on a continuous basis. Trade receivables and contracts in progress Customer credit risk is managed by each business unit subje c t to the Group’s established policy, procedures and control s relating to customer credit risk management. An impairment analysis is performed at each reporting date per company and using a provision matrix per company to measure expected credit losses. The provision rates are based on days past due for groupings of various customer segments with similar loss patterns (i.e., by legal entity). The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Generally, trade receivables are written-off if past due for more than one year and are not subject to enforcement activity. The maximum exposure to credit risk at the reporting date is the carrying value of each class of financial assets at amortized cost or fair value through OCI as disclosed in Note 20 . The Group does not hold collateral as security. The Group evaluates the concentration of risk with respect to trade receivables as low, as its customers are located in several jurisdictions and industries and operate in largely independent markets. Set out below is the information about the credit risk exposure on the Group’s trade receivables using a provision matrix: in 000€ Total Non-due Less than 30 days 31-60 days 61-90 days 91-180 days More than 181 days December 31, 2019 40,977 31,528 4,924 2,094 733 981 717 December 31, 2018 36,891 26,208 5,395 1,479 931 1,512 1,366 December 31, 2017 35,582 21,630 6,920 1,765 1,526 1,614 2,127 Capital management The primary objective of the Group’s shareholders’ capital management strategy is to ensure it maintains healthy capital ratios to support its business and maximize shareholder value. Capital is defined as the Group shareholder’s equity. The Group consistently reviews its capital structure and makes adjustments in light of changing economic conditions. The Group made no changes to its capital management objectives, policies or processes during the years ended December 31, 2019 , 2018 and 2017 .

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2019
Related party transactions [abstract]
Disclosure of related party [text block]	2 6 Related party transactions The compensation of key management personnel of the Group is as follows: For the year ended December 31 in 000€ 2019 2018 2017 Short-term employee benefits 2,394 2,334 2,190 Post-employment benefits 85 80 80 Total 2,479 2,414 2,270 Warrants granted − − − Warrants outstanding 359,266 557,935 573,980 The amounts disclosed in the table are the amounts recognized as an expense during the reporting period related to key management personnel (senior management and executive committee members). In the year ending December 31, 2019 the compensation to key management by means of share based payments amounts to K€214 . The following table provides the total amount of transactions that have been entered into with related parties for the relevant financial year: in 000€ Sale of goods to Purchases from Depreciation Interest expense Right-of-Use Assets Receivables Lease liabilities Other liabilities Non-executive directors of the group 2019 − 128 − 37 − − − 1,053 2018 − 123 − 51 − − − 1,038 2017 − 96 − 50 − − − 965 Shareholders of the group 2019 − 113 − 9 − − − 131 2018 − 123 − 10 − − − 261 2017 − 172 − 11 − − − 371 Joint ventures 2019 1,431 − − − − 1,279 − − 2018 1,156 241 − − − 1,281 − 22 2017 714 23 − − − 804 − 28 Non-controlling interests 2019 − − 26 9 617 − 652 − 2018 − − − − − − − − 2017 − − − − − − − − Related party - Ailanthus NV Ailanthus is a shareholder and director of the group. The Group rent apartments on a regular basis from Ailanthus NV in order to host our employees from foreign subsidiaries who are visiting our headquarters in Leuven. The total amount paid to Ailanthus NV for rent in 2019 was K€113 ( 2018 : K€123 ; 2017 : K€172 ). Related party - shareholders of Engimplan (non-controlling interest) The subsidiary Engimplan rents the office and production building from its non-controlling shareholders for a initial term of 10 years, with an extension option for an additional 10 years (assessed not to be reasonable certain to be exercised). The monthly lease payment amount to K€7 . The lease has been accounted for under IFRS 16 resulting in a lease liability at December 31, 2019 of K€617 . Related party - Convertible debt The Group has issued on October 28, 2013 1,000 convertible bonds for a total amount of K€1,000 . The bonds have been fully subscribed by a member of our senior management. We refer to Note 15 for more details. Joint ventures The rece ivable for the amount of K€1,279 is accounted for under the other non-current assets and trade receivables and relates to the services and goods delivered to the joint venture RSPRINT. In the course of 2018 the Group also purchased a 3D printer from RSPRINT for the amount of K€200 .

Events subsequent to the statem

Events subsequent to the statement of financial position date	12 Months Ended
	Dec. 31, 2019
Disclosure of non-adjusting events after reporting period [abstract]
Disclosure of events after reporting period [text block]	27 Events subsequent to the statement of financial position date Impact of coronavirus The outbreak of a novel coronavirus, was first identified in December 2019 in Wuhan, China, and has since spread globally. In response to the pandemic, governments worldwide have closed business, restricted travel and implemented emergency quarantines , and businesses and individuals have reduced travel, cancelled meetings and events and implemented of work- from -home policies, which have caused significant disruption to the global economy and normal business operations. The coronavirus public health crisis is expected to have broader macroeconomic implications, including a decrease in or halt to economic growth, the effects of which could be long lasting . In an effort to protect the health and safety of employees, we, and many of our customers, partners, suppliers and other counterparties, currently require that employees work from home and restrict travel as much as possible, which affects, amongst other things, their ability to attend industry events and to engage in commercial visits. In the event we or our customers, partners, suppliers and other counterparties maintain or expand these restrictions , we may suffer disruptions to business operations including the closure of manufacturing facilities, warehouses and logistics supply chains worldwide. Furthermore, t he coronavirus and the responses thereto could have a range of other effects on us. For example, the implementation of busi ness continuity plans in a fast- moving public health emergency could have an adverse effect on our internal controls (potentially giving rise to significant deficiencies or material weaknesses) and increase our vulnerability to information technology and other systems disruptions. As of April 30, 2020, we are unable to predict the duration and severity o f the spread of the coronavirus and the political and economic responses thereto and a s a result, we are unable to assess with certainty its impact on our business and operations, results of operations, financial condition, cash flow s and liquidity . The coronavirus and related responses are developing rapidly , making their impact highly uncertain , and are subject to many factors beyond our control, such as the speed of contagion, the implementation of effective preventative and contai nment measures, the development of effective medical solutions, the timing and scope of governmental restrictions on public gatherings, mobility and other activities, financial and other market reactions, and reactions and responses of the public . While we expect we will suffer adverse effects, the more severe the outbreak is and the longer it lasts, the effects on us and our business will be more materially adverse. Based on our current assessment of the COVID -19 pandemic, we have considered various hypothetical scenarios on how our business, results of operations, and financial condition could be impacted during the year 2020. In these scenarios we take the general view, but without any certainty as we are reviewing the situation constantly, that our business will be impacted very significantly in the second quarter of 2020, and will subsequently continue to be weak for the rest of the year, although that our current assessment of the situation is that our business may gradually improve during the remainder of 2020. However, in the current situation, in view of the many uncertainties of this unprecedented crisis, we find it very hard to gain any visibility beyond the second quarter. The Materialise software segment, represented 24% of the total sales exiting 2019 a nd had an Adjusted EBITDA margin of 33.2% in 2019 . We believe that an important part of the software sales of our Materialise software segment are, at least temporarily, at risk. A significant portion of the sales of this segment comes from parties that either sell or use 3D printing systems. The weakness of the 3D printing industry in general is expected to weigh very negatively on 3D printing system sales and thus also on our software sales, definite ly in the second quarter of 2020 with a possible extens ion into the second half of 2020 . The Materialise m edica l segment, which represented 34% of the total sales exiting 2019 a nd had an Adjusted EBITDA margin of 17.7% in 2019 , designs, produces and sells customized implants, surgical guides and models as well as visualization and planning software to research institutes, universities, medical device companies and hospitals. A significant percentage of this segment’s revenue stems, directly or indirectly, from elective surgeries, almost all of which are now being postponed due to the U.S. Centers for Disease Control and Prevention , or CDC , guidelines, which require hospitals to prioritize preparation for and response to the pandemic . As a result, these revenues (and at least the timing thereof) become uncertain, which will result in a significant reduction of sales of our Materialise medical segment, definite ly in the second quarter of 2020 , and possibly in the next quarters as well, depending on how the pandemic evolves. The remaining 42% of the total sales exiting 2019 comes from the Materialise m anufacturing segment, which operates as part of the overall manufacturing sector in Europe, which includes subsectors such as automotive, aviation, machine parts and consumer products, all of whi ch are heavily impacted by the c orona virus crisis. The European automotive market was particularly weak before the COVID -19 outbreak, and we now expect an even slower recovery than previously estimated . Other European industrial subsectors are not faring much better in this market and will likely face larger declines than previously expected. Order intake within the Materialise m anufacturing segment has been slowing down, which will significantly impact the segment’s second quarter results and which may impact the results beyond this quarter, as a function of how the crisis develops in general and how the industry as a whole, and our customers in particular, subsequently recover from the situation. We also expect an increase of bad debt, delay in trade payments, and that we will not be able to adjust and align all of our costs according to the expected decrease of revenue. We experienced the first negative effects of this crisis on our reven ues in the first quarter of 2020 . In these analyses, we considered a major negative impact in the second quarter, and only a gradual and partial recovery in the third and fourth quarter of this year. From these analyses, we conclude that (according to the currently most likely scenarios), the going concern principle should be maintained, and that the principle covenants of our credit facilities (at EIB and KBC), ‘minimum cash’ and ‘Net Debt / Adjusted EBITDA’, will not be violated. We believe that the expected situation does not impact the current valuation of our inventories, investments, intangible assets (including goodwill), long-lived assets, or our debt. While we continue to monitor the situation regularly, we believe that eventually the 3D printing industry will recover and may even come out of this crisis stronger, as the crisis appears to be underscoring certain advantages of the 3D printing technology, in particular its flexibility in terms of part design, speed, production of smaller strategic batches and localization. Therefore, while we try to adjust our costs and capital spending in proportion to the short term reduction of our revenues, we currently take the view that these cost and spending reductions should, where possible, be as moderate and temporary as possible, since we believe that continued innovation during the current crisis may give us a competitive advantage going forward. This strategy involves significant risks , including risks in terms of its impact on our cash position , and as the crisis lasts longer, we may no t be able to sustain this strategy and it might have negative implications for our long term competitive position . Warrant exercises In c onnection with the exercise of 21,750 warrants, representing 21,750 shares, from the 201 5 warrant plan in the course of March 2020 , the share capital was raised for the amount of K€1 and the share premium was raised for the amount of K€140 by deed before the notary on April 16 , 2020 (we refer to Note 14 for further information about the share based payment plans). As per April 16, 2020 t he funds received in connection with the exercise of the warrants ( K€140 ) were accounted for on a restricted bank account cla ssified under the Cash and Cash Equiv alents . There are no other significant events subsequent to the statement of financial position date that would require adjustments or disclosures to the financial statements.

Overview of consolidated entiti

Overview of consolidated entities	12 Months Ended
	Dec. 31, 2019
Overview of consolidated entites [abstract]
Disclosure of interests in subsidiaries [text block]	28 Overview of consolidated entities Name Country of incorporation % equity interest 2019 2018 2017 Materialise NV Belgium 100% 100% 100% Materialise France SAS France 100% 100% 100% Materialise GmbH Germany 100% 100% 100% Materialise Japan K.K. Japan 100% 100% 100% Materialise Czech Republic SRO Czech Republic 100% 100% 100% Materialise USA, LLC United States 99% 99% 99% Materialise UK Limited United Kingdom 100% 100% 100% OBL SAS France 100% 100% 100% Materialise Austria GmbH Austria 100% 100% 100% Materialise Malaysia SDN. Bhd. Malaysia 100% 100% 100% Materialise Ukraine LLC Ukraine 100% 100% 100% RapidFit NV Belgium 83% 83% 83% Meridian Technique Limited United Kingdom 100% 100% 100% OrthoView Holdings Limited United Kingdom 100% 100% 100% Meridian (Corporate Trustee) Limited (liquidated) United Kingdom — — 100% OrthoView Limited (liquidated) United Kingdom — — 100% Materialise SA Poland 100% 100% 100% Materialise Colombia SAS Colombia 100% 100% 100% RSPRINT powered by Materialise NV (joint venture) Belgium 50% 50% 50% Materialise Shanghai Co.Ltd China 100% 100% 100% Engimplan Engenharia de Implante Industria & Comércio Ltda Brazil 75% — — Engimplan Holding Ltda Brazil 100% — — Materialise Australia PTY Ltd Australia 100% 100% 100% Materialise S.R.L. Italy 100% 100% 100% ACTech GmbH Germany 100% 100% 100% ACTech Holding GmbH Germany 100% 100% 100% ACTech, Inc United States 100% 100% 100%

Non GAAP measures

Non GAAP measures	12 Months Ended
	Dec. 31, 2019
Disclosure of non GAAP measures [abstract]
Disclosure of non GAAP measures [text block]	29 Non-GAAP Measures EBITDA and Adjusted EBITDA is used in the Note 21 Segments as one of the basis of the Segments performance measurement. We calculate EBITDA as net profit plus income taxes, financial expenses (less financial income), depreciation and amortization, and share in loss of joint venture. We calculate Adjusted EBITDA by adding non-recurring initial public offering related expenses, non-cash share -based compensation expenses and acquisition-related expenses of business combinations to EBITDA.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2019
Summary of significant accounting policies [abstract]
Disclosure of basis of consolidation [text block]	Basis for consolidation The consolidated financial statements comprise the financial statements of the Group and its subsidiaries. Entities are fully consolidated from the date of acquisition, which is the date when the Group obtains control, and continue to be consolidated until the date when such control ceases. The financial statements of the entities are prepared for the same reporting period as the parent company, using consistent accounting policies. All intra-Group balances, transactions, unrealized gains and losses resulting from intra-Group transactions and dividends are fully eliminated. The Group attributes profit or loss and each component of other comprehensive income to the owners of the parent company and to the non-controlling interest based on present ownership interests, even if the results in the non-controlling interest have a negative balance. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over the subsidiary, it will derecognize the assets (including goodwill) and liabilities of the subsidiary, any non-controlling interest and the other components of equity related to the subsidiary. Any surplus or deficit arising from the loss of control is recognized in profit or loss. If the Group retains an interest in the previous subsidiary, then such interest is measured at fair value at the date the control is lost. The proportion allocated to the parent and non-controlling interests in preparing the consolidated financial statements is determined based solely on present ownership interests. In 2019, Engimplan entered into the consolidated scope - see note 28.
Description of accounting policy for transactions with non-controlling interests [text block]	Non-controlling interests The Group has the choice, on a transaction by transaction basis, to initially recognize any non-controlling interest in the acquiree which is a present ownership interest and entitles its holders to a proportionate share of the entity’s net assets in the event of liquidation at either acquisition date fair value or, at the present ownership instruments’ proportionate share in the recognized amounts of the acquiree’s identifiable net assets. Other components of non-controlling interest such as outstanding share options are generally measured at fair value. The Group has not elected to take the option to use fair value in acquisitions completed to date. Currently the only non-controlling interest resulting from business combinations coming from Engimplan.
Description of accounting policy for foreign currency translation [text block]	Foreign currency translation The Group’s consolidated financial statements are presented in euros, which is also the parent company’s functional currency. For each entity, the Group determines the functional currency, and items included in the financial statements of each entity are measured using the functional currency. Financial statements of foreign subsidiaries Foreign subsidiaries use the local currencies of the country where they operate. The statement of financial position is translated into euro at the closing rate on the reporting date and their income statement is translated at the average exchange rate at each month-end. Differences resulting from the translation of the financial statements of said subsidiaries are recognized in other comprehensive income as "exchange differences on translation of foreign operations". Foreign currency transactions Transactions denominated in foreign currencies are translated into euro at the exchange rate at the end of the previous month-end. Monetary items in the statement of financial position are translated at the closing rate at each reporting date and the relevant translation adjustments are recognized in financial or operating result depending on its nature.
Description of accounting policy for business combinations and goodwill [text block]	Business combinations and goodwill Business combinations are accounted for using the acquisition method at the acquisition date, which is the date at which the Group obtains control over the entity. The cost of an acquisition is measured as the amount of the consideration transferred to the seller, measured at the acquisition date fair value, and the amount of any non-controlling interest in the acquiree. The Group measures goodwill initially at cost at the acquisition date, being: the fair value of the consideration transferred to the seller, plus the amount of any non-controlling interest in the acquiree, plus if the business combination is achieved in stages, the fair value of the existing equity interest in the acquiree re-measured at the acquisition date, less the fair value of the net identifiable assets acquired and assumed liabilities Goodwill is recognized as an intangible asset with any impairment in carrying value being charged to the consolidated income statement. Where the fair value of identifiable assets, liabilities and contingent liabilities exceed the fair value of consideration paid, the excess is credited in full to the consolidated income statement on acquisition date. Acquisition costs incurred are expensed and included in general and administrative expenses. Any contingent consideration to be transferred by the acquirer will be recognized at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration, which is deemed to be an asset or liability, will be recognized either as a profit or loss or as a change to other comprehensive income. If the contingent consideration is classified as equity, it should not be re-measured until it is finally settled within equity. Acquisition of non-controlling interests are accounted for as an equity transaction.
Description of accounting policy for investments in joint ventures [text block]	Investments in joint ventures The Group carries investment in a joint venture (RS Print NV). The Group’s investments in its joint venture is accounted for using the equity method. Under the equity method, the investment in the joint venture was initially recognized at cost. The carrying amount of the investment is adjusted to recognize changes in the Group’s share of net assets of the joint venture since the acquisition date. Goodwill relating to the joint venture is included in the carrying amount of the investment and is not tested for impairment individually. The income statement reflects the Group’s share of the results of operations of the joint venture. Any change in other comprehensive income of the joint venture is presented as part of the Group’s other comprehensive income. In addition, when there has been a change recognized directly in the equity of the joint venture, the Group recognizes its share of the change in the statement of changes in equity. Unrealized gains and losses resulting from transactions between the Group and the joint venture are eliminated to the extent of the interest in the joint venture. After application of the equity method, the Group determines whether it is necessary to recognize an impairment loss on its investment in its joint venture. At each reporting date, the Group determines whether there is objective evidence that the investment in the joint venture is impaired. If there is such evidence, the Group calculates the amount of impairment as the difference between the recoverable amount of the Group’s interest in the joint venture (higher of value in use and fair value less costs to sell), and then recognizes the loss as ‘Share of profit or loss of joint ventures’ in the income statement.
Description of accounting policy for property, plant and equipment [text block]	Property, plant & equipment Property, plant and equipment is stated at cost, net of accumulated depreciation and/or accumulated impairment losses, if any. Such cost includes borrowing costs directly attributable to construction projects if the asset necessarily takes a substantial period of time to get ready for its intended use, it is probable that they will result in future economic benefits to the group and the cost can be measured reliably. When significant parts of property, plant and equipment are required to be replaced at intervals, the Group recognizes such parts as individual assets with specific useful lives and depreciates them accordingly. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the property, plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognized in the income statement as incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows: Buildings: 20-30 years Machinery: 5-12 years IT assets: 3-5 years Fixtures & Furniture: 10-15 years Vehicles: 2-4 years Leasehold Building Improvements: 10 years Land is not depreciated. An item of property, plant and equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the income statement when the asset is derecognized. The assets’ residual values, useful lives and methods of depreciation are reviewed at each financial year-end and adjusted prospectively, if appropriate.
Description of accounting policy for leases [text block]	Right-of-use assets and related liabilities Right-of-use assets: The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the short er of its estimated useful life and the lease term: Property leased Assets: Lease terms up to 10 years or useful life of 10 - 15 years when reasonable certain ownership will be obtained at the end of the lease Leased machines: Lease terms up to 10 years or useful life of 5 - 10 years when reasonable certain ownership will be obtained at the end of the lease Leased vehicles: Lease terms up to 4 years or useful life of 4 years when reasonable certain ownership will be obtained at the end of the lease Right-of-use assets are subject to impairment. Lease liabilities: At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Short-term leases and leases of low-value assets: The Company applies the short-term lease recognition exemption to its short-term leases of machinery and equipment (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option) however this exemption is not applied for property leases . It also applies the lease of low-value assets recognition exemption to leases of office equipment that are consid ered of low value (i.e., below k€ 5). Lease payments on short-term leases and low-value assets are recognized in the income statement when incurred.
Description of accounting policy for borrowing costs [text block]	Borrowing costs Borrowing costs directly attributable to the acquisition, construction or production of a qualified asset that necessarily takes a substantial period of time to prepare for its intended use or sale are capitalized as part of the cost of the respective assets. All other borrowing costs are expensed in the period they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.
Description of accounting policy for research and development expense [text block]	Research and development Research and development includes the costs incurred by activities related to the development of software solutions (new products, updates and enhancements), guides and other products. Development activities involve the application of research findings or other knowledge to a plan or a design of new or substantially improved (software) products before the start of the commercial use. Development expenditures on an individual project are recognized as an intangible asset when the Group can demonstrate: the technical feasibility of completing the intangible asset so that the asset will be available for use or sale; its intention to complete and its ability to use or sell the asset; how the asset will generate future economic benefits; the availability of resources to complete the asset; and the ability to measure reliably the expenditure during development. The Group has determined that the conditions for recognizing internally generated intangible assets from proprietary software, guide and other product development activities are not met until shortly before the products are available for sale, unless either (i) the Group has strong evidence that the above criteria are met and a detailed business plan is available showing the asset will on a reasonable basis generate future economic benefits or (ii) the development is done based upon specific request of the customer, it is highly likely that the Group will be able to market the product also to other parties than the customer, the development is subject to an agreement and the substance of the agreement is that the customer reimburses the Group for a significant portion , but not all, of the development expenses incurred. As such, development expenditures not satisfying the above criteria and expenditures on the research phase of internal projects are recognized in the consolidated income statement as incurred. Internally generated intangible assets from proprietary software are amortized over their useful l ives, starting from the moment they are ready for use/available for sale . Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete and the asset is available for use. It is amortised over the period of expected future benefit , which is determined on a project-by-project basis . Amortisat ion is recorded in cost of sales. During the period of development, the asset is tested for impairment at least annually or whenever there is an indication of impairment.
Description of accounting policy for intangible assets other than goodwill [text block]	Intangible assets other than goodwill and capitalized development expenditures Intangible assets comprise acquired technology and customer portfolio, patents and licenses and technology and customers acquired in connection with business combinations. Those intangible assets are measured on initial recognition at cost, except for the acquired technology and customers arising from business combinations, which are measured initially at fair value. Following initial recognition, intangible assets other than goodwill are carried at cost less any accumulated amortization and accumulated impairment losses, if any. The useful life of the intangible assets is as follows: Software: 3 years; Patents and licenses: 10 years; Acquired customers and Technology: 5-20 years; Order Backlog: Period over which orders will be completed. The intangible assets with finite lives are amortized over their useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. The amortization expense on intangible assets with finite lives acquired through business combination is recognized in the consolidated income statement in the line " net other operating income ".
Description of accounting policy for impairment of non-financial assets [text block]	Impairment of goodwill and other non-financial assets (excluding inventories and deferred tax assets) Impairment tests on goodwill and other intangible assets with indefinite useful economic lives, assets under construction or capitalized development expenses which are not amortized yet, are undertaken annually at the financial year end. Other non-financial assets and goodwill are subject to impairment tests whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Where the carrying value of an asset exceeds its recoverable amount (i.e. the higher of value in use and fair value less costs to sell), the asset is written down accordingly. Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the smallest Group of assets to which it belongs for which there are separately identifiable cash flows: its cash generating units (CGUs). Goodwill is allocated on initial recognition to each of the Group’s CGUs that are expected to benefit from the synergies of the combination giving rise to the goodwill. The Group bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Group’s CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. For longer periods, a long-term growth rate is calculated and applied to future cash flows projected after the fifth year. Impairment charges are included in profit or loss, except, where applicable, to the extent they reverse gains previously recognized in other comprehensive income. An impairment loss recognized for goodwill is not reversed. Where goodwill forms part of a cash-generating unit and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal of the operation. Goodwill disposed of in this circumstance is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained.
Description of accounting policy for inventory and contract in progress [text block]	Inventories and Contracts in progress Inventories are valued at the lower of cost and net realizable value. Costs incurred in bringing each product to its present location and condition are accounted for as follows: Raw materials: purchase cost on a first in, first out basis; and Finished goods and work in progress: cost of direct materials and labor and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs . Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. A write-off of inventories is estimated based on an ageing or rotation analysis. Work in progress relates to production of inventory for which a customer has not yet been secured, while contracts in progress are contract assets that relate to production for specific customers in performance of a signed contract. We refer also to the accounting policy on revenue recognition.
Description of accounting policy for financial assets [text block]	Financial assets Financial assets are classified at initial recognition, and subsequently measured at amortised cost, fair value through other comprehensive income (OCI), and fair value through profit or loss. The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Group’s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient, the Group initially measures a financial asset at its fair value plus transaction costs, i n the case of a financial asset not at fair value through profit or loss or OCI . Trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient are measured at the transaction price. For purposes of subsequent measurement, fin ancial assets are classified in four categories: Financial assets at amortise d cost; Financial assets at fair value through OCI with recycling of cumulative gains and losses (debt instruments) ; Financial assets designated at fair value through OCI with no recycling of cumulative gains and losses upon derecognition (equity instruments) ; and Financial assets at fair value through profit or loss . Financial assets measured at amortized cost This category is the most relevant to the Group. The Group measures financial assets at amortised cost if both of the following conditions are met: The financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows ; and The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding . Financial assets , trade and other receivables, cash and cash equivalents at amortised cost are subsequently measured using the effective interest rate (EIR) method and are subject to impairment. Gains and losses are recognised in profit or loss when the asset is derecognised, modified or impaired. Financial assets at fair value through OCI with recycling of cumulative gains and losses (debt instruments) The Group currently does not have financial assets at fair value through OCI with recycling of cumulative gains and losses. Financial assets designated at fair value through OCI with no recycling of cumulative gains and losses upon derecognition (equity instruments) The Group has irrevocably elected at initial recognition to classify the minority interest in the non-listed equity investment Essentium Inc, as disclosed in Note 10 and Note 20, as a financial asset designated at fair value through OCI as this measurement is most representative of the business model for this asset. Gain and losses on these financial assets are never recycled to profit and loss. Dividends are recognised as other operational income in the consolidated income statement when the right of payment has been established, except when the Group benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment. Financial assets measured at fair value through profit or loss The Group does have the following financial assets classified as financial assets at fair value through profit or loss : a call option on non -controlling interests in RapidF it+ as disclosed in Note 13; derivatives, a convertible loan granted to a company as disclosed in Note 10;. Those financial assets are carried in the statement of financial position at fair value with changes recognized in the income statement in the lines financial income/expense. Derecognition A financial asset is derecognized when: The rights to receive cash flows from the asset have expired, or The Group has transferred its rights to receive cash flows from the assets. Impairment of financial assets Further disclosures relating to impairment of financial assets are also provided in Note 3 Significant accounting judgments, estimates and assumptions. The Group recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. A loss allowance is recognized at each reporting date based on lifetime ECLs. The Group established a provision matrix that is based on its historical loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. For all other receivables, ECLs are based on the differ ence between the contractual cas h flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms. ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).
Description of accounting policy for financial liabilities [text block]	Financial liabilities All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Group’s financial liabilities include trade and other payables, loans and borro wings including bank overdrafts and derivative financial instruments including written put options over non-controlling interests. Financial liabilities at amortized cost The trade and other payables, and loans and borrowings are classified as financial liabilities at amortized cost. Those financial liabilities are measured at amortized cost using the effective interest rate method. Gains and losses are recognized in the income statement when the liabilities are derecognized as well as through the effective interest rate method amortization process. Financial liabilities at fair value through profit and loss The derivative financial instruments are classified as financial liabilities at fair value through profit and loss except for the written put options on non-controlling interests which is disclosed below. Written put options on non-controlling interest The Group recognizes a financial liability for the written put options on non-controlling interest. The written put options have a variable redemption price based on a formula as specified in the contract (see Note 13 ). The financial liability is initially recognized at fair value and the fair value is reclassified from non-controlling interest and, for any amount higher than the non-controlling interest, from consolidated reserves. The fair value is determined as the present value of the redemption amount. Any change in the fair value as a result of a change in the estimated redemption price is recognized directly in consolidated reserves. Any unwinding effect of the present value of the redemption price is recognized directly in profit and loss (financial cost). No share of profit is allocated to the non-controlling interest. Upon exercise of the written put option, the carrying value will be offset with the cash payment received. When the written put option is not exercised, the carrying value of the financial liability is derecognized against non-controlling interest with the difference going to consolidated reserves. Compound financial instruments The Group has issued convertible debt which is accounted for as a compound financial instrument. For those instruments, the Group determines the carrying amount of the liability component by measuring the fair value of a similar liability (including any embedded non-equity derivative features) that does not have an associated equity component. The carrying amount of the equity instrument is then determined by deducting the fair value of the financial liability from the fair value of the compound financial instrument as a whole. Derecognition A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. Offsetting Financial assets and financial liabilities are offset and the net amount is reported in the consolidated statement of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the assets and settle the liabilities simultaneously.
Description of accounting policy for issued capital [text block]	Share capital Financial instruments issued by the Group are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Group’s ordinary shares are classified as equity instruments.
Description of accounting policy for provisions [text block]	Provisions Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.
Description of accounting policy for employee benefits [text block]	Pensions benefits The Group has a defined contribution obligation where the Group pays contributions based on salaries to an insurance company, in accordance with the laws and agreements in each country. The Belgian defined contribution pension plans are by law with variable minimum returns based on the Belgian government bonds, with a minimum of 1.75% and a maximum of 3.75% , effective for contributions paid as from 2016. For contribution paid until 2015, the minimum guaranteed return is 3.25% on employer contributions and 3.75% on employee contributions. These plans qualify as defined benefit plans. Contributions are recognized as expenses for the period in which employees perform the corresponding services. Outstanding payments at the end of the period are shown as other current liabilities. Those plans are accounted for as a defined benefit plan however are considered not material.
Description of accounting policy for share-based payment transactions [text block]	Share based payments Directors and employees (including senior executives) of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments (equity-settled transactions). The Group currently has only warrants and share-appreciation rights as share-based payments. Equity-settled transactions Equity-settled share-based payments to employees and others providing similar services are measured, indirectly, at the fair value of the equity instruments granted. The cost of equity-settled transactions is recognized, together with a corresponding increase in other capital reserves in equity, over the period in which the performance and/or service conditions are fulfilled. The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group’s best estimate of the number of equity instruments that will ultimately vest. The income statement expense or credit for a period represents the movement in cumulative expense recognized at the beginning and end of that period and is recognized as employee benefits expense. The Group does currently only have equity-settled share-based payments that have service-based vesting conditions and no instruments with market vesting conditions. No expense is recognized for awards that do not ultimately vest. When the terms of an equity-settled award are modified, the minimum expense recognized is the expense as if the terms had not been modified, if the original terms of the award are met. An additional expense is recognized for any modification that increases the total fair value of the share-based payment transaction, or is otherwise beneficial to the employee as measured at the date of modification. When an equity-settled award is cancelled, it is treated as if it vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the entity or the employee are not met. However, if a new award is substituted for the cancelled award, and designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph. Cash-settled transactions The Group has cash-settled share-based payment transaction for certain employees in certain countries due to legal requirements (in the form of share-appreciation rights). The cost of cash-settled transactions is measured initially at fair value at the grant date. This fair value is expensed over the period until the vesting date with recognition of a corresponding liability. The liability is remeasured to fair value at each reporting date up to, and including the settlement date, with changes in fair value recognized in employee benefits expense.
Description of accounting policy for recognition of revenue [text block]	Revenue from contracts with customers The Group’s revenue, which is presented net of sales taxes, is primarily generated by the sale of our software and 3D printed products and services. Software revenue is comprised of perpetual and periodic licenses, maintenance revenue and software development service fees. Perpetual license holders may opt to take an annual maintenance contract, which leads to annual fees. Periodic licenses entitle the customer to maintenance, support and product updates without additional charge. Revenue from prototyp es and end products involving 3D printing techno logy is derived from our network o f production centers and may include support and services such as pre-production collaboration p rior to the actual production . The Group sells its products and software through its direct sales force and through authorized distributors. Software license revenue, maintenance and/or software development service fees may be bundled in one arrangement, or may be sold separately. The Group recognizes revenue for goods including software based on the five-step model as a result of the application of IFRS 15 since January 1, 2018. Identify the contract(s) with a customer; Identify the performance obligations in the contract; Determine the transaction price; Allocate the transaction price to the performance obligations in the contract; and Recognize revenue when (or as) the entity satisfies a performance obligation. Revenue from contracts with customers is recognized when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group is expected to be entitled in exchange from those goods and services. If the consideration in a contract includes a variable amount, the Group estimates the amount of consideration to which it will be entitled in exchange for transferring the goods to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty with the variable consideration is subsequently resolved. Variable consideration is mainly related to quantities sold, volume (step-based) rebates and development time spend. P rototypes and end products involving 3D printing technology The Group recognizes revenue on the sale of goods to the customer or distributor at a point in time when control of the asset is transferred, generally upon shipment or delivery taking into account the shipment terms (usually Ex-works or FOB Time of Shipment Incoterms (International Commercial Terms)). Perpetual licensed software The sale and/or license of software products is deemed to have occurred at a point in time, i.e. when a customer either has taken possession of or has the ability to take immediate possession of the software and the software key. Perpetual software licenses can include one year maintenance and support services as a separate performance obligation. The Company sells these maintenance services also on a stand-alone basis and is therefore capable of determining their stand-alone selling price. On this basis, the amount of the embedded maintenance is separated from the fee for the perpetual license and is recognized ratably over the period to which they relate. Time-based licensed software The time-based license agreements include the use of a software license for a fixed term and maintenance and support services during the same period. The Company does not sell time-based licenses without maintenance and support services and therefore revenues is satisfied over time for the entire arrangements and is recognized ratably over the term. Maintenance and support services Maintenance and support services are satisfied over time and as such, t he Group recognizes this revenue ratably on a straight-line basis over the term that the maintenance service is provided. In general, maintenance services are not automatically renewed. A maintenance and support contract may include a reinstatement for previous years when the customer did not have a maintenance and support contract previously. Revenue from reinstatements are recognized immediately when the maintenance and support services commence. Software development services (SDS) SDS include customized development of software components for customers. Revenue from SDS agreements when distinct from other performance obligations is satisfied over time. Revenue is then recognized either on time and material basis or on the stage of completion of each service contract and when the stage of completion can be measured reliably. The Company determines the percentage-of-completion by comparing labor hours incurred to-date to the estimated total labor hours required to complete the project. The Company considers labor hours to be the most reliable available measure of progress on these projects. Adjustments to the Company’s estimates of the time to completion are made when facts resulting in a change become known. When the estimate indicates that a loss will be incurred, such loss is recognized immediately. Contracts with m ultiple performance obligations The Group has entered into a number contracts with multiple performance obligations , such as when selling perpetual licenses that may include maintenance and support (included in price of perpetual licenses) and time-based licenses (that include embedded m aintenance and support, both of which may be sold with software development services, training, and other product sales). In some cases, the Group delivers software development services bundled with the sale of the software. The Group evaluates whether each performance obligation is distinct from each other, i.e. the customer can benefit from the good or service on its own, or with readily available resources. Certain development services significantly modify and/or enhance the software license and as such are not considered distinct and combined with the software license. In those contracts, whether sold to end-customers or to collaboration partners, the Group uses either price list, historical pricing information or management’s best estimate of selling prices (e.g. also using a cost-plus method) to determine the stand-alone selling price for each distinct performance obligation, including software and software-related serv ic es such as maintenance and support. In general, elements in such arrangements are also sold on a stand-alone basis and stand-alone selling prices are readily available. Revenue is allocated to each di stinct performance obligation ( " PO " ) based o n the relative percentage of the stand-alone selling price for each PO compared to the total of stand-alone selling prices for all PO over the total transaction price and is recognized when the revenue recognition criteria described above are met. Contracts with collaboration partners in the medical segment also include multiple elements such as software, maintenance and support services, training, software development services, 3D printed products and royalties. Revenue from those contracts is determined and recognized consistent with other multiple element arrangements. For certain contracts with collaboration partners, the Company also receives up-front fees, paid by customers for certain exclusivity rights granted only on previously acquired perpetual software licenses, which may be bundled with transfer of title, rights and ownership of certain software products and maintenance and support services. In case the up-front fees do not relate to already delivered good or services, the Group include the up-front fees in the total transaction price which is then allocated to all the distinct performance obligations. Other contracts with collaboration partners include prepaid fees to purchase a maximum number of " Plan Only " cases during a 12-month period. In this case, the prepaid fees are recognized over the period of 12 months based on the expected number of " Plan Only " cases that will be purchased. Contract assets A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If the Group performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognised for the earned consideration that is conditional. Contract assets are only contracts in progress that are disclosed with the line inventory and contracts in progress in the statement of financial position. We refer to our accounting policies regarding Inventories and Contracts in Progress Contract liabilities A contract liability is the obligation to transfer goods or services to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before the Group transfers goods or services to the customer, a contract liability is recognised when the payment is made or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Gr oup performs under the contract. Contract liabilities are presented as deferred income in the statement of financial position. Contract costs The Group does not have significant costs to obtain contracts and those costs are expensed as incurred. The Group may have costs incurred in fulfilling contracts that are accounted for as intangible assets. When those costs are not in scope of another standards, these costs are accounted for under contracts in progress (see contract assets). For certain contracts, the Group may have significant software development expenses that are not considered a " distinct performance obligation " which are accounted for as an intangible assets. The Group evaluates whether those costs meet the recognition criteria for an intangible assets and when criteria are not met, expenses those costs as incurred.
Description of accounting policy for government grants [text block]	Government grants Government grants are recognized when there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to development costs or another expense, it is recognized as income over the grant period necessary to match the income on a systematic basis to the costs that it is intended to compensate. When the grant relates to the construction of buildings, it is recognized as income over the depreciation period of the related building. Such grants have been received from the federal and regional governments and from the European Union in the forms of grants linked to certain of its research and development programs, reduced payroll taxes and the financing of the construction of an office building in Leuven (Belgium) and in Freiberg (Germany). Where retention of a government grant related to assets or to income, is dependent on the Company satisfying certain criteria, it is initially recognized as deferred income. When the criteria for retention have been satisfied, the deferred income balance is released to other operating income in the consolidated income statement on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate. Any government grants recognized as income do not have any unfulfilled conditions or other contingencies attached to them, as otherwise we would not be recognizing income for such.
Description of accounting policy for finance income and costs [text block]	Other financial income and expenses Other financial income and expenses include mainly foreign currency gains or losses on financial transactions and bank related expenses.
Description of accounting policy for income tax [text block]	Current income tax Income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Current income tax relating to items that are recognized directly in equity is recognized in equity and not in the income statement. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.
Description of accounting policy for deferred income tax [text block]	Deferred tax Deferred tax is calculated using the liability method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized for all deductible temporary differences, carry forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.
Description of accounting policy for taxes other than income tax [text block]	Sales tax Revenue, expenses and assets are recognized net of the amount of VAT, except: Where the sales tax incurred on a purchase of assets or services is not recoverable from the taxation authority, in which case the sales tax is recognized as part of the cost of acquisition of the asset or as part of the expense item as applicable; and Receivables and payables that are stated with the amount of sales tax included. The net amount of sales tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the statement of financial position.
Explanation of not applied new standards or interpretations [text block]	New and revised standards not yet adopted The standards, interpretations and amendments issued by the IASB and relevant for the Group, but not yet effective are not expected to have a material impact on the Group’s future consolidated financial statements: Amendments to IAS 1 and IAS 8 Definition of Material (applicable for annual periods beginning on or after January 1, 2020) Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-current (applicable for annual periods beginning on or after January 1, 2022) Amendments to IFRS 3 Business Combinations (applicable for annual periods beginning on or after January 1, 2020) Amendments to IFRS 9, IAS 39 and IFRS 7 Interest Rate Benchmark Reform (applicable for annual periods beginning on or after January 1, 2020) Amendments to references to the Conceptual Framework in IFRS standards (applicable for annual periods beginning on or after January 1, 2020) IFRS 17 Insurance Contracts (applicable for annual periods begin ning on or after January 1, 2021 )

IFRS 16 Lease Liabilities (Tabl

IFRS 16 Lease Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of IFRS16 lease liabilities [abstract]
IFRS 16 Lease Liabilities [Text Block]	As at January 1, 2019 (in 000€) Non-cancellable operating lease commitments disclosed at December 31, 2018 5,442 Discounted using the company’s incremental borrowing rate (268) Add: finance lease liabilities recognized at December 31, 2018 6,809 (Less) short-term/low-value leases recognized on a straight-line basis as an expense (88) Add/(Less) adjustments related to different treatment extension and termination options (101) Lease liability recognized as at January 1, 2019 11,794

IFRS 16 Right-of-use assets (Ta

IFRS 16 Right-of-use assets (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of quantitative information about right-of-use assets [abstract]
Basis of preparation IFRS 16 right-of-use assets [text block]	(in 000€) As at December 31, 2019 As at January 1, 2019 Buildings 3,843 3,255 Vehicles 882 849 Other materials 301 880 Total right-of-use assets 5,026 4,984 Total lease liabilities 5,026 4,984

Business combinations (Tables)

Business combinations (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of detailed information about business combination [abstract]
Acquisition of ACTech [text block]	in 000€ Carrying value at acquisition date Fair value adjust- ments Fair value at acquisi- tion date Assets Technology − 515 515 Customer relations − 17,092 17,092 Other intangible assets 6,330 (5,345) 985 Property, plant & equipment 19,986 243 20,229 Deferred tax assets 503 (415) 88 Other non-current financial assets 56 − 56 Inventory 2,356 433 2,789 Trade receivables 5,176 − 5,176 Cash & cash equivalents 2,244 − 2,244 Other assets 542 − 542 Total Assets 37,193 12,523 49,716 Liabilities Deferred tax liabilities (47) (5,977) (6,024) Deferred income (1,298) 1,298 − Loans & borrowings (11,308) − (11,308) Trade payables (777) − (777) Tax payables (3,664) 1,214 (2,450) Other liabilities (9,062) − (9,062) Total Liabilities (26,156) (3,465) (29,621) Total identified assets and liabilities 11,037 9,058 20,095 Goodwill − − 8,812 Acquisition price − − 28,907 Cash & cash equivalents acquired (2,244) Acquisition price in cash including escrow 29,417 Total cash flow 27,173
Acquisition of Engimplan [Text Block]	in 000€ Carrying value at acquisition date Fair value adjust- ments Fair value at acquisi- tion date Assets Software 214 − 214 Customer relations − 2,530 2,530 Trademarks − 556 556 Other intangible assets 9 − 9 Property, plant & equipment 2,268 101 2,369 Right-of-use assets 633 − 633 Deferred tax assets − − − Other non-current financial assets 3 − 3 Inventory 2,084 96 2,180 Trade receivables 1,802 − 1,802 Other current assets 391 − 391 Cash from capital increase 5,750 − 5,750 Cash & cash equivalents 316 − 316 Total Assets 13,470 3,283 16,753 Liabilities Deferred tax liabilities − − − Deferred income (83) − (83) Loans & borrowings (1,443) − (1,443) Lease liabilities (633) − (633) Trade payables (271) − (271) Tax payables (100) − (100) Payroll related payables (298) − (298) Other liabilities (914) − (914) Total Liabilities (3,742) − (3,742) Total identified assets and liabilities 9,728 3,283 13,011 Goodwill − − 2,639 Non-controlling interest − − (3,253) Acquisition price − − 12,397 Cash & cash equivalents acquired (316) Cash from capital increase (5,750) Acquisition price in cash 12,397 Total cash flow 6,331

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2019
Non-current Assets [Abstract]
Disclosure of information for cash-generating units [text block]	As of December 31, in 000€ 2019 2018 2017 CGU: MAT NV SAM BE 3,241 3,241 3,241 CGU: e-Prototypy 800 794 818 CGU: ACTech 8,812 8,812 8,812 CGU: OrthoView 4,683 4,467 4,504 CGU: MAT NV Manufacturing (Metal) 177 177 177 CGU: Engimplan 2,461 − − Total 20,174 17,491 17,552
Disclosure of reconciliation of changes in goodwill [text block]	in 000€ Gross Impair- ment Total At January 1, 2017 8,964 (104) 8,860 Additions 8,812 − 8,812 Impairment − − − Currency translation (120) − (120) At December 31, 2017 17,656 (104) 17,552 Additions − − − Currency translation (61) − (61) At December 31, 2018 17,595 (104) 17,491 Additions 2,639 − 2,639 Currency translation 44 − 44 At December 31, 2019 20,278 (104) 20,174

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of detailed information about intangible assets [abstract]
Disclosure of detailed information about intangible assets [text block]	in 000€ Patents and licenses Software Acquired customers, technology and backlogs Developed technology and software under construction Total Acquisition value At January 1, 2017 3,788 3,769 7,596 − 15,153 Additions 749 3,718 − − 4,467 Acquisition of a subsidiary 115 242 18,433 − 18,790 Disposals (159) (143) − − (302) Transfer between accounts − (98) − − (98) Currency translation − (5) (183) − (188) Other 4 155 (251) − (92) At December 31, 2017 4,497 7,638 25,595 − 37,730 Additions 554 807 32 951 2,344 Acquisition of a subsidiary − − − − − Disposals (759) (221) − − (980) Transfer between accounts 2 − − 364 366 Currency translation − − (48) − (48) Other − 17 − − 17 At December 31, 2018 4,294 8,241 25,579 1,315 39,429 Additions 209 656 − 1,328 2,193 Acquisition of a subsidiary 38 214 3,048 9 3,309 Disposals − (45) (32) − (77) Transfer between accounts (109) 1,601 − (988) 504 Currency translation 1 (10) 86 20 97 Other 3 10 − (32) (19) At December 31, 2019 4,436 10,667 28,681 1,652 45,436 in 000€ Patents and licenses Software Acquired customers, technology and backlogs Developed technology and software under construction Total Amortization At January 1, 2017 (2,042) (1,251) (2,095) − (5,388) Amortization charge for the year (609) (1,634) (1,579) − (3,822) Disposals 2 77 − − 79 Transfer between accounts − 98 − − 98 Currency translation − 4 45 − 49 Other (117) (279) 250 − (146) At December 31, 2017 (2,766) (2,985) (3,379) − (9,130) Amortization charge for the year (749) (2,310) (2,005) − (5,064) Disposals 854 206 − − 1,060 Transfer between accounts − − − − − Currency translation − 1 22 − 23 Other − 8 − − 8 At December 31, 2018 (2,661) (5,080) (5,362) − (13,103) Amortization charge for the year (246) (2,582) (2,031) − (4,859) Disposals − 23 − − 23 Transfer between accounts 109 (96) − − 13 Currency translation − (25) (126) − (151) Other − 20 16 − 36 At December 31, 2019 (2,798) (7,740) (7,503) − (18,041) Net carrying value At December, 31 2019 1,638 2,927 21,178 1,652 27,395 At December, 31 2018 1,633 3,161 20,217 1,315 26,326 At December 31, 2017 1,731 4,653 22,216 − 28,600 At January, 1 2017 1,746 2,518 5,501 − 9,765

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of detailed information about property, plant and equipment [abstract]
Disclosure of detailed information about property, plant and equipment [text block]	in 000€ Land and buildings Plant and equipment Right-of-use assets Construc- tion in progress Total Acquisition value At January 1, 2018 40,184 67,117 14,303 3,754 125,358 Additions 3,079 9,476 792 5,210 18,557 Disposals (99) (1,882) (17) (387) (2,385) Transfers 2,728 2,953 (732) (5,547) (598) Currency Translation (119) (25) (19) (26) (189) Other 4 (82) − (2) (80) At December 31, 2018 45,777 77,557 14,327 3,002 140,663 Impact of adoption of IFRS 16 − − 4,984 − 4,984 Additions 302 7,363 3,429 5,807 16,901 Acquired from business combinations 61 2,291 633 17 3,002 Disposals (37) (6,091) (753) − (6,881) Transfers (3,360) 7,077 117 (4,338) (504) Currency Translation 150 199 8 6 363 Other* − (73) (1,099) (80) (1,252) At December 31, 2019 42,893 88,323 21,646 4,414 157,276 Depreciation At January 1, 2018 (4,504) (27,166) (6,623) − (38,293) Depreciation charge for the year (1,560) (8,010) (2,346) (307) (12,223) Disposals 26 2,102 6 − 2,134 Transfers (18) (253) 514 − 243 Currency Translation (15) (53) 8 − (60) Other − 73 − − 73 At December 31, 2018 (6,071) (33,307) (8,441) (307) (48,126) Depreciation charge for the year (1,199) (9,082) (4,058) − (14,339) Disposals 36 5,704 359 − 6,099 Transfers 200 (1,551) 1,031 307 (13) Currency Translation (25) (190) (2) − (217) Other 220 (34) 51 − 237 At December 31, 2019 (6,839) (38,460) (11,060) − (56,359) Net book value At December 31, 2019 36,054 49,863 10,586 4,414 100,917 At December 31, 2018 39,706 44,250 5,886 2,695 92,537 At January 1, 2018 35,680 39,951 7,680 3,754 87,065 in 000€ Land and buildings Plant and equipment Right-of-use assets Construc- tion in progress Total Acquisition value At January 1, 2017 19,797 40,199 11,241 4,652 75,889 Additions 377 10,560 2,246 17,334 30,517 Acquired from business combinations 9,362 10,318 136 414 20,230 Disposals (31) (1,046) (39) 218 (898) Transfers 11,527 7,439 (425) (18,914) (373) Currency Translation (185) (118) 5 88 (210) Other (663) (235) 1,139 (38) 203 At December 31, 2017 40,184 67,117 14,303 3,754 125,358 Depreciation At January 1, 2017 (5,093) (22,263) (3,470) − (30,826) Depreciation charge for the year (831) (5,531) (2,327) − (8,689) Disposals 15 842 18 − 875 Transfers 521 (444) 296 − 373 Currency Translation 31 166 (1) − 196 Other 853 64 (1,139) − (222) At December 31, 2017* (4,504) (27,166) (6,623) − (38,293) Net book value At December 31, 2017 35,680 39,951 7,680 3,754 87,065 At January 1, 2017 14,704 17,936 7,771 4,652 45,063
Disclosure of quantitative information about right-of-use assets [text Block]	in 000€ Buildings Vehicles Equipment Total Acquisition value At January 1, 2019 before adoption IFRS 16 935 2,542 10,850 14,327 Impact of adoption of IFRS 16 3,255 849 880 4,984 At January 1, 2019 after adoption IFRS 16 4,190 3,391 11,730 19,311 Additions 2,222 1,118 89 3,429 Acquired from business combinations 633 − − 633 Modifications (9) (40) (496) (545) Disposals (550) (147) (56) (753) Currency Translation 4 − 4 8 Transfers − (47) 164 117 Other (2) − (552) (554) At December 31, 2019 6,488 4,275 10,883 21,646 Depreciation At January 1, 2019 (1,011) (1,189) (6,241) (8,441) Depreciation charge for the year (1,953) (1,060) (1,045) (4,058) Acquired from business combinations − − − − Modifications − − − − Disposals 257 147 56 460 Currency Translation (1) − (1) (2) Transfers − 41 990 1,031 Other 3 31 (84) (50) At December 31, 2019 (2,705) (2,030) (6,325) (11,060) Net book value At December 31, 2019 3,783 2,245 4,558 10,586 At January 1, 2019 before adoption IFRS 16 (76) 1,353 4,609 5,886 At January 1, 2019 after adoption IFRS 16 3,179 2,202 5,489 10,870
Disclosure of Property, plant and equipment - Income statement impact [text block]	(in 000€) 2019 Depreciation expense (4,058) Interest expense on lease liabilities (204) Expenses related to short-term leases/ low-value assets/ variable lease payments (725)
Disclosure of Property, plant and equipment - Potential future cashflows following the extensions [text block]	(in 000€) 2019 Potential cash flows for extension options that are not reasonably certain to be exercised: 843 Potential cash flows for termination options that are reasonably certain to be exercised 174

Investments in joint ventures (

Investments in joint ventures (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of joint ventures [abstract]
Disclosure of joint ventures table [Text block]	in 000€ 2019 2018 2017 Joint venture’s statement of financial position Current assets 1546 850 1,256 Non-current assets 93 114 212 Goodwill − − − Current liabilities (1,114) (756) (692) Non-current liabilities (448) (1,096) (788) Shareholders’ deficit (surplus) (77) 888 12 The joint venture income (loss) Revenue 1,736 1,186 817 Profit (loss) (785) (876) (723)
Disclosure of movement carrying value of joint venture [text block]	in 000€ Carrying value as of January 1, 2017 − Additional investment 500 Transfer from receivables − Share in loss (469) Carrying value as of December 31, 2017 31 Additional investment − Transfer from receivables 444 Share in loss (475) Carrying value as of December 31, 2018 − Additional investment 875 Transfer to receivables (444) Share in loss (392) Carrying value as of December 31, 2019 39

Inventories and contracts in pr

Inventories and contracts in progress (Tables)	12 Months Ended
	Dec. 31, 2019
Inventory and contract in progress [abstract]
Disclosure of inventories and contracts in progress [text block]	As of December 31, in 000€ 2019 2018 2017* Raw materials 7,400 5,616 4,970 Work in progress 2,805 2,151 3,377 Finished goods 1,996 1,390 1,414 Contracts in progress 495 829 1,266 Total inventories and contracts in progress 12,696 9,986 11,027

Other assets (Tables)

Other assets (Tables)	12 Months Ended
	Dec. 31, 2019
Other assets [abstract]
Disclosure of other non-current assets table [text block]	As of December 31, in 000€ 2019 2018 2017 Tax credits 3,015 3,006 2,446 Guarantees and deposits 415 405 362 Non-current receivable on joint venture 138 1,096 804 Non-listed equity investments 3,046 2,701 − Convertible loan 2,750 − − Other 27 29 55 Total non-current assets 9,391 7,237 3,667
Disclosure of other current assets table [text block]	As of December 31, in 000€ 2019 2018 2017 Deferred charges 2,632 2,046 2,021 Tax credits 695 185 219 Accrued income 486 958 524 Other tax receivables 3,127 2,286 2,910 Other non-trade receivables 1,676 1,461 2,001 Total current assets 8,616 6,936 7,675

Trade receivables (Tables)

Trade receivables (Tables)	12 Months Ended
	Dec. 31, 2019
Trade and other receivables [abstract]
Disclosure of trade receivables [text block]	As of December 31, in 000€ 2019 2018 2017 Trade receivables 42,509 38,764 36,572 Write off receivables (1,532) (1,873) (990) Total 40,977 36,891 35,582
Disclosure of impairment loss (reversal of impairment loss) on trade receivables [text block]	in 000€ At January 1, 2017 (511) Addition (620) Usage 12 Reversal 129 At December 31, 2017 (990) At January 1, 2018 (990) Addition (1,284) Usage 182 Reversal 219 At December 31, 2018 (1,873) Addition (141) Usage 131 Reversal 351 At December 31, 2019 (1,532)

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	12 Months Ended
	Dec. 31, 2019
Cash and cash equivalents [abstract]
Disclosure of cash and cash equivalents tables [text block]	As of December 31, in 000€ 2019 2018 2017 Cash at bank 123,337 105,846 33,611 Cash equivalents 5,560 9,660 9,564 Total 128,897 115,506 43,175

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Disclosure of classes of share capital [text block]	in 000€, except share data Total number of ordinary shares Total share- holders' capital Total share- premium Outstanding at January 1, 2017 47,325,438 2,729 79,019 Equity settled share-based payments expense − − 820 Outstanding at January 1, 2018 47,325,438 2,729 79,839 Transfer share capital to share premium − − − Capital increase in cash - public offering 5,403,125 312 59,575 Expenses directly attributable to public offering − − (4,003) Capital increase via exercise of warrants 162,198 9 593 Equity settled share-based payments expense − − 633 Outstanding at January 1, 2019 52,890,761 3,050 136,637 Capital increase in cash - public offering and private placement − − − Expenses directly attributable to public offering − − − Capital increase via exercise of warrants 281,752 16 1,252 Equity settled share-based payments expense − − 201 Outstanding on December 31, 2019 53,172,513 3,066 138,090
Disclosure of reserves within equity [text block]	As of December 31, in 000€ 2019 2018 2017* Legal reserve 279 279 279 (Accumulated deficit) (474) (2,127) (3,990) Reserves (195) (1,848) (3,711)

Share based payment plans (Tabl

Share based payment plans (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Disclosure of terms and conditions of share-based payment plan arrangements of the parent [text block]	2019 2018 2017 Outstanding at January 1* 1,318,049 1,458,360 1,681,000 Granted − 2,000 − Forfeited / Cancelled (42,952) (69,104) (119,784) Exercised (310,045) (73,207) (102,856) Outstanding at December 31* 965,052 1,318,049 1,458,360 Exercisable at December 31 296,859 252,793 −
Disclosure of terms and conditions of share-based payment plan arrangements of the 2013 warrant plan [text block]	2019 2018 2017 Outstanding at January 1 300,040 320,640 435,096 Granted − − − Forfeited / Cancelled (3,500) (1,500) (11,600) Exercised (178,164) (19,100) (102,856) Outstanding at December 31 118,376 300,040 320,640 Exercisable at December 31 15,300 89,892 −
Disclosure of terms and conditions of share-based payment plan arrangements of the IPO warrant plan [text block]	2019 2018 2017 Outstanding at January 1 589,052 671,503 727,599 Granted − − − Forfeited / Cancelled (20,252) (42,209) (56,096) Exercised (103,588) (40,242) − Outstanding at December 31 465,212 589,052 671,503 Exercisable at December 31 169,071 114,012 −
Disclosure of terms and conditions of share-based payment plan arrangements of the 2015 warrant plan [text block]	2019 2018 2017 Outstanding at January 1 325,200 329,000 350,000 Granted − 2,000 − Forfeited / Cancelled (14,800) (5,800) (21,000) Exercised − − − Outstanding at December 31 310,400 325,200 329,000 Exercisable at December 31 96,500 32,700 −
Disclosure of inputs into the model of equity settled share-based payment plans [text block]	2015 (Sept 16) 2015 (Nov) IPO 2014 (Nov) IPO 2014 (June) 2013 (Dec) * 2013 (Oct) * Return dividend 0% 0% 0% 0% 0% 0% Expected volatility 47% 47% 50% 46% 50% 53% Risk-free interest rate 0.24% 1.17% 1.12% 1.70% 2.56% 2.43% Expected life 4.30 5.50 5.50 5.50 5.50 5.50 Exercise price (in €) 6.45 8.81 8.81 8.81 8.54 7.86 Stock price (in €) 6.42 8.08 8.67 8.81 18.09 18.09 Fair value SAR (in €) 2.41 3.30 3.94 3.83 12.23 12.77
Disclosure of terms and conditions of share-based payment plan arrangements of the cash-settled plans [text block]	2019 2018 2017 Outstanding at January 1 103,757 137,217 168,305 Granted − − − Forfeited / Cancelled (4,400) (19,595) (31,088) Exercised (28,293) (13,865) − Outstanding at December 31 71,064 103,757 137,217 Exercisable at December 31 15,988 16,189 −
Disclosure of inputs into the model of cash settled share-based payment plans [text block]	2019 2018 2017 Return dividend 0% 0% 0% Expected volatility 49% 49% 49% Risk-free interest rate 0.10% 0.77% 0.73% Expected life 0.25 1.25 2.25 Exercise price (in €) 8.81 8.81 8.81 Stock price (in €) 16.32 17.49 10.61 Fair value SAR (in €) 7.52 9.09 3.85
Disclosure of terms and conditions of share-based payment plan arrangements of the Rapidfit+ plan [text block]	2019 2018 2017 Outstanding at January 1 199 199 199 Granted − − − Forfeited / Cancelled (13) − − Exercised − − − Outstanding at December 31 186 199 199 Exercisable at December 31 184 − −
Disclosure of inputs into the model of the Rapidfit+ plan [text block]	2014 Return dividend 0% Expected volatility 50% Risk-free interest rate 2.29% Expected life 5.5 Exercise price 553.9 Fair value option 262.7

Loans and borrowings (Tables)

Loans and borrowings (Tables)	12 Months Ended
	Dec. 31, 2019
Debt instruments held [abstract]
Disclosure of detailed information about borrowings [text block]	As of December 31 in 000€ 2019 2018 2017 K€35,000 EIB bank loan 35,000 10,000 − K€28,000 acquisition bank loan 21,612 24,576 27,513 K€18,000 secured bank loans 17,429 17,739 17,575 K€12,300 bank loans ACTech 11,850 12,300 9,247 K€8,750 other facility loans 3,599 4,299 4,982 Bank investment loans - top 20 outstanding 22,132 23,801 21,441 Bank investment loans - other 4,429 3,808 2,289 Lease liabilities (2018 and 2017: Finance leases) 9,876 6,809 9,164 Institutional loan 824 1,492 1,105 Convertible bonds 1,000 1,000 1,000 Related party loan 187 214 241 Total loans and borrowings 127,938 106,038 94,557 Current 16,838 13,598 12,769 Non-Current 111,100 92,440 81,788
Disclosure of reconciliation of liabilities arising from financing activities [text block]	For the year ended December 31 in 000€ 2019 2018 2017 At January 1, 106,038 94,557 33,806 Proceeds from loans & borrowings 29,000 32,554 54,319 Repayment of loans & borrowings (12,126) (18,820) (11,904) New leases 8,326 792 2,906 Repayment of leases (5,283) (3,102) (2,947) Loans acquired from business combination 2,076 − 18,205 Net foreign exchange movements (92) 57 172 At December 31, 127,938 106,038 94,557

Other non-current liabilities (

Other non-current liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Miscellaneous non-current liabilities [abstract]
Disclosure other non-current liabilities [text block]	As of December 31, in 000€ 2019 2018 2017 Written-put option RapidFit+ − − 788 Contingent consideration − − 648 Provisions 122 82 109 Other 574 786 359 Total 696 868 1,904

Deferred income (Tables)

Deferred income (Tables)	12 Months Ended
	Dec. 31, 2019
Accruals and deferred income [abstract]
Disclosure of information about deferred income [text block]	As of December 31 in 000€ 2019 2018 2017 Deferred maintenance & license 27,667 22,606 18,723 Deferred (project) fees 4,647 4,838 3,765 Deferred government grants 359 338 71 Total 32,672 27,782 22,559 current 27,641 23,195 18,791 non-current 5,031 4,587 3,768

Other current liabilities (Tabl

Other current liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Miscellaneous current liabilities [abstract]
Disclosure of detailed information of other current liabilities [text block]	As of December 31 in 000€ 2019 2018 2017 Payroll-related liabilities 10,281 10,111 9,274 Non-income tax payables 2,262 2,175 2,063 Accrued charges 1,080 789 769 Advances received 715 713 870 Other current liabilities 3,348 1,554 520 Total 17,686 15,342 13,496

Fair value (Tables)

Fair value (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of fair value of financial assets and liabilities [abstract]
Disclosure of fair value measurement of assets [text block]	Carrying value Fair value in 000€ 2019 2018 2017 2019 2018 2017 Financial assets Debt instruments measured at amortized cost Trade receivables (current) 40,977 36,891 35,582 40,977 36,891 35,582 Other financial assets (non-current) 580 1,530 1,221 580 1,530 1,221 Other current non-trade receivables 1,676 1,461 2,001 1,676 1,461 2,001 Cash & cash equivalents 128,897 115,506 43,175 128,897 115,506 43,175 Total debt instruments 172,130 155,388 81,979 172,130 155,388 81,979 Financial assets at fair value through profit or loss Derivatives 9 117 218 9 117 218 Convertible loan 2,750 − − 2,794 − − Total financial assets measured at fair value 2,759 117 218 2,803 117 218 Equity instruments designated at fair value through OCI Non-listed equity investments 3,046 2,701 − 3,047 2,701 − Total Equity instruments designated at fair value through OCI 3,046 2,701 − 3,047 2,701 −
Disclosure of fair value measurement of liabilities [text block]	Carrying value Fair value in 000€ 2019 2018 2017 2019 2018 2017 Financial liabilities measured at amortized cost Loans & Borrowings including lease liabilities 127,939 106,037 94,557 128,930 105,026 95,351 Trade payables 18,517 18,667 15,670 18,517 18,667 15,670 Other liabilities excl. written put option on NCI 3,187 778 1,133 3,187 778 1,133 Total financial liabilities measured at amortized cost 149,643 125,482 111,360 150,634 124,471 112,154 Financial liabilities measured at fair value Contingent consideration − 450 905 − 450 905 Cash settled share based payments − 786 351 − 786 351 Written put option on NCI 875 845 788 875 845 788 Derivatives 478 194 8 478 194 8 Total financial liability measured at fair value 1,353 2,275 2,052 1,353 2,275 2,052 Total non-current 112,549 94,521 85,276 112,288 93,289 85,890 Total current 38,447 33,236 28,136 39,699 33,457 28,316

Segment information (Tables)

Segment information (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of operating segments [abstract]
Disclosure segment information [text block]	in 000€ Materialise Software Materialise Medical Materialise Manufacturing Total segments Unallocated Consolidated For the year ended December 31, 2019 Revenues 41,654 60,808 94,156 196,618 61 196,679 Segment Adjusted EBITDA 13,812 10,774 12,154 36,740 (10,084) 26,656 Segment Adjusted EBITDA % 33.2% 17.7% 12.9% 18.7% − 13.6% For the year ended December 31, 2018 Revenues 37,374 52,252 94,956 184,582 139 184,721 Segment Adjusted EBITDA 11,536 10,252 10,785 32,573 (9,047) 23,526 Segment Adjusted EBITDA % 30.9% 19.6% 11.4% 17.6% − 12.7% For the year ended December 31, 2017 Revenues 35,770 42,841 63,712 142,323 250 142,573 Segment Adjusted EBITDA 13,926 4,400 4,439 22,765 (8,155) 14,610 Segment Adjusted EBITDA % 38.9% 10.3% 7.0% 16.0% − 10.2%
Disclosure of segment EBITDA [text block]	For the year ended December 31, in 000€ 2019 2018 2017 Segment Adjusted EBITDA 36,740 32,573 22,765 Depreciation, amortization and impairment (19,198) (17,287) (12,576) Corporate research and development (1,859) (1,913) (2,017) Corporate headquarter costs (11,077) (10,358) (9,690) Other operating income (expense) 2,410 2,149 1,910 Operating profit 7,016 5,164 392 Financial expenses (3,682) (4,864) (4,728) Financial income 1,377 3,627 3,210 Income taxes (2,595) (425) (522) Share in loss of joint venture (392) (475) (469) Net (loss) profit 1,724 3,027 (2,117)
Disclosure of revenue by geographical areas [text block]	As of December 31, in 000€ 2019 2018 2017 United States of America 56,235 42,217 32,926 Americas other than USA 3,395 1,700 2,194 Belgium 7,917 9,350 8,145 Germany 31,185 30,436 27,011 France 20,110 22,282 18,737 Switzerland 14,907 13,135 7,782 United Kingdom 13,804 11,946 10,911 Italy 6,707 4,392 4,224 Netherlands 5,825 7,382 7,986 Other Europe 17,329 21,455 3,144 Asia Pacific 19,265 20,426 19,513 Total 196,679 184,721 142,573
Disclosure of non-current assets by geographical areas [text block]	As of December 31, in 000€ 2019 2018 2017 United States of America (USA) 4,194 3,953 3,880 Americas other than USA 8,374 62 29 Belgium 49,426 48,873 46,573 Germany 57,918 56,096 56,410 Poland 15,506 16,206 15,441 Rest of Europe 10,410 10,125 10,140 Asia-Pacific 2,658 1,039 744 Total 148,486 136,354 133,217

Income and expenses (Tables)

Income and expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of income and expenses [abstract]
Disclosure of revenue from contracts with customers [text block]	For the year ended December 31, 2019 in 000€ Materialise Software Materialise Medical Materialise Manufacturing Total segments Unallocated Consolidated Geographical markets United States of America (USA) 11,188 29,100 15,947 56,235 − 56,235 Americas other than USA 487 2,071 837 3,395 − 3,395 Europe (without Belgium) & Africa 18,767 21,356 69,744 109,867 − 109,867 Belgium 183 2,101 5,572 7,856 61 7,917 Asia Pacific 11,029 6,180 2,056 19,265 − 19,265 Total revenue from contracts with customers 41,654 60,808 94,156 196,618 61 196,679 Type of goods or service Software revenue (non-medical) 41,654 − − 41,654 − 41,654 Software revenue (medical) − 19,407 − 19,407 − 19,407 Medical devices and services − 41,401 − 41,401 − 41,401 Manufacturing − − 94,156 94,156 − 94,156 Other − − − − 61 61 Total revenue from contracts with customers 41,654 60,808 94,156 196,618 61 196,679 Timing of revenue recognition Goods/Services transferred at a point in time 21,190 45,730 88,988 155,908 61 155,969 Goods/Services transferred over time 20,464 15,078 5,168 40,710 − 40,710 Total revenue from contracts with customers 41,654 60,808 94,156 196,618 61 196,679 For the year ended December 31, 2018 in 000€ Materialise Software Materialise Medical Materialise Manufacturing Total segments Unallocated Consolidated Geographical markets United States of America (USA) 8,804 23,940 9,439 42,183 34 42,217 Americas other than USA 193 1,404 101 1,698 2 1,700 Europe (without Belgium) & Africa 17,026 19,073 74,852 110,951 77 111,028 Belgium 155 1,824 7,364 9,343 7 9,350 Asia Pacific 11,196 6,011 3,200 20,407 19 20,426 Total revenue from contracts with customers 37,374 52,252 94,956 184,582 139 184,721 Type of goods or service Software revenue (non-medical) 37,374 − − 37,374 − 37,374 Software revenue (medical) − 17,045 − 17,045 − 17,045 Medical devices and services − 35,207 − 35,207 − 35,207 Complex metal parts production (ACTech) − − 43,438 43,438 − 43,438 Other − − − − 139 139 Total revenue from contracts with customers 37,374 52,252 94,956 184,582 139 184,721 Timing of revenue recognition Goods/Services transferred at a point in time 20,326 39,682 90,614 150,622 139 150,761 Goods/Services transferred over time 17,048 12,570 4,342 33,960 − 33,960 Total revenue from contracts with customers 37,374 52,252 94,956 184,582 139 184,721
Disclosure of revenue by category [text block]	For the year ended December 31 in 000€ 2019 2018 2017 Software revenue (non-medical) 41,654 37,374 35,770 Software revenue (medical) 19,407 17,045 15,619 Medical devices and services 41,401 35,207 27,222 Manufacturing 94,156 94,956 63,712 Other 61 139 250 Total 196,679 184,721 142,573
Disclosure of contract balances [text block]	As of December 31, in 000€ 2019 2018 Trade receivables, included in 'trade and other receivables' 42,509 38,764 Contract assets / contracts in progress 495 829 Contract liabilities / deferred income 32,314 27,444 Total 75,318 67,037
Disclosure of Cost of sales [text block]	For the year ended December 31 in 000€ 2019 2018 2017 Purchase of goods and services (37,870) (39,114) (34,480) Amortization and depreciation (10,837) (9,910) (7,560) Payroll expenses (37,715) (33,036) (20,806) Other expenses (550) (239) (106) Total (86,972) (82,299) (62,952)
Disclosure of Research and Development Expense [text block]	For the year ended December 31 in 000€ 2019 2018 2017 Purchase of goods and services (2,583) (3,590) (3,140) Amortization and depreciation (1,483) (830) (686) Payroll expenses (19,219) (17,935) (16,054) Other (63) (61) (79) Total (23,348) (22,416) (19,959)
Disclosure of Sales and marketing expenses [text block]	For the year ended December 31 in 000€ 2019 2018 2017 Purchase of goods and services (9,228) (9,775) (8,035) Amortization and depreciation (1,346) (725) (505) Payroll expenses (42,055) (35,585) (30,175) Other (360) (218) (220) Total (52,989) (46,303) (38,935)
Disclosure of General and Administrative Expenses [text block]	For the year ended December 31 in 000€ 2019 2018 2017 Purchase of goods and services (9,856) (9,892) (7,053) Amortization and depreciation (3,630) (3,828) (2,761) Payroll expenses (18,078) (18,442) (14,858) Other (222) (148) (204) Total (31,786) (32,310) (24,876)
Disclosure of net other operating incomes expenses [text block]	For the year ended December 31 in 000€ 2019 2018 2017 Government grants 5,263 4,658 4,342 Amortization intangibles purchase price allocation (2,013) (1,994) (1,064) Allowance for doubtful debtors 210 (1,065) (454) Capitalized expenses (asset construction) 166 16 123 Net foreign currency exchange gains / (losses) − 246 (235) Tax Credits 665 706 899 Fair value adjustment Cenat liability − 192 − Personnel related income 37 168 − Other 1,104 844 930 Total 5,432 3,771 4,541
Disclosure of Payroll Expenses [text block]	For the year ended December 31 in 000€ 2019 2018 2017 Short-term employee benefits (87,775) (76,023) (60,195) Social security expenses (15,647) (14,139) (11,200) Expenses defined contribution plans (1,033) (936) (926) Other employee expenses (12,612) (13,900) (9,572) Total (117,067) (104,998) (81,893) 2,177 2,009 1,862
Disclosure of financial expenses [text block]	For the year ended December 31 in 000€ 2019 2018 2017 Interest expense (2,146) (1,747) (1,026) Foreign currency losses (832) (2,748) (3,131) Other financial expenses (704) (369) (571) Total (3,682) (4,864) (4,728)
Disclosure of financial income [text block]	For the year ended December 31 in 000€ 2019 2018 2017 Foreign currency exchange gains 955 3,047 2,830 Amortization discount interest free loans − − 6 Other finance income 422 580 374 Total 1,377 3,627 3,210

Income tax and deferred tax (Ta

Income tax and deferred tax (Tables)	12 Months Ended
	Dec. 31, 2019
Income tax and deferred tax [abstract]
Disclosure of income tax [text block]	As of December 31, in 000€ 2019 2018 2017 Estimated tax liability for the year (2,926) (1,216) (1,530) Tax adjustments to the previous year − − 412 Deferred income taxes 331 791 596 Total income taxes for the period (2,595) (425) (522)
Disclosure of deferred taxes [text block]	Asset/(liability) Income/(expense) in 000€ 2019 2018 2017 2019 2018 2017 Tax losses, notional interest deduction and other tax benefits − 26 − − − − Amortization development assets and other intangible assets 38 224 304 − − − Depreciation property, plant & equipment 70 30 − − − − Other items 84 35 − − − − Total deferred tax assets 192 315 304 (124) 11 (32) Property, plant & equipment (403) (694) (698) − − − Intangible assets (4,937) (5,370) (6,656) − − − Investment grants (301) (312) − − − − Inventory valuation (89) 141 − − − − Other items (17) 9 (61) − − − Total deferred tax liabilities (5,747) (6,226) (7,415) 455 780 628 Total deferred tax income (loss) − − − 331 791 596
Disclosure of relationship between tax expense and accounting profit [text block]	For the year ended December 31 in 000€ 2019 2018 2017 Profit (loss) before taxes 4,319 3,452 (1,595) Income tax at statutory rate of 29.58% (2017: 33.99%) (1,278) (1,021) 542 Effect of different local tax rate 63 166 433 Tax adjustments to the previous period (367) 80 412 Non-deductible expenses (554) (1,141) (818) Capitalized initial public offering transaction costs − − − Research and development tax credits & patent income deduction 179 337 44 Notional interest deduction Belgium − − − Non recognition of deferred tax asset (1,579) (546) (1,505) Recognition of deferred tax assets on previous years tax losses 119 653 − Non-taxable income 925 606 556 Use of previous years tax losses and tax credits for which no − − 12 Taxes on other basis − 280 (117) Other (103) 161 (81) Income tax expense as reported in the consolidated income statement (2,595) (425) (522)

Earnings per share (Tables)

Earnings per share (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings per share [abstract]
Net profit (loss) used for the earnings per share calculation [text block]	For the year ended December 31 in 000€ 2019 2018 2017* Net profit attributable to ordinary equity holders of the parent for basic earnings 1,646 3,027 (2,117) Interest on convertible bonds 50 50 − Net profit attributable to ordinary equity holders of the parent adjusted for the effect of dilution 1,696 3,077 (2,117)
Share data used for the earnings per share calculation [text block]	For the year ended December 31 in 000 2019 2018 2017 Weighted average number of ordinary shares for basic earnings per share 52,915 49,806 47,325 Effect of dilution: Share options 563 382 − Convertible loan 509 509 − Weighted average number of ordinary shares adjusted for effect of dilution 53,987 50,697 47,325
Earnings per share [text block]	For the year ended December 31 2019 2018 2017* Earnings per share attributable to the owners of the parent Basic 0.03 0.06 (0.04) Diluted 0.03 0.06 (0.04)

Commitments and contingent li_2

Commitments and contingent liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Capital commitments [abstract]
Disclosure of Operational lease commitments [Text Block]	As of December 31, in 000€ 2019 2018 2017 Within one year 28 2,053 1,721 Between one and three years 49 2,302 1,504 Between four and five years − 785 406 More than five years − 302 77 Total 77 5,442 3,708
Disclosure of future minimum lease payments [text block]	December 31, 2019 December 31, 2018 December 31, 2017 in 000€ Minimum lease payments Present value of payments Minimum lease payments Present value of payments Minimum lease payments Present value of payments Within one year − − 2,876 2,829 3,179 3,034 Between two and three years − − 3,398 3,236 5,017 4,643 Between four and five years − − 655 604 1,361 1,269 More than five years − − 149 140 285 218 Total − − 7,078 6,809 9,842 9,164 Less finance charges − − (269) − (678) − Present value of minimum lease payments − − 6,809 6,809 9,164 9,164

Risks (Tables)

Risks (Tables)	12 Months Ended
	Dec. 31, 2019
Risks [abstract]
Disclosure of liquidity risk [text block]	in 000€ Less than 1 year 2 to 3 years 4-5 years More than 5 years Total At December 31, 2019 Loan & borrowings 14,300 33,034 41,672 34,447 123,453 Lease liabilities 3,685 4,907 1,040 720 10,352 Trade payables 18,517 − − − 18,517 Other current liabilities and advances received 4,063 − − − 4,063 Total 40,565 37,941 42,712 35,167 156,385 Less than 1 year 2 to 3 years 4-5 years More than 5 years Total At December 31, 2018 Loan & borrowings 14,491 42,100 33,636 23,870 114,097 Trade payables 18,667 − − − 18,667 Other current liabilities 2,267 − − − 2,267 Total 35,425 42,100 33,636 23,870 135,031 Less than 1 year 2 to 3 years 4-5 years More than 5 years Total At December 31, 2017* Loan & borrowings 14,331 37,933 22,286 32,699 107,249 Trade payables 15,670 − − − 15,670 Other current liabilities 1,390 − − − 1,390 Total 31,391 37,933 22,286 32,699 124,309
Disclosure of aging of trade receivables [text block]	in 000€ Total Non-due Less than 30 days 31-60 days 61-90 days 91-180 days More than 181 days December 31, 2019 40,977 31,528 4,924 2,094 733 981 717 December 31, 2018 36,891 26,208 5,395 1,479 931 1,512 1,366 December 31, 2017 35,582 21,630 6,920 1,765 1,526 1,614 2,127

Overview of consolidated enti_2

Overview of consolidated entities (Tables)	12 Months Ended
	Dec. 31, 2019
Overview of consolidated entites [abstract]
Disclosure of interests in subsidiaries [Text block]	28 Overview of consolidated entities Name Country of incorporation % equity interest 2019 2018 2017 Materialise NV Belgium 100% 100% 100% Materialise France SAS France 100% 100% 100% Materialise GmbH Germany 100% 100% 100% Materialise Japan K.K. Japan 100% 100% 100% Materialise Czech Republic SRO Czech Republic 100% 100% 100% Materialise USA, LLC United States 99% 99% 99% Materialise UK Limited United Kingdom 100% 100% 100% OBL SAS France 100% 100% 100% Materialise Austria GmbH Austria 100% 100% 100% Materialise Malaysia SDN. Bhd. Malaysia 100% 100% 100% Materialise Ukraine LLC Ukraine 100% 100% 100% RapidFit NV Belgium 83% 83% 83% Meridian Technique Limited United Kingdom 100% 100% 100% OrthoView Holdings Limited United Kingdom 100% 100% 100% Meridian (Corporate Trustee) Limited (liquidated) United Kingdom — — 100% OrthoView Limited (liquidated) United Kingdom — — 100% Materialise SA Poland 100% 100% 100% Materialise Colombia SAS Colombia 100% 100% 100% RSPRINT powered by Materialise NV (joint venture) Belgium 50% 50% 50% Materialise Shanghai Co.Ltd China 100% 100% 100% Engimplan Engenharia de Implante Industria & Comércio Ltda Brazil 75% — — Engimplan Holding Ltda Brazil 100% — — Materialise Australia PTY Ltd Australia 100% 100% 100% Materialise S.R.L. Italy 100% 100% 100% ACTech GmbH Germany 100% 100% 100% ACTech Holding GmbH Germany 100% 100% 100% ACTech, Inc United States 100% 100% 100%

Related party transactions (Tab

Related party transactions (Tables)	12 Months Ended
	Dec. 31, 2019
Related party transactions [abstract]
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block]	For the year ended December 31 in 000€ 2019 2018 2017 Short-term employee benefits 2,394 2,334 2,190 Post-employment benefits 85 80 80 Total 2,479 2,414 2,270 Warrants granted − − − Warrants outstanding 359,266 557,935 573,980
Disclosure of transactions between related parties [text block]	in 000€ Sale of goods to Purchases from Depreciation Interest expense Right-of-Use Assets Receivables Lease liabilities Other liabilities Non-executive directors of the group 2019 − 128 − 37 − − − 1,053 2018 − 123 − 51 − − − 1,038 2017 − 96 − 50 − − − 965 Shareholders of the group 2019 − 113 − 9 − − − 131 2018 − 123 − 10 − − − 261 2017 − 172 − 11 − − − 371 Joint ventures 2019 1,431 − − − − 1,279 − − 2018 1,156 241 − − − 1,281 − 22 2017 714 23 − − − 804 − 28 Non-controlling interests 2019 − − 26 9 617 − 652 − 2018 − − − − − − − − 2017 − − − − − − − −

Basis of preparation - IFRS 16

Basis of preparation - IFRS 16 Lease Liabilities (Detail) - Lease liabilities [member] € in Thousands	Dec. 31, 2018EUR (€)
IFRS 16 lease liabilities [line items]
Non-cancellable operating lease commitments disclosed at 31 December 2018	€ 5,442
Discounted using the company's incremental borrowing rate	(268)
Add: finance lease liabilities recognized at 31 December 2018	6,809
(Less) short-term/low-value leases recognized on a straight-line basis as an expense	(88)
Add/(Less) adjustments related to different treatment extension and termination options	(101)
Lease liabilities recognized as at 1 January 2019	€ 11,794

Basis of preparation - IFRS 1_2

Basis of preparation - IFRS 16 Lease liabilities Narrative (Detail) € in Thousands	Dec. 31, 2018EUR (€)
Additional information disclosed [abstract]
The weighted average discount rate applied to the lease liabilities at 1 January 2019	2.9887%
The net book value of finance leases under IAS 17 for which the carrying amount has not been reassessed	€ 5,886

Basis of preparation - IFRS 1_3

Basis of preparation - IFRS 16 Right Of Use Asset (Detail) - Right-of-use asset [Member] - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018
Basis of preparation - Quantitative information about right-of-use assets [line items]
Buildings	€ 3,843	€ 3,255
Vehicles	882	849
Other assets	301	880
Total right-of-use assets	5,026	4,984
Total lease liabilities	€ 5,026	€ 4,984

Summary of significant accoun_3

Summary of significant accounting policies Narrative (Detail)	Dec. 31, 2019
Contributions paid as from 2016 [abstract]
Minimum guaranteed return	1.75%
Maximum guaranteed return	3.75%
Contributions paid until 2015 [abstract]
Minimum guaranteed return employer contributions	3.25%
Minimum guaranteed return employee contributions	3.75%

Significant accounting judgemen

Significant accounting judgements, estimates and assumptions Narrative (Detail) - EUR (€)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Significant accounting judgements, estimates and assumptions
Capitalized software development new planner	€ 461,000
Capitalized 3D printed product medical	1,376,000
Tax losses carried forward	37,440,000	€ 25,285,000	€ 11,948,000
Other tax credits Materialize NV	25,172,000	15,592,000	4,581,000
Notional interest deduction	€ 0	0	315,000
Belgian Patent Income Deduction %	80.00%
Innovation Income Deduction	85.00%
Deferred tax assets recognized	€ 0	0	0
Unrecognized deferred tax assets	10,737,000	11,906,000	7,904,000
Net profit would have increased by	6,855,000
Tax losses utilized	23,141,000
Goodwill	20,174,000	17,491,000	17,552,000	[1]
Impairment charges on goodwill	0	€ 0	€ 0
Fluidda - Notional amount	2,500,000
Fluidda - Carrying value	€ 2,750,000
Fluidda - Interest rate	10.00%
Fluidda - Discount rate	13.88%
Fluidda - Maturity years	7
Fluidda - Sensitivity WACC	2.00%
Fluidda - Sensitivity WACC -	€ (267,000)
Fluidda - Sensitivity WACC +	298,000
Change useful life - impact	1,000,000
Greenmachine - carrying value	€ 1,804,000
Greenmachine - discount rate	10.00%
[1]	* The year 2017 has been restated to reflect the final accounting of the business combination with ACTech.

Business combinations - Cenat N

Business combinations - Cenat Narrative (Detail) - Cenat [member] - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Carrying value at acquisition date [member]
Contribution to the
Measurement gain 2018		€ 192
Fair value at acquisition date [member]
Contribution to the
Payment shareholders Jan 21, 2019	€ 450

Business combinations - ACTech

Business combinations - ACTech (Details) - ACTech [member] € in Thousands	Dec. 31, 2019EUR (€)
Fair value at acquisition date [member]
Assets [Abstract]
Technology	€ 515
Customer relations	17,092
Other intangible assets	985
Property, plant and equipment	20,229
Deferred tax assets	88
Other non-current financial assets	56
Inventory	2,789
Trade receivables	5,176
Cash and cash equivalents	2,244
Other assets	542
Total Assets	49,716
Liabilities [Abstract]
Deferred tax liabilities	(6,024)
Deferred income	0
Loans and borrowings	(11,308)
Trade payables	(777)
Tax payables	(2,450)
Other liabilities	(9,062)
Total Liabilities	(29,621)
Total identified assets and liabilities	20,095
Goodwill	8,812
Acquisition price	28,907
Cash and cash equivalents acquired	(2,244)
Acquisition price in cash including escrow	29,417
Total cash flow	27,173
Carrying value at acquisition date [member]
Assets [Abstract]
Technology	0
Customer relations	0
Other intangible assets	6,330
Property, plant and equipment	19,986
Deferred tax assets	503
Other non-current financial assets	56
Inventory	2,356
Trade receivables	5,176
Cash and cash equivalents	2,244
Other assets	542
Total Assets	37,193
Liabilities [Abstract]
Deferred tax liabilities	(47)
Deferred income	(1,298)
Loans and borrowings	(11,308)
Trade payables	(777)
Tax payables	(3,664)
Other liabilities	(9,062)
Total Liabilities	(26,156)
Total identified assets and liabilities	11,037
Fair value adjustments [member]
Assets [Abstract]
Technology	515
Customer relations	17,092
Other intangible assets	(5,345)
Property, plant and equipment	243
Deferred tax assets	(415)
Other non-current financial assets	0
Inventory	433
Trade receivables	0
Cash and cash equivalents	0
Other assets	0
Total Assets	12,523
Liabilities [Abstract]
Deferred tax liabilities	(5,977)
Deferred income	1,298
Loans and borrowings	0
Trade payables	0
Tax payables	1,214
Other liabilities	0
Total Liabilities	(3,465)
Total identified assets and liabilities	€ 9,058

Business combinations - ACTec_2

Business combinations - ACTech Narrative (Detail) - ACTech [member] - Provisional fair value at acquisition date [member] € in Thousands	12 Months Ended
	Dec. 31, 2019EUR (€)
Disclosure of detailed information about business combination [line items]
Difference final and provision fair value assets and liabilities	€ 2,432
Fair value customer relationship	17,092
Fair value patented technology	515
Fair value order backlog	826
Fair value tax contingency	222
Trade receivables recognised as of acquisition date	5,176
Escrow amount	3,788
Indemnification assets	222
Acquisition costs	609
Contribution of revenue	9,965
Contribution to net profit	275
Proforma contribution revenue	37,096
Proforma contribution net profit	€ 2,060

Business combinations - Engimpl

Business combinations - Engimplan (Detail) - Engimplan [member] € in Thousands	12 Months Ended
	Dec. 31, 2019EUR (€)
Fair value at acquisition date [member]
Assets [Abstract]
Software	€ 214
Customer relations	2,530
Trademarks	556
Other intangible assets	9
Property, plant and equipment	2,369
Right-of-use assets	633
Deferred tax assets	0
Other non-current financial assets	3
Inventory	2,180
Trade receivables	1,802
Other current assets	391
Cash from capital increase	(5,750)
Cash and cash equivalents	316
Total Assets	16,753
Liabilities [Abstract]
Deferred tax liabilities	0
Deferred income	(83)
Loans and borrowings	(1,443)
Lease liabilities	(633)
Trade payables	(271)
Tax payables	(100)
Payroll related payables	(298)
Other liabilities	(914)
Total Liabilities	(3,742)
Total identified assets and liabilities	13,011
Goodwill	2,639
Non-controlling interest	(3,253)
Acquisition price	12,397
Cashflow from business combination
Cash and cash equivalents acquired	(316)
Cash from capital increase	(5,750)
Acquisition price in cash	12,397
Total cash flow	6,331
Carrying value at acquisition date [member]
Assets [Abstract]
Software	214
Customer relations	0
Trademarks	0
Other intangible assets	9
Property, plant and equipment	2,268
Right-of-use assets	633
Deferred tax assets	0
Other non-current financial assets	3
Inventory	2,084
Trade receivables	1,802
Other current assets	391
Cash from capital increase	(5,750)
Cash and cash equivalents	316
Total Assets	13,470
Liabilities [Abstract]
Deferred tax liabilities	0
Deferred income	(83)
Loans and borrowings	(1,443)
Lease liabilities	(633)
Trade payables	(271)
Tax payables	(100)
Payroll related payables	(298)
Other liabilities	(914)
Total Liabilities	(3,742)
Total identified assets and liabilities	9,728
Goodwill	0
Non-controlling interest	0
Acquisition price	0
Fair value adjustments [member]
Assets [Abstract]
Software	0
Customer relations	2,530
Trademarks	556
Other intangible assets	0
Property, plant and equipment	101
Right-of-use assets	0
Deferred tax assets	0
Other non-current financial assets	0
Inventory	96
Trade receivables	0
Other current assets	0
Cash from capital increase	0
Cash and cash equivalents	0
Total Assets	3,283
Liabilities [Abstract]
Deferred tax liabilities	0
Deferred income	0
Loans and borrowings	0
Lease liabilities	0
Trade payables	0
Tax payables	0
Payroll related payables	0
Other liabilities	0
Total Liabilities	0
Total identified assets and liabilities	3,283
Goodwill	0
Non-controlling interest	0
Acquisition price	€ 0

Business combinations - Engim_2

Business combinations - Engimplan Narrative (Detail) - Engimplan [member] - Fair value at acquisition date [member] € in Thousands	12 Months Ended
	Dec. 31, 2019EUR (€)
Disclosure of detailed information about business combination [line items]
Fair value customer relationship	€ 2,530
Fair value trademarks	556
Consideration paid for 40% of the shares	€ 6,647
Voting interest before capital increase	40.00%
Capital increase	€ 5,750
Voting interest after capital increase	75.00%
Contribution to net profit	€ 315
Contribution of revenue	2,437
Proforma contribution net profit	(1,258)
Acquisition costs	€ 140

Goodwill (Detail)

Goodwill (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill [line items]
CGU: MAT NV SAM BE	€ 3,241	€ 3,241	€ 3,241
CGU: e-Prototype	800	794	818
CGU: Actech	8,812	8,812	8,812
CGU: OrthoView	4,683	4,467	4,504
CGU: MAT NV Manufacturing (Metal)	177	177	177
CGU: Engimplan	2,461	0	0
Total Goodwill	€ 20,174	€ 17,491	€ 17,552	[1]
[1]	* The year 2017 has been restated to reflect the final accounting of the business combination with ACTech.

Goodwill - Movement table (Deta

Goodwill - Movement table (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Carrying amount [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Goodwill, beginning balance	€ 17,491	€ 17,552	€ 8,860
Additions	2,639	0	8,812
Impairment			0
Currency translation	44	(61)	(120)
Goodwill, ending balance	20,174	17,491	17,552
Gross carrying amount [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Goodwill, beginning balance	17,595	17,656	8,964
Additions	2,639	0	8,812
Impairment			0
Currency translation	44	(61)	(120)
Goodwill, ending balance	20,278	17,595	17,656
Accumulated impairment [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Goodwill imparement, beginning balance	(104)	(104)	(104)
Additions	0	0	0
Impairment			0
Currency translation	0	0	0
Goodwill imparement, ending balance	€ (104)	€ (104)	€ (104)

Goodwill - Movement table Narra

Goodwill - Movement table Narrative (Detail) € in Thousands	12 Months Ended
	Dec. 31, 2019EUR (€)
Orthoview [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Increase (decrease) through net exchange differences, goodwill	€ 216
Engimplan [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Increase (decrease) through net exchange differences, goodwill	(178)
e-Prototypy [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Increase (decrease) through net exchange differences, goodwill	€ 6

Goodwill - Impairment (Detail)

Goodwill - Impairment (Detail)	Dec. 31, 2019EUR (€)
MAT NV SAM BE
Disclosure of information for cash-generating units [line items]
Discount rate	10.96%
Perpetual growth rate	5.00%
Carrying value	€ 39,132,000
e-Prototypy [member]
Disclosure of information for cash-generating units [line items]
Discount rate	14.52%
Perpetual growth rate	2.00%
Carrying value	€ 3,940,000
Discount rate increase	1.00%
Orthoview [member]
Disclosure of information for cash-generating units [line items]
Discount rate	11.97%
Perpetual growth rate	1.00%
Carrying value	€ 9,269,000
Discount rate increase	1.00%
Perpetual growth rate decrease	0.00%
ACTech [member]
Disclosure of information for cash-generating units [line items]
Discount rate	9.40%
Perpetual growth rate	1.00%
Carrying value	€ 26,284,000
Discount rate increase	1.00%
Five year projection decrease	5
Engimplan [member]
Disclosure of information for cash-generating units [line items]
Discount rate	17.05%
Perpetual growth rate	3.00%
Carrying value	€ 15,710,000
Discount rate increase	1.00%
Five year projection decrease	5

Intangible assets (Detail)

Intangible assets (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total | Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	€ 39,429	€ 37,730	€ 15,153
Additions	2,193	2,344	4,467
Acquisition of a subsidiary	3,309	0	18,790
Disposals	(77)	(980)	(302)
Transfer between accounts	504	366	(98)
Currency translation	97	(48)	(188)
Other	(19)	17	(92)
Intangible assets at end of period	45,436	39,429	37,730
Total | Accumulated depreciation and amortization [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	(13,103)	(9,130)	(5,388)
Depreciation charge for the year	(4,859)	(5,064)	(3,822)
Disposals	23	1,060	79
Transfer between accounts	13	0	98
Currency translation	(151)	23	49
Other	36	8	(146)
Intangible assets at end of period	(18,041)	(13,103)	(9,130)
Total | Carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	26,326	28,600	9,765
Intangible assets at end of period	27,395	26,326	28,600
Patents and licenses [member] | Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	4,294	4,497	3,788
Additions	209	554	749
Acquisition of a subsidiary	38	0	115
Disposals	0	(759)	(159)
Transfer between accounts	(109)	2	0
Currency translation	1	0	0
Other	3	0	4
Intangible assets at end of period	4,436	4,294	4,497
Patents and licenses [member] | Accumulated depreciation and amortization [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	(2,661)	(2,766)	(2,042)
Depreciation charge for the year	(246)	(749)	(609)
Disposals	0	854	2
Transfer between accounts	109	0	0
Currency translation	0	0	0
Other	0	0	(117)
Intangible assets at end of period	(2,798)	(2,661)	(2,766)
Patents and licenses [member] | Carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	1,633	1,731	1,746
Intangible assets at end of period	1,638	1,633	1,731
Software [member] | Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	8,241	7,638	3,769
Additions	656	807	3,718
Acquisition of a subsidiary	214	0	242
Disposals	(45)	(221)	(143)
Transfer between accounts	1,601	0	(98)
Currency translation	(10)	0	(5)
Other	10	17	155
Intangible assets at end of period	10,667	8,241	7,638
Software [member] | Accumulated depreciation and amortization [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	(5,080)	(2,985)	(1,251)
Depreciation charge for the year	(2,582)	(2,310)	(1,634)
Disposals	23	206	77
Transfer between accounts	(96)	0	98
Currency translation	(25)	1	4
Other	20	8	(279)
Intangible assets at end of period	(7,740)	(5,080)	(2,985)
Software [member] | Carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	3,161	4,653	2,518
Intangible assets at end of period	2,927	3,161	4,653
Acquired customers and technology [member] | Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	25,579	25,595	7,596
Additions	0	32	0
Acquisition of a subsidiary	3,048	0	18,433
Disposals	(32)	0	0
Transfer between accounts	0	0	0
Currency translation	86	(48)	(183)
Other	0	0	(251)
Intangible assets at end of period	28,681	25,579	25,595
Acquired customers and technology [member] | Accumulated depreciation and amortization [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	(5,362)	(3,379)	(2,095)
Depreciation charge for the year	(2,031)	(2,005)	(1,579)
Disposals	0	0	0
Transfer between accounts	0	0	0
Currency translation	(126)	22	45
Other	16	0	250
Intangible assets at end of period	(7,503)	(5,362)	(3,379)
Acquired customers and technology [member] | Carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	20,217	22,216	5,501
Intangible assets at end of period	21,178	20,217	22,216
Developed technology and software under construction [member] | Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	1,315	0	0
Additions	1,328	951	0
Acquisition of a subsidiary	9	0	0
Disposals	0	0	0
Transfer between accounts	(988)	364	0
Currency translation	20	0	0
Other	(32)	0	0
Intangible assets at end of period	1,652	1,315	0
Developed technology and software under construction [member] | Accumulated depreciation and amortization [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	0	0	0
Depreciation charge for the year	0	0	0
Disposals	0	0	0
Transfer between accounts	0	0	0
Currency translation	0	0	0
Other	0	0	0
Intangible assets at end of period	0	0	0
Developed technology and software under construction [member] | Carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning of period	1,315	0	0
Intangible assets at end of period	€ 1,652	€ 1,315	€ 0

Remaining amortization period o

Remaining amortization period on intangibles resulting from business combinations (Detail) - EUR (€)	Dec. 31, 2019	Dec. 31, 2018
Orthoview [member] | Acquired customers and technology [member]
Remaining amortization method [line items]
Remaining amortization period customer related intangible assets acquisition	4.75	5.75
ACTech [member] | Acquired customers and technology [member]
Remaining amortization method [line items]
Remaining amortization period customer related intangible assets acquisition	17.75	18.75
Cenat [member] | Acquired customers and technology [member]
Remaining amortization method [line items]
Remaining amortization period customer related intangible assets acquisition	5.25	6.25
Engimplan [member] | Acquired customers and technology [member]
Remaining amortization method [line items]
Remaining amortization period customer related intangible assets acquisition	9.58
General [member] | Patents and licenses [member]
Remaining amortization method [line items]
Remaining amortization period technology related intangible assets acquisition	7.68
General [member] | Software [member]
Remaining amortization method [line items]
Remaining amortization period technology related intangible assets acquisition	1.45

Property, plant and equipment_2

Property, plant and equipment (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total | Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	€ 140,663	€ 125,358	€ 75,889
Impact of adoption IFRS16	4,984
Additions	16,901	18,557	30,517
Acquired from business combinations	3,002		20,230
Disposals	(6,881)	(2,385)	(898)
Transfers	(504)	(598)	(373)
Currency Translation	363	(189)	(210)
Other	(1,252)	(80)	203
Property, plant and equipment end of period	157,276	140,663	125,358
Total | Accumulated depreciation and amortization [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	(48,126)	(38,293)	(30,826)
Depreciation charge for the year	(14,339)	(12,223)	(8,689)
Disposals	6,099	2,134	875
Transfers	(13)	243	373
Currency Translation	(217)	(60)	196
Other	237	73	(222)
Property, plant and equipment end of period	(56,359)	(48,126)	(38,293)
Total | Carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	92,537	87,065	45,063
Property, plant and equipment end of period	100,917	92,537	87,065
Land and buildings | Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	45,777	40,184	19,797
Impact of adoption IFRS16	0
Additions	302	3,079	377
Acquired from business combinations	61		9,362
Disposals	(37)	(99)	(31)
Transfers	(3,360)	2,728	11,527
Currency Translation	150	(119)	(185)
Other	0	4	(663)
Property, plant and equipment end of period	42,893	45,777	40,184
Land and buildings | Accumulated depreciation and amortization [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	(6,071)	(4,504)	(5,093)
Depreciation charge for the year	(1,199)	(1,560)	(831)
Disposals	36	26	15
Transfers	200	(18)	521
Currency Translation	(25)	(15)	31
Other	220	0	853
Property, plant and equipment end of period	(6,839)	(6,071)	(4,504)
Land and buildings | Carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	39,706	35,680	14,704
Property, plant and equipment end of period	36,054	39,706	35,680
Plant and equipment | Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	77,557	67,117	40,199
Impact of adoption IFRS16	0
Additions	7,363	9,476	10,560
Acquired from business combinations	2,291		10,318
Disposals	(6,091)	(1,882)	(1,046)
Transfers	7,077	2,953	7,439
Currency Translation	199	(25)	(118)
Other	(73)	(82)	(235)
Property, plant and equipment end of period	88,323	77,557	67,117
Plant and equipment | Accumulated depreciation and amortization [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	(33,307)	(27,166)	(22,263)
Depreciation charge for the year	(9,082)	(8,010)	(5,531)
Disposals	5,704	2,102	842
Transfers	(1,551)	(253)	(444)
Currency Translation	(190)	(53)	166
Other	(34)	73	64
Property, plant and equipment end of period	(38,460)	(33,307)	(27,166)
Plant and equipment | Carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	44,250	39,951	17,936
Property, plant and equipment end of period	49,863	44,250	39,951
Leased assets | Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	14,327	14,303	11,241
Impact of adoption IFRS16	4,984
Additions	3,429	792	2,246
Acquired from business combinations	633		136
Disposals	(753)	(17)	(39)
Transfers	117	(732)	(425)
Currency Translation	8	(19)	5
Other	(1,099)	0	1,139
Property, plant and equipment end of period	21,646	14,327	14,303
Leased assets | Accumulated depreciation and amortization [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	(8,441)	(6,623)	(3,470)
Depreciation charge for the year	(4,058)	(2,346)	(2,327)
Disposals	359	6	18
Transfers	1,031	514	296
Currency Translation	(2)	8	(1)
Other	51	0	(1,139)
Property, plant and equipment end of period	(11,060)	(8,441)	(6,623)
Leased assets | Carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	5,886	7,680	7,771
Property, plant and equipment end of period	10,586	5,886	7,680
Construction in progress | Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	3,002	3,754	4,652
Impact of adoption IFRS16	0
Additions	5,807	5,210	17,334
Acquired from business combinations	17		414
Disposals	0	(387)	218
Transfers	(4,338)	(5,547)	(18,914)
Currency Translation	6	(26)	88
Other	(80)	(2)	(38)
Property, plant and equipment end of period	4,414	3,002	3,754
Construction in progress | Accumulated depreciation and amortization [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	(307)	0	0
Depreciation charge for the year	0	(307)	0
Disposals	0	0	0
Transfers	307	0	0
Currency Translation	0	0	0
Other	0	0	0
Property, plant and equipment end of period	0	(307)	0
Construction in progress | Carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment beginning of period	2,695	3,754	4,652
Property, plant and equipment end of period	€ 4,414	€ 2,695	€ 3,754

Property, Plant and equipment N

Property, Plant and equipment Narrative (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property, plant and equipment [member]
Capital expenditures [line items]
new machines and installations acquired and leased	€ 7,757	€ 10,747
computer and IT infrastructure	1,268	1,781
new building constructions	4,865	2,491	€ 12,762
New finance leases	4,062
Increase through leased motor vehicles	1,119	792	1,596
Net loss on disposal of PPE	165	(83)	25
Total accumulated depreciation finance leases machinery property, plant and equipment	1,045	1,745	1,864
Land and buildings pledges as security	26,270	27,319	28,526
Other fixed assets pledges - carrying value	2,884	3,533	13,340
Transfers from assets under construction to PP&E	4,031
Gross-up net amount PPA ACTECH	2,050
Excercising purchase option	362
IFRS 16 Implementation	1,510
Green Machine Project	1,870
Buidlings Germany	1,464
Decrease of depreciation charges 2019	1,147
Depreciation charge 2020	478
Depreciation charge 2021	276
Includes modification right of use assets	(554)
Investments related to leased vehicles	1,118	792
Machinery [member]
Capital expenditures [line items]
new machines and installations acquired and leased			11,947
Leased assets [member]
Capital expenditures [line items]
new machines and installations acquired and leased			1,444
Finance leases - total, net	€ 3,048	€ 4,608	€ 6,613

Property, plant and equipment -

Property, plant and equipment - Income Statement Impact (Detail) € in Thousands	12 Months Ended
	Dec. 31, 2019EUR (€)
Income statement impact [Line items]
Depreciation expense	€ (4,058)
Interest expense on lease liabilities	(204)
Expenses related to short-term leases/low-value assets/variable lease payments	€ (725)

Property, plant and equipment_3

Property, plant and equipment - Potential future cash flows following the extension (Detail) € in Thousands	Dec. 31, 2019EUR (€)
Disclosure of potential future cash flows following the extension [abstract]
Potential cash flows for extension options that are not reasonably certain to be exercised	€ 843
Potential cash flows for termination options that are reasonably cetain to be exercised	€ 174

Property, plant and equipment_4

Property, plant and equipment - Right-of-use assets (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Classes of assets [member] | Gross carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets before adoption IFRS16		€ 14,327
Impact of adoption IFRS16		4,984
Right-of-use assets, beginning of period	€ 19,311
Additions	3,429
Acquired from business combinations	633
Modifications	(545)
Disposals	(753)
Currency translation	8
Transfers	117
Other	(554)
Right-of-use assets, end of period	21,646
Classes of assets [member] | Accumulated depreciation and amortization [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets, beginning of period	(8,441)
Depreciation charge for the year	(4,058)
Acquired from business combinations	0
Modifications	0
Disposals	460
Currency translation	(2)
Transfers	1,031
Other	(50)
Right-of-use assets, end of period	(11,060)
Classes of assets [member] | Carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets before adoption IFRS16		5,886
Right-of-use assets, beginning of period	10,870
Right-of-use assets, end of period	10,586
Buildings [member] | Gross carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets before adoption IFRS16		935
Impact of adoption IFRS16		3,255
Right-of-use assets, beginning of period	4,190
Additions	2,222
Acquired from business combinations	633
Modifications	(9)
Disposals	(550)
Currency translation	4
Transfers	0
Other	(2)
Right-of-use assets, end of period	6,488
Buildings [member] | Accumulated depreciation and amortization [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets, beginning of period	(1,011)
Depreciation charge for the year	(1,953)
Acquired from business combinations	0
Modifications	0
Disposals	257
Currency translation	(1)
Transfers	0
Other	3
Right-of-use assets, end of period	(2,705)
Buildings [member] | Carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets before adoption IFRS16		(76)
Right-of-use assets, beginning of period	3,179
Right-of-use assets, end of period	3,783
Vehicles [member] | Gross carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets before adoption IFRS16		2,542
Impact of adoption IFRS16		849
Right-of-use assets, beginning of period	3,391
Additions	1,118
Acquired from business combinations	0
Modifications	(40)
Disposals	(147)
Currency translation	0
Transfers	(47)
Other	0
Right-of-use assets, end of period	4,275
Vehicles [member] | Accumulated depreciation and amortization [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets, beginning of period	(1,189)
Depreciation charge for the year	(1,060)
Acquired from business combinations	0
Modifications	0
Disposals	147
Currency translation	0
Transfers	41
Other	31
Right-of-use assets, end of period	(2,030)
Vehicles [member] | Carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets before adoption IFRS16		1,353
Right-of-use assets, beginning of period	2,202
Right-of-use assets, end of period	2,245
Other [member] | Gross carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets before adoption IFRS16		10,850
Impact of adoption IFRS16		880
Right-of-use assets, beginning of period	11,730
Additions	89
Acquired from business combinations	0
Modifications	(496)
Disposals	(56)
Currency translation	4
Transfers	164
Other	(552)
Right-of-use assets, end of period	10,883
Other [member] | Accumulated depreciation and amortization [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets, beginning of period	(6,241)
Depreciation charge for the year	(1,045)
Acquired from business combinations	0
Modifications	0
Disposals	56
Currency translation	(1)
Transfers	990
Other	(84)
Right-of-use assets, end of period	(6,325)
Other [member] | Carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets before adoption IFRS16		€ 4,609
Right-of-use assets, beginning of period	5,489
Right-of-use assets, end of period	€ 4,558

Investment in associates and jo

Investment in associates and joint ventures (Detail) - Entity's total for joint ventures [member] - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Joint venture's statement of financial position [abstract]
Current assets	€ 1,546	€ 850	€ 1,256
Non-current assets	93	114	212
Goodwill	0	0	0
Current liabilities	(1,114)	(756)	(692)
Non-current liabilities	(448)	(1,096)	(788)
Shareholders' deficit (surplus)	(77)	888	12
The joint venture income (loss) [abstract]
Revenue	1,736	1,186	817
Profit (loss)	€ (785)	€ (876)	€ (723)

Investment in associates and _2

Investment in associates and joint ventures Nattarive (Detail) - Entity's total for joint ventures [member] - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of joint ventures [line items]
Cash and cash equivalents	€ 247	€ 175	€ 128
Amortization and depreciation	€ (25)	€ (30)	€ (50)

Investment in associates and _3

Investment in associates and joint ventures - Detail movement (Detail) - Detail movement [member] - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Detail movement [line items]
Investments in joint ventures, beginning balance	€ 0	€ 31	€ 0
Additional investment	875	0	500
Transfer from receivables		444	0
Transfer to receivebles	(444)
Share in loss of joint venture	(392)	(475)	(469)
Investments in joint ventures, ending balance	€ 39	€ 0	€ 31

Inventory and Contracts in Pr_2

Inventory and Contracts in Progress (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Inventory and contracts in progress [abstract]
Raw materials	€ 7,400	€ 5,616	€ 4,970
Work in progress	2,805	2,151	3,377
Finished goods	1,996	1,390	1,414
Contracts in progress	495	829	1,266
Total inventories and contracts in progress	€ 12,696	€ 9,986	€ 11,027

Inventory and Contracts in Pr_3

Inventory and Contracts in Progress Narrative (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Inventory and contracts in progress [abstract]
Total costs incurred contract in progress	€ 366
Total profit recognized contracts in progress	129
Total amount inventory written off as an expense	526	€ 229	€ 48
Advances received	€ 22	€ 370	€ 0

Other non-current assets (Detai

Other non-current assets (Detail) - Other non current assets [member] - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other non current assets [line items]
Tax credits	€ 3,015	€ 3,006	€ 2,446
Guarantees and deposits	415	405	362
Non-current receivable on joint venture	138	1,096	804
Non-listed equity investments	3,046	2,701	0
Convertible loan	2,750	0	0
Other	27	29	55
Total non-current assets	€ 9,391	€ 7,237	€ 3,667

Ohter non-current assets narrat

Ohter non-current assets narrative (Detail)	Dec. 31, 2019EUR (€)
Other non-current assets narratvive [abstract]
Fluidda - Notional amount	€ 2,500,000
Fluidda - Interest rate	10.00%
Fluidda - Maturity years	7

Other current assets (Detail)

Other current assets (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Miscellaneous current assets [abstract]
Deferred charges	€ 2,632	€ 2,046	€ 2,021
Tax credits	695	185	219
Accrued income	486	958	524
Other tax receivables	3,127	2,286	2,910
Other non-trade receivables	1,676	1,461	2,001
Total current assets	€ 8,616	€ 6,936	€ 7,675	[1]
[1]	* The year 2017 has been restated to reflect the final accounting of the business combination with ACTech.

Other current assets Narrative

Other current assets Narrative (Detail) - Miscellaneous current assets narrative [member] - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other non current assets [line items]
Receivable related to factoring included in non-trade receivables			€ 646
Receivable related to factoring included trade receivables	€ 362	€ 445
Indemnification assets	€ 222

Trade receivables (Detail)

Trade receivables (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Trade receivables [line items]
Trade receivables	€ 42,509	€ 38,764	€ 36,572
Write off receivables	(1,532)	(1,873)	(990)
Total	€ 40,977	€ 36,891	€ 35,582	[1]
[1]	* The year 2017 has been restated to reflect the final accounting of the business combination with ACTech.

Trade receivebles - Movement ta

Trade receivebles - Movement table bad debt reserve (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Overview of impairment changes to receivables [abstract]
Beginning of period	€ (1,873)	€ (990)	€ 511
Addition	(141)	(1,284)	(620)
Usage	131	182	12
Reversal	351	219	129
End of period	€ (1,532)	€ (1,873)	€ (990)

Cash and cash equivalents (Deta

Cash and cash equivalents (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash and cash equivalents [line items]
Cash at bank	€ 123,337	€ 105,846	€ 33,611
Cash equivalents	5,560	9,660	9,564
Total	€ 128,897	€ 115,506	€ 43,175	[1]
[1]	* The year 2017 has been restated to reflect the final accounting of the business combination with ACTech.

Cash and cash equivalents Narra

Cash and cash equivalents Narrative (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash and cash equivalents [abstract]
Amounts from exercise of warrants not executed	€ 0	€ 209	€ 0

Equity (Detail)

Equity (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total number of ordinary shares [member]
Disclosure of classes of share capital [line items]
Outstanding, shares, beginning of period	52,890,761	47,325,438	47,325,438
Transfer share capital to share premium		€ 0
Capital increase in cash - public offering	€ 0	5,403,125
Expenses directly attributable to public offering	€ 0	€ 0
Capital increase via exercise warrants on, number of shares	281,752	162,198
Equity-settled share-based payment expense	€ 0	€ 0	€ 0
Outstanding, shares, end of period	53,172,513	52,890,761	47,325,438
Total shareholders' capital [member]
Disclosure of classes of share capital [line items]
Outstanding, beginning of period	€ 3,050	€ 2,729	€ 2,729
Transfer share capital to share premium		0
Capital increase in cash - public offering	0	312
Expenses directly attributable to public offering	0	0
Capital increase via exercise warrants	16	9
Equity-settled share-based payment expense	0	0	0
Outstanding, end of period	3,066	3,050	2,729
Total share-premium [member]
Disclosure of classes of share capital [line items]
Outstanding, beginning of period	136,637	79,839	79,019
Transfer share capital to share premium		0
Capital increase in cash - public offering	0	59,575
Expenses directly attributable to public offering	0	(4,003)
Capital increase via exercise warrants	1,252	593
Equity-settled share-based payment expense	201	633	820
Outstanding, end of period	€ 138,090	€ 136,637	€ 79,839

Equity Narrative (Detail)

Equity Narrative (Detail) - EUR (€) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share capital [member]
Equity narrative [line items]
Par value per share	€ 0.058	€ 0.058	€ 0.058
Average price per share, capital increase via exerciese of warrants	€ 4.5
Reserves [member]
Equity narrative [line items]
Legal reserves percent increase	5.00%
Legal reserve max percent of capital	10.00%
Non-controlling interest [Member]
Equity narrative [line items]
Non-controlling interest percent in Engimplan	25.00%
Non-controlling interest percent in rapdit fit	17.00%
RapidFit+ [member]
Equity narrative [line items]
Non-controlling interest amount Engimplan	€ 3,107
Written put option Rapid Fit Plus	875	€ 845	€ 788
Written put option Rapid Fit Plus undiscounted estimated redemption amount	875	875	€ 875
Written put option Rapid Fit Plus initial reclassification from non-controlling interest	264
Written put option Rapid Fit Plus iniitial reclassification from consolidated reserves	64
Written put option Rapid Fit Plus increase/decrease written put option	€ 273
Issued dilution warrants to non-controlling interest	10
Net capital increase in cash - public offering		€ 55,572

Equity - Reserve table (Detail)

Equity - Reserve table (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other reserves [line items]
Legal reserve	€ 279	€ 279	€ 279
(Accumulated deficit)	(474)	(2,127)	(3,990)
Reserves	€ (195)	€ (1,848)	€ (3,711)

Share-based payment plan (Detai

Share-based payment plan (Detail) - EUR (€)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
All plans Materialise [member]
Disclosure of share-based payment plan [line items]
Outstanding at beginning of period	1,318,049	1,458,360	1,681,000
Granted	0	2,000	0
Forfeited / Cancelled	(42,952)	(69,104)	(119,784)
Exercised	(310,045)	(73,207)	(102,856)
Outstanding at end of period	965,052	1,318,049	1,458,360
Exercisable at the end of period	296,859	252,793	0
2007-2013 plan [member]
Disclosure of share-based payment plan [line items]
Outstanding at beginning of period	300,040	320,640	435,096
Granted	0	0	0
Forfeited / Cancelled	(3,500)	(1,500)	(11,600)
Exercised	(178,164)	(19,100)	(102,856)
Outstanding at end of period	118,376	300,040	320,640
Exercisable at the end of period	15,300	89,892	0
IPO plan [member]
Disclosure of share-based payment plan [line items]
Outstanding at beginning of period	589,052	671,503	727,599
Granted	0	0	0
Forfeited / Cancelled	(20,252)	(42,209)	(56,096)
Exercised	(103,588)	(40,242)	0
Outstanding at end of period	465,212	589,052	671,503
Exercisable at the end of period	169,071	114,012	0
2015 plan [member]
Disclosure of share-based payment plan [line items]
Outstanding at beginning of period	325,200	329,000	350,000
Granted	0	2,000	0
Forfeited / Cancelled	(14,800)	(5,800)	(21,000)
Exercised	0	0	0
Outstanding at end of period	310,400	325,200	329,000
Exercisable at the end of period	96,500	32,700	0
IPO plan cash settled [member]
Disclosure of share-based payment plan [line items]
Outstanding at beginning of period	103,757	137,217	168,305
Granted	0	0	0
Forfeited / Cancelled	(4,400)	(19,595)	(31,088)
Exercised	(28,293)	(13,865)	0
Outstanding at end of period	71,064	103,757	137,217
Exercisable at the end of period	15,988	16,189	0

Share-based payments - Details

Share-based payments - Details grants Materialise (Detail)	12 Months Ended
	Dec. 31, 2019EUR (€)€ / shares
Plan 2015 (sept 16) [member]
Disclosure of details grants Materialise [line items]
Return dividend	0.00%
Expected volatility	47.00%
Risk-free interest rate	0.24%
Expected life | €	4.3
Exercise price (in EUR)	€ 6.45
Stock price (in EUR)	6.42
Fair value SAR	€ 2.41
IPO 2015 (Nov) [member]
Disclosure of details grants Materialise [line items]
Return dividend	0.00%
Expected volatility	47.00%
Risk-free interest rate	1.17%
Expected life | €	5.5
Exercise price (in EUR)	€ 8.81
Stock price (in EUR)	8.08
Fair value SAR	€ 3.3
IPO 2014 (Nov) [member]
Disclosure of details grants Materialise [line items]
Return dividend	0.00%
Expected volatility	50.00%
Risk-free interest rate	1.12%
Expected life | €	5.5
Exercise price (in EUR)	€ 8.81
Stock price (in EUR)	8.67
Fair value SAR	€ 3.94
IPO 2014 (June) [member]
Disclosure of details grants Materialise [line items]
Return dividend	0.00%
Expected volatility	46.00%
Risk-free interest rate	1.70%
Expected life | €	5.5
Exercise price (in EUR)	€ 8.81
Stock price (in EUR)	8.81
Fair value SAR	€ 3.83
2013 (Dec) [member]
Disclosure of details grants Materialise [line items]
Return dividend	0.00%
Expected volatility	50.00%
Risk-free interest rate	2.56%
Expected life | €	5.5
Exercise price (in EUR)	€ 8.54
Stock price (in EUR)	18.09
Fair value SAR	€ 12.23
2013 (Oct) [member]
Disclosure of details grants Materialise [line items]
Return dividend	0.00%
Expected volatility	53.00%
Risk-free interest rate	2.43%
Expected life | €	5.5
Exercise price (in EUR)	€ 7.86
Stock price (in EUR)	18.09
Fair value SAR	€ 12.77

Share-based payments - Detail_2

Share-based payments - Details share-based payment arrangements Materialise (Details)	12 Months Ended
	Dec. 31, 2019EUR (€)shares€ / shares
2007-2013 plan [member]
Disclosure of details share-based payment arrangements Materialise [line items]
vesting% first period	25.00%
vesting% second period	25.00%
vesting% third period	25.00%
vesting% fourth period	25.00%
Number of warrants granted 1	301,096
Number of warrants granted 2	166,800
Exercise price range 1 | € / shares	€ 7.86
Exercise price range 2 | € / shares	€ 8.54
Maximum number of warrants	29,594
Number of warrants exercised	44,541
Weighted average share price at exercise date | €	€ 18.4
Number of shares issued - exercised warrants	178,164
IPO plan [member]
Disclosure of details share-based payment arrangements Materialise [line items]
Contractual term | €	10
vesting% first period	25.00%
vesting% second period	25.00%
vesting% third period	25.00%
vesting% fourth period	25.00%
Number of warrants granted 1	979,898
Number of warrants granted 2	36,151
Number of warrants granted 3	18,180
Exercise price range 1 | € / shares	€ 8.81
Number of warrants exercised	103,588
Weighted average share price at exercise date | €	€ 18.4
Number of shares issued - exercised warrants	103,588
2015 plan [member]
Disclosure of details share-based payment arrangements Materialise [line items]
vesting% first period	10.00%
vesting% second period	20.00%
vesting% third period	30.00%
vesting% fourth period	40.00%
Number of warrants granted 1	350,000
Number of warrants granted 2	2,000
Exercise price range 1 | € / shares	€ 6.45
Exercise price range 2 | € / shares	€ 10.08
Maximum number of warrants	1,400,000
SAR [member]
Disclosure of details share-based payment arrangements Materialise [line items]
vesting% first period	25.00%
vesting% second period	25.00%
vesting% third period	25.00%
vesting% fourth period	25.00%
Number of warrants granted 1	215,688
Exercise price range 1 | € / shares	€ 8.81

Share-based payments - Expense

Share-based payments - Expense and weighted average narrative (Detail) - Details expense and weighted average [domain member]	12 Months Ended
	Dec. 31, 2019EUR (€)€ / shares	Dec. 31, 2018EUR (€)€ / shares	Dec. 31, 2017EUR (€)€ / shares
Details expense and weighted average [line items]
Expense for equity-settled share-based payment Materialise	€ 401,000	€ 640,000	€ 819,000
Expense for cash-settled shared-based payment Materialise	€ (11,000)	€ 435,000	€ 204,000
Weighted-average remaining estimated life	5.2	5.95	5.62
Weighted-average fair value of warrants outstanding | € / shares	€ 4.48	€ 5.62	€ 5.6
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at end of period | € / shares	€ 7.88	€ 7.99	€ 8.05
Cash settled liability share options granted	€ 574,000	€ 786,000	€ 351,000
Intrinsic-value cash-settled warrants	€ 120,070	€ 140,521	€ 0

Share-based payments - Detail_3

Share-based payments - Details grants Materialise cash settled (Detail) - Materialise cash settled share based payment plan [member]	12 Months Ended
	Dec. 31, 2019EUR (€)€ / shares	Dec. 31, 2018EUR (€)€ / shares	Dec. 31, 2017EUR (€)€ / shares
Disclosure of details grants materialise cash settled [line items]
Return dividend	0.00%	0.00%	0.00%
Expected volatility	49.00%	49.00%	49.00%
Risk-free interest rate	0.10%	0.77%	0.73%
Expected life | €	0.25	1.25	2.25
Exercise price (in EUR)	€ 8.81	€ 8.81	€ 8.81
Stock price (in EUR)	16.32	17.49	10.61
Fair value SAR	€ 7.52	€ 9.09	€ 3.85

Share-based payments - Detail_4

Share-based payments - Details grants Rapidfit (Detail) - Rapidfit+ plan [member]	12 Months Ended
	Dec. 31, 2019shares	Dec. 31, 2018shares	Dec. 31, 2017EUR (€)shares
Disclosure of Rapidfit+ details grants [line items]
Outstanding at beginning of period	199	199	199
Granted	0	0	0
Forfeited / Cancelled	(13)	0	0
Exercised	0	0	0
Outstanding at end of period	186	199	199
Exercisable at the end of period	184	0	0

Share-based payments - Detail_5

Share-based payments - Details grants Rapidfit cash settled (Detail) - Rapidfit+ plan [member]	12 Months Ended
	Dec. 31, 2019EUR (€)€ / shares
Disclosure of Rapidfit+ details grants cash settled [line items]
Return dividend	0.00%
Expected volatility	50.00%
Risk-free interest rate	2.29%
Expected life | €	5.5
Exercise price (in EUR)	€ 553.92
Fair value SAR	€ 262.7

Share-based payments - Detail_6

Share-based payments - Details grants Rapidfit narrative (Detail) - Rapidfit+ plan [member] - EUR (€)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of Rapidfit+ details grants narrative [line items]
Maximum number of warrants	300
Number of warrants granted	199
Share-based payment expense	€ 2,000	€ 7,000	€ 10,000

Loans and borrowings (Detail)

Loans and borrowings (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Details loans and borrowings [line items]
K EUR 35,000 EIB bank loan	€ 35,000	€ 10,000	€ 0
K EUR 28,000 acquisition bank loan	21,612	24,576	27,513
K EUR 18,000 secured bank loans	17,429	17,739	17,575
K EUR 12,300 bank loans ACTech	11,850	12,300	9,247
K EUR 8,750 other facility loans	3,599	4,299	4,982
Bank investment loans - top 20 outstanding	22,132	23,801	21,441
Bank investment loans - other	4,429	3,808	2,289
Lease liabilities (2018 and 2017: Finance leases)	9,876	6,809	9,164
Institutional loan	824	1,492	1,105
Convertible bonds	1,000	1,000	1,000
Related party loan	187	214	241
Total loans and borrowings	127,938	106,038	94,557
Current	16,838	13,598	12,769
Non-current	€ 111,100	€ 92,440	€ 81,788

Loans and borrowings Narrative

Loans and borrowings Narrative (Detail)	12 Months Ended
	Dec. 31, 2019EUR (€)shares€ / shares	Dec. 31, 2018EUR (€)	Dec. 31, 2017EUR (€)
Details loans and borrowings Narrative [line items]
Loan Principal K EUR 28,000	€ 28,000,000
Monthly reimbursable portion	18,000,000
Bullet portion	€ 10,000,000
Interest percentage	1.10%
Loan principal K EUR 18,000	€ 18,000,000
Belgian facility financing	12,000,000
Drawn		€ 11,739,000	€ 11,739,000
Polish facility financing	€ 6,000,000
Interest percentage	1.20%
First tranche	€ 10,000,000
Margin interest percentage first tranche	2.40%
Second tranche	€ 25,000,000
Margin interest percentage second tranche	2.72%
Loan principal K EUR 12,300	€ 12,300,000
Refinanced part March 2018	€ 9,300,000
Interest percentage	1.60%
Mortgage	€ 4,650,000
New investment credit June 2018	€ 3,000,000
Fixed interest rate credit June 2018	1.50%
Loan principal K EUR 8,750	€ 8,750,000
Facility loan 2005	2,000,000
Facility loan 2006	300,000
Facility loan 2012	5,000,000
Czech republic offices loan 2008	€ 1,750,000
Repayment schedule	15
Interest rate lower range	4.30%
Interest rate upper range	5.40%
Weighted average interest rate	1.10%
Institutional loan K EUR 2,000	€ 2,000,000
K EUR 2,000 institutional loan - max credit limit	€ 2,000,000
Interest rate	0.25%
Convertible bond K EUR 1,000	€ 1,000,000
Convertible number of bonds | shares	1,000
Nominal value per bond | € / shares	€ 1,000
Contractual life	7
Interest rate	3.70%
Conversion price	1.97
Fair value	€ 907,000
Amount recognized in consolidated reserves	€ 93,000
K EUR 1,000 convertible bond - max number of shares to be issued | shares	508,904
Related party loan	€ 187,000	214,000	241,000
Interest rate	4.23%
Related party loan - interest expense	€ 9,000	€ 10,000	€ 11,000
Lease liability related party	€ 617,000
Lease liabilities interest rate	2.00%

Loans and borrowings - Movement

Loans and borrowings - Movement table (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Detail movement table [line items]
Balance at beginning of period	€ 106,038	€ 94,557	€ 33,806
Proceeds from loans and borrowings	29,000	32,554	54,319
Repayment of loans and borrowings	(12,126)	(18,820)	(11,904)
New leases	8,326	792	2,906
Repayment leases	(5,283)	(3,102)	(2,947)
Loans acquired from business combination	2,076	0	18,205
Net foreign exchange movements	(92)	57	172
Balance at end of period	€ 127,938	€ 106,038	€ 94,557

Other non-current liabilities_2

Other non-current liabilities (Detail) - Miscellaneous non-current liabilities [member] - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Miscellaneous non-current liabilities [line items]
Written put option Rapid Fit Plus	€ 0	€ 0	€ 788
Contingent consideration	0	0	648
Provisions	122	82	109
Other	574	786	359
Total	€ 696	€ 868	€ 1,904

Other non-current liabilities N

Other non-current liabilities Narrative (Detail) - Miscellaneous non-current liabilities [member] - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other non-current liabilities [line items]
Contingent consideration (LT + ST)		€ 450
Cash settled share based payment plan	€ 574	€ 786	€ 351

Tax Payables Narrative (Detail)

Tax Payables Narrative (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of tax payables [abstract]
Tax payables	€ 3,363	€ 2,313	€ 2,023	[1]
[1]	* The year 2017 has been restated to reflect the final accounting of the business combination with ACTech.

Deferred income (Detail)

Deferred income (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accruals and deferred income [abstract]
Deferred maintenance and license	€ 27,667	€ 22,606	€ 18,723
Deferred (project) fees	4,647	4,838	3,765
Deferred government grants	359	338	71
Total	32,672	27,782	22,559
Deferred income classified as current	27,641	23,195	18,791	[1]
Deferred income classified as non-current	€ 5,031	€ 4,587	€ 3,768	[1]
[1]	* The year 2017 has been restated to reflect the final accounting of the business combination with ACTech.

Other current liabilities (Deta

Other current liabilities (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Miscellaneous current liabilities [line items]
Payroll-related liabilities	€ 10,281	€ 10,111	€ 9,274
Non-income tax payables	2,262	2,175	2,063
Accrued charges	1,080	789	769
Advances received	715	713	870
Other current liabilities	3,348	1,554	520
Total	€ 17,686	€ 15,342	€ 13,496	[1]
[1]	* The year 2017 has been restated to reflect the final accounting of the business combination with ACTech.

Other current liabilities Narra

Other current liabilities Narrative (Detail) - Other current liabilities narrative [member] - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other current liabilities narrative [line items]
Contingent Consideration from Business Combinations Classified as Current	€ 0	€ 450	€ 257
Written put option payable Rapidfit current	875	€ 845	€ 0
Various Accruals	1,110
Interest Rate Swaps	€ 478

Fair value of financial assets

Fair value of financial assets (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
At carrying value [member]
Debt instruments measured at amortized cost [abstract]
Trade receivables (current)	€ 40,977	€ 36,891	€ 35,582
Other financial assets (non-current)	580	1,530	1,221
Other current non-trade receivables	1,676	1,461	2,001
Cash and cash equivalents	128,897	115,506	43,175
Total debt instruments	172,130	155,388	81,979
Financial assets at fair value through profit or loss [abstract]
Derivatives	9	117	218
Convertible loan	2,750	0	0
Total financial assets measured at fair value	2,759	117	218
Equity instruments designated at fair value through OCI [abstract]
Non-listed equity investments	3,046	2,701	0
Total equity instruments designated at fair value through OCI	3,046	2,701	0
At fair value [member]
Debt instruments measured at amortized cost [abstract]
Trade receivables (current)	40,977	36,891	35,582
Other financial assets (non-current)	580	1,530	1,221
Other current non-trade receivables	1,676	1,461	2,001
Cash and cash equivalents	128,897	115,506	43,175
Total debt instruments	172,130	155,388	81,979
Financial assets at fair value through profit or loss [abstract]
Derivatives	9	117	218
Convertible loan	2,794	0	0
Total financial assets measured at fair value	2,803	117	218
Equity instruments designated at fair value through OCI [abstract]
Non-listed equity investments	3,047	2,701	0
Total equity instruments designated at fair value through OCI	€ 3,047	€ 2,701	€ 0

Fair value of financial liabili

Fair value of financial liabilities (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
At carrying value [member]
Financial liabilities measured at amortized cost [abstract]
Loans and borrowings including lease liabilities	€ 127,939	€ 106,037	€ 94,557
Trade payables	18,517	18,667	15,670
Other liabilities excl. written put option on NCI	3,187	778	1,133
Total financial liabilities measured at amortized cost	149,643	125,482	111,360
Financial liabilities measured at fair value [abstract]
Contingent consideration	0	450	905
Cash settled share based payments	0	786	351
Written put option on NCI	875	845	788
Derivatives	478	194	8
Total financial liability measured at fair value	1,353	2,275	2,052
Total non-current	112,549	94,521	85,276
Total current	38,447	33,236	28,136
At fair value [member]
Financial liabilities measured at amortized cost [abstract]
Loans and borrowings including lease liabilities	128,930	105,026	95,351
Trade payables	18,517	18,667	15,670
Other liabilities excl. written put option on NCI	3,187	778	1,133
Total financial liabilities measured at amortized cost	150,634	124,471	112,154
Financial liabilities measured at fair value [abstract]
Contingent consideration	0	450	905
Cash settled share based payments	0	786	351
Written put option on NCI	875	845	788
Derivatives	478	194	8
Total financial liability measured at fair value	1,353	2,275	2,052
Total non-current	112,288	93,289	85,890
Total current	€ 39,699	€ 33,457	€ 28,316

Fair value Narrative (Detail)

Fair value Narrative (Detail) € in Thousands	Dec. 31, 2019EUR (€)
Fair value Narrative [abstract]
Fluidda - Sensitivity WACC	2.00%
Fluidda - Sensitivity WACC -	€ (267)
Fluidda - Sensitivity WACC +	€ 298

Segment information (Detail)

Segment information (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total segments
Disclosure of operating segments [line items]
Revenue	€ 196,618	€ 184,582	€ 142,323
Segment adjusted EBITDA	€ 36,740	€ 32,573	€ 22,765
Segment adjusted EBITDA %	18.686%	17.6469%	15.9953%
Materialise Software [Member]
Disclosure of operating segments [line items]
Revenue	€ 41,654	€ 37,374	€ 35,770
Segment adjusted EBITDA	€ 13,812	€ 11,536	€ 13,926
Segment adjusted EBITDA %	33.1589%	30.8664%	38.9321%
Materialise Medical [Member]
Disclosure of operating segments [line items]
Revenue	€ 60,808	€ 52,252	€ 42,841
Segment adjusted EBITDA	€ 10,774	€ 10,252	€ 4,400
Segment adjusted EBITDA %	17.7181%	19.6203%	10.2705%
Materialise Manufacturing [Member]
Disclosure of operating segments [line items]
Revenue	€ 94,156	€ 94,956	€ 63,712
Segment adjusted EBITDA	€ 12,154	€ 10,785	€ 4,439
Segment adjusted EBITDA %	12.9084%	11.3579%	6.9673%
Unallocated amounts [Member]
Disclosure of operating segments [line items]
Revenue	€ 61	€ 139	€ 250
Segment adjusted EBITDA	€ (10,084)	€ (9,047)	€ (8,155)
Segment adjusted EBITDA %	0.00%	0.00%	0.00%
Consolidated Segments [Member]
Disclosure of operating segments [line items]
Revenue	€ 196,679	€ 184,721	€ 142,573
Segment adjusted EBITDA	€ 26,656	€ 23,526	€ 14,610
Segment adjusted EBITDA %	13.553%	12.736%	10.2474%

Segment reconciliation (Detail)

Segment reconciliation (Detail) - Consolidated entity [member] - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of operating segments [line items]
Segment adjusted EBITDA	€ 36,740	€ 32,573	€ 22,765
Depreciation, amortization and impairment	(19,198)	(17,287)	(12,576)
Corporate research and development	(1,859)	(1,913)	(2,017)
Corporate headquarter costs	(11,077)	(10,358)	(9,690)
Other operating income (expense)	2,410	2,149	1,910
Operating profit (loss)	7,016	5,164	392
Financial expenses	(3,682)	(4,864)	(4,728)	[1]
Financial income	1,377	3,627	3,210
Income taxes	(2,595)	(425)	(522)
Share in loss of joint venture	(392)	(475)	(469)
Net (loss) profit for the year	€ 1,724	€ 3,027	€ (2,117)
[1]	* The year 2017 has been restated to reflect certain reclassification adjustments and the final accounting of the ACTech business combination.

Segment reconciliation - Revenu

Segment reconciliation - Revenue by geographical area (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
United States of America (USA) [member]
Disclosure of geographical areas [line items]
Revenue	€ 56,235	€ 42,217	€ 32,926
Americas other than USA [member]
Disclosure of geographical areas [line items]
Revenue	3,395	1,700	2,194
Belgium [member]
Disclosure of geographical areas [line items]
Revenue	7,917	9,350	8,145
Germany [member]
Disclosure of geographical areas [line items]
Revenue	31,185	30,436	27,011
France [member]
Disclosure of geographical areas [line items]
Revenue	20,110	22,282	18,737
Switserland [member]
Disclosure of geographical areas [line items]
Revenue	14,907	13,135	7,782
United Kingdom [member]
Disclosure of geographical areas [line items]
Revenue	13,804	11,946	10,911
Italy [member]
Disclosure of geographical areas [line items]
Revenue	6,707	4,392	4,224
Netherlands [member]
Disclosure of geographical areas [line items]
Revenue	5,825	7,382	7,986
Other Europe [member]
Disclosure of geographical areas [line items]
Revenue	17,329	21,455	3,144
Asia-Pacific [member]
Disclosure of geographical areas [line items]
Revenue	19,265	20,426	19,513
All countries [member]
Disclosure of geographical areas [line items]
Revenue	€ 196,679	€ 184,721	€ 142,573

Segment reconciliation - Non-cu

Segment reconciliation - Non-current assets by geographical area (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
United States of America (USA) [member]
Disclosure of non-current assets by geographical areas [Line items]
Non-current assets other than financial instruments, deferred tax assets	€ 4,194	€ 3,953	€ 3,880
Americas other than USA [member]
Disclosure of non-current assets by geographical areas [Line items]
Non-current assets other than financial instruments, deferred tax assets	8,374	62	29
Belgium [member]
Disclosure of non-current assets by geographical areas [Line items]
Non-current assets other than financial instruments, deferred tax assets	49,426	48,873	46,573
Germany [member]
Disclosure of non-current assets by geographical areas [Line items]
Non-current assets other than financial instruments, deferred tax assets	57,918	56,096	56,410
Poland [member]
Disclosure of non-current assets by geographical areas [Line items]
Non-current assets other than financial instruments, deferred tax assets	15,506	16,206	15,441
Rest of Europe [member]
Disclosure of non-current assets by geographical areas [Line items]
Non-current assets other than financial instruments, deferred tax assets	10,410	10,125	10,140
Asia-Pacific [member]
Disclosure of non-current assets by geographical areas [Line items]
Non-current assets other than financial instruments, deferred tax assets	2,658	1,039	744
All countries [member]
Disclosure of non-current assets by geographical areas [Line items]
Non-current assets other than financial instruments, deferred tax assets	€ 148,486	€ 136,354	€ 133,217

Income and expenses - Revenue p

Income and expenses - Revenue per type of good or service (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
All categories [member]
Disclosure of revenue by category [line items]
Revenue	€ 196,679	€ 184,721	€ 142,573
Software (non-medical) [member]
Disclosure of revenue by category [line items]
Revenue	41,654	37,374	35,770
Software (medical) [member]
Disclosure of revenue by category [line items]
Revenue	19,407	17,045	15,619
Medical devices and services [member]
Disclosure of revenue by category [line items]
Revenue	41,401	35,207	27,222
Manufacturing [member]
Disclosure of revenue by category [line items]
Revenue	94,156	94,956	63,712
Other category [member]
Disclosure of revenue by category [line items]
Revenue	€ 61	€ 139	€ 250

Income and expenses - Disaggreg

Income and expenses - Disaggregated revenue information (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total segments
Disclosure of geographical areas [abstract]
United States of America (USA)	€ 56,235	€ 42,183
Americas other than USA	3,395	1,698
Europe (without Belgium) & Africa	109,867	110,951
Belgium	7,856	9,343
Asia Pacific	19,265	20,407
Total revenue from contracts with customers	196,618	184,582
Type of goods or services [abstract]
Software revenue (non-medical)	41,654	37,374
Software revenue (medical)	19,407	17,045
Medical devices and services	41,401	35,207
Complex metal parts production (ACTech)		43,438
Manufacturing	94,156
Other	0	0
Total revenue from contracts with customers	196,618	184,582
Timing of revenue recognition [abstract]
Goods/Services transferred at point in time	155,908	150,622
Goods/Services transferred over time	40,710	33,960
Total revenue from contracts with customers	196,618	184,582
Materialise Software [Member]
Disclosure of geographical areas [abstract]
United States of America (USA)	11,188	8,804
Americas other than USA	487	193
Europe (without Belgium) & Africa	18,767	17,026
Belgium	183	155
Asia Pacific	11,029	11,196
Total revenue from contracts with customers	41,654	37,374
Type of goods or services [abstract]
Software revenue (non-medical)	41,654	37,374
Software revenue (medical)	0	0
Medical devices and services	0	0
Complex metal parts production (ACTech)		0
Manufacturing	0
Other	0	0
Total revenue from contracts with customers	41,654	37,374
Timing of revenue recognition [abstract]
Goods/Services transferred at point in time	21,190	20,326
Goods/Services transferred over time	20,464	17,048
Total revenue from contracts with customers	41,654	37,374
Materialise Medical [Member]
Disclosure of geographical areas [abstract]
United States of America (USA)	29,100	23,940
Americas other than USA	2,071	1,404
Europe (without Belgium) & Africa	21,356	19,073
Belgium	2,101	1,824
Asia Pacific	6,180	6,011
Total revenue from contracts with customers	60,808	52,252
Type of goods or services [abstract]
Software revenue (non-medical)	0	0
Software revenue (medical)	19,407	17,045
Medical devices and services	41,401	35,207
Complex metal parts production (ACTech)		0
Manufacturing	0
Other	0	0
Total revenue from contracts with customers	60,808	52,252
Timing of revenue recognition [abstract]
Goods/Services transferred at point in time	45,730	39,682
Goods/Services transferred over time	15,078	12,570
Total revenue from contracts with customers	60,808	52,252
Materialise Manufacturing [Member]
Disclosure of geographical areas [abstract]
United States of America (USA)	15,947	9,439
Americas other than USA	837	101
Europe (without Belgium) & Africa	69,744	74,852
Belgium	5,572	7,364
Asia Pacific	2,056	3,200
Total revenue from contracts with customers	94,156	94,956
Type of goods or services [abstract]
Software revenue (non-medical)	0	0
Software revenue (medical)	0	0
Medical devices and services	0	0
Complex metal parts production (ACTech)		43,438
Manufacturing	94,156
Other	0	0
Total revenue from contracts with customers	94,156	94,956
Timing of revenue recognition [abstract]
Goods/Services transferred at point in time	88,988	90,614
Goods/Services transferred over time	5,168	4,342
Total revenue from contracts with customers	94,156	94,956
Unallocated amounts [Member]
Disclosure of geographical areas [abstract]
United States of America (USA)	0	34
Americas other than USA	0	2
Europe (without Belgium) & Africa	0	77
Belgium	61	7
Asia Pacific	0	19
Total revenue from contracts with customers	61	139
Type of goods or services [abstract]
Software revenue (non-medical)	0	0
Software revenue (medical)	0	0
Medical devices and services	0	0
Complex metal parts production (ACTech)		0
Manufacturing	0
Other	61	139
Total revenue from contracts with customers	61	139
Timing of revenue recognition [abstract]
Goods/Services transferred at point in time	61	139
Goods/Services transferred over time	0	0
Total revenue from contracts with customers	61	139
Consolidated Segments [Member]
Disclosure of geographical areas [abstract]
United States of America (USA)	56,235	42,217
Americas other than USA	3,395	1,700
Europe (without Belgium) & Africa	109,867	111,028
Belgium	7,917	9,350
Asia Pacific	19,265	20,426
Total revenue from contracts with customers	196,679	184,721
Type of goods or services [abstract]
Software revenue (non-medical)	41,654	37,374
Software revenue (medical)	19,407	17,045
Medical devices and services	41,401	35,207
Complex metal parts production (ACTech)		43,438
Manufacturing	94,156
Other	61	139
Total revenue from contracts with customers	196,679	184,721
Timing of revenue recognition [abstract]
Goods/Services transferred at point in time	155,969	150,761
Goods/Services transferred over time	40,710	33,960
Total revenue from contracts with customers	€ 196,679	€ 184,721

Income and expenses - Contract

Income and expenses - Contract balances (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Contract Balances [Line Items]
Trade receivables, included in 'trade and other receivables'	€ 42,509	€ 38,764
Contract assets / Contracts in progress	495	829
Contract liabilities / Deferred income	32,314	27,444
Total	€ 75,318	€ 67,037

Income and expenses - Contrac_2

Income and expenses - Contract Balance Narrative (Detail) € in Thousands	12 Months Ended
	Dec. 31, 2019EUR (€)
Contract balances narrative
Revenue that was included in contract liability at beginning of period	€ 27,444

Income and expenses - Cost of s

Income and expenses - Cost of sales (Detail) - Total cost of sales [member] - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cost of sales [line items]
Purchase of goods and services	€ (37,870)	€ (39,114)	€ (34,480)
Amortization and depreciation	(10,837)	(9,910)	(7,560)
Payroll expenses	(37,715)	(33,036)	(20,806)
Other	(550)	(239)	(106)
Total	€ (86,972)	€ (82,299)	€ (62,952)

Income and expenses - Research

Income and expenses - Research and development expenses (Detail) - Research and development expenses [member] - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Research and development expenses [line items]
Purchase of goods and services	€ (2,583)	€ (3,590)	€ (3,140)
Amortization and depreciation	(1,483)	(830)	(686)
Payroll expenses	(19,219)	(17,935)	(16,054)
Other	(63)	(61)	(79)
Total	€ (23,348)	€ (22,416)	€ (19,959)

Income and expenses - Sales and

Income and expenses - Sales and marketing expenses (Detail) - Sales and marketing expenses [member] - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Sales and marketing expenses [line items]
Purchase of goods and services	€ (9,228)	€ (9,775)	€ (8,035)
Amortization and depreciation	(1,346)	(725)	(505)
Payroll expenses	(42,055)	(35,585)	(30,175)
Other	(360)	(218)	(220)
Total	€ (52,989)	€ (46,303)	€ (38,935)

Income and expenses - General a

Income and expenses - General and administrative expenses (Detail) - General and administrative expenses [member] - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
General and administrative expenses [line items]
Purchase of goods and services	€ (9,856)	€ (9,892)	€ (7,053)
Amortization and depreciation	(3,630)	(3,828)	(2,761)
Payroll expenses	(18,078)	(18,442)	(14,858)
Other	(222)	(148)	(204)
Total	€ (31,786)	€ (32,310)	€ (24,876)

Income and expenses - Net other

Income and expenses - Net other operating income (expense) (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Analysis of income and expense [abstract]
Government grants	€ 5,263	€ 4,658	€ 4,342
Amortization intangibles purchase price allocation	(2,013)	(1,994)	(1,064)
Allowance for doubtful debtors	210	(1,065)	(454)
Capitalized expenses (asset construction)	166	16	123
Net foreign currency exchange gains / (losses)	0	246	(235)
Tax Credits	665	706	899
Fair value adjustment Cenat liability	0	192	0
Personnel related income	37	168	0
Other	1,104	844	930
Total	€ 5,432	€ 3,771	€ 4,541	[1]
[1]	* The year 2017 has been restated to reflect certain reclassification adjustments and the final accounting of the ACTech business combination.

Income and expenses - Payroll e

Income and expenses - Payroll expenses (Detail) - Payroll expenses [domain member]	12 Months Ended
	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)	Dec. 31, 2017EUR (€)
Payroll expenses [line items]
Short-term employee benefits	€ (87,775,000)	€ (76,023,000)	€ (60,195,000)
Social security expenses	(15,647,000)	(14,139,000)	(11,200,000)
Expenses defined contribution plans	(1,033,000)	(936,000)	(926,000)
Other employee expenses	(12,612,000)	(13,900,000)	(9,572,000)
Total	€ (117,067,000)	€ (104,998,000)	€ (81,893,000)
Total registered employees at the end of the period	2,177	2,009	1,862

Income and expenses - Financial

Income and expenses - Financial expense (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Financial expense [line items]
Interest expense	€ (2,146)	€ (1,747)	€ (1,026)
Foreign currency losses	(832)	(2,748)	(3,131)
Other financial expenses	(704)	(369)	(571)
Total	€ (3,682)	€ (4,864)	€ (4,728)

Income and expenses - Financi_2

Income and expenses - Financial income (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Financial income [line items]
Foreign currency exchange gains	€ 955	€ 3,047	€ 2,830
Amortization discount interest free loans	0	0	6
Other finance income	422	580	374
Total	€ 1,377	€ 3,627	€ 3,210	[1]
[1]	* The year 2017 has been restated to reflect certain reclassification adjustments and the final accounting of the ACTech business combination.

Income and expenses - Income ta

Income and expenses - Income taxes - Current income taxes (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current income taxes [abstract]
Estimated tax liability for the period	€ (2,926)	€ (1,216)	€ (1,530)
Tax adjustments to the previous period	0	0	412
Deferred income taxes	331	791	596
Total income taxes for the period	€ (2,595)	€ (425)	€ (522)	[1]
[1]	* The year 2017 has been restated to reflect certain reclassification adjustments and the final accounting of the ACTech business combination.

Income and expenses - Income _2

Income and expenses - Income taxes - Deferred tax (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Assets/(liabilities) [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax losses, notional interest deduction and other tax benefits	€ 0	€ 26	€ 0
Amortization development assets and other intangible assets	38	224	304
Depreciation property, plant and equipment	70	30	0
Other items	84	35	0
Total deferred tax assets	192	315	304
Property, plant and equipment	(403)	(694)	(698)
Intangible assets	(4,937)	(5,370)	(6,656)
Investment grants	(301)	(312)	0
Inventory valuation	(89)	141	0
Other items	(17)	9	(61)
Total deferred tax liabilities	(5,747)	(6,226)	(7,415)
Total deferred tax income (loss)	0	0	0
Income/(expense) [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax losses, notional interest deduction and other tax benefits	0	0	0
Amortization development assets and other intangible assets	0	0	0
Depreciation property, plant and equipment	0	0	0
Other items	0	0	0
Income expense from total defered tax assets	(124)	11	(32)
Property, plant and equipment	0	0	0
Intangible assets	0	0	0
Investment grants	0	0	0
Inventory valuation	0	0	0
Other items	0	0	0
Income expense from total deferred tax liabilities	455	780	628
Total deferred tax income (loss)	€ 331	€ 791	€ 596

Income and expenses - Income _3

Income and expenses - Income taxes - Deferred tax Narrative (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]
Belgian Patent Income Deduction in percentage	80.00%
Innovation Income Deduction	85.00%
Unused tax loss carry-forward, tax credits and other	€ 37,440	€ 25,285	€ 11,948
Unused tax loss carry-forward, tax credits and other (MAT NV)	25,172	15,592	4,581
Unused notional interest deduction - expiration date 2018	€ 0	€ 0	€ 315

Income and expenses - Income _4

Income and expenses - Income taxes - Relationship tax Expense and accounting profit (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Relationship tax expense and accounting profit [line items]
Profit (loss) before tax	€ 4,319	€ 3,452	€ (1,595)
Income tax at statutory rate of 29.58% (2017: 33.99%)	(1,278)	(1,021)	542
Effect of different local tax rate	63	166	433
Tax adjustments to the previous period	(367)	80	412
Non-deductible expenses	(554)	(1,141)	(818)
Capitalized initial public offering transaction costs	0	0	0
Research and development tax credits and patent income deduction	179	337	44
Notional interest deduction Belgium	0	0	0
Non recognition of deferred tax asset	(1,579)	(546)	(1,505)
Recognition of deferred tax assets on previous years tax losses	119	653	0
Non-taxable income	925	606	556
Use of previous years tax losses and tax credits for which no deferred tax assets was recognized	0	0	12
Taxes on other basis	0	280	(117)
Other	(103)	161	(81)
Income tax expenses as reported in the consolidated income statement	€ (2,595)	€ (425)	€ (522)	[1]
[1]	* The year 2017 has been restated to reflect certain reclassification adjustments and the final accounting of the ACTech business combination.

Earnings per share attributable

Earnings per share attributable to ordinary owners of the parent (Detail) - € / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	[1]
Earnings per share attributable to ordinary owners of the parent [line items]
Basic	€ 0.031106	€ 0.060776	€ (0.044733)
Diluted	€ 0.031415	€ 0.060694	€ (0.044733)
[1]	* The year 2017 has been restated to reflect certain reclassification adjustments and the final accounting of the ACTech business combination.

Weighted average number of ordi

Weighted average number of ordinary shares for basic earnings per share (Detail) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Weighted average ordinary shares and adjusted weighted average ordinary shares [abstract]
Weighted average number of ordinary shares for basic earnings per share	52,915	49,806	47,325
Effect of dilution:
Share options	563	382	0
Convertible loan	509	509	0
Weighted average number of ordinary shares adjusted for effect of dilution	53,987	50,697	47,325

Net profit attributable to ordi

Net profit attributable to ordinary equity holders of the parent for basic earnings (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Profit (loss), attributable to ordinary equity holders of parent entity [abstract]
Net profit attributable to ordinary equity holders of the parent for basic earnings	€ 1,646	€ 3,027	€ (2,117)
Interest on convertible bonds	50	50	0
Net profit attributable to ordinary equity holders of the parent adjusted for the effect of dilution	€ 1,696	€ 3,077	€ (2,117)

Commitment and contingent liabi

Commitment and contingent liabilities - Operational lease commitments (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total aggregated time bands [member]
Disclosure of operating lease commitments [line items]
Operating lease commitments	€ 77	€ 5,442	€ 3,708
Not later than one year [member]
Disclosure of operating lease commitments [line items]
Operating lease commitments	28	2,053	1,721
Between two and three years [member]
Disclosure of operating lease commitments [line items]
Operating lease commitments	49	2,302	1,504
Between four and five years [member]
Disclosure of operating lease commitments [line items]
Operating lease commitments	0	785	406
Later than five years [member]
Disclosure of operating lease commitments [line items]
Operating lease commitments	€ 0	€ 302	€ 77

Commitment and contingent lia_2

Commitment and contingent liabilities - Operational lease commitments Narrative (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operational lease commitments narrative [abstract]
Total lease payments recognised in income statement	€ 725	€ 2,956	€ 2,909

Commitment and contingent lia_3

Commitment and contingent liabilities - Capital lease commitments (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total aggregated time bands [member]
Disclosure of capital lease commitments [line items]
Minimum lease payments	€ 0	€ 7,078	€ 9,842
Present value of payments	0	6,809	9,164
Not later than one year [member]
Disclosure of capital lease commitments [line items]
Minimum lease payments	0	2,876	3,179
Present value of payments	0	2,829	3,034
Between two and three years [member]
Disclosure of capital lease commitments [line items]
Minimum lease payments	0	3,398	5,017
Present value of payments	0	3,236	4,643
Between four and five years [member]
Disclosure of capital lease commitments [line items]
Minimum lease payments	0	655	1,361
Present value of payments	0	604	1,269
Later than five years [member]
Disclosure of capital lease commitments [line items]
Minimum lease payments	0	149	285
Present value of payments	0	140	218
Less finance charges [member]
Disclosure of capital lease commitments [line items]
Minimum lease payments	0	(269)	(678)
Present value of payments	0	0	0
Present value of minimum lease payments [member]
Disclosure of capital lease commitments [line items]
Minimum lease payments	0	6,809	9,164
Present value of payments	€ 0	€ 6,809	€ 9,164

Commitment and contingent lia_4

Commitment and contingent liabilities - Mortgages and pledges (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Mortages and pledges narrative [abstract]
Carrying value property, plant and equipment related to mortgages and loans	€ 29,154	€ 30,853	€ 28,526
Total outstanding mortgages and pledges	77,849	124,428	85,186
Pledges on business goodwill	36,992	70,300	29,000
Current and other fixed assets pledges as security	€ 3,301	€ 21,142	€ 9,131

Commitment and contingent lia_5

Commitment and contingent liabilities - Other commitments (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other commitments narrative [abstract]
Outstanding non-cancellable contracts with future commitment	€ 11,640	€ 6,383	€ 7,638
Committed expenditures in property, plant and equipment	0	€ 0	€ 672
Estimated financial effect of contingent liabilities	€ 2,700

Risks - Foreign Currency Sensit

Risks - Foreign Currency Sensitivity (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Foreign currency narrative [line items]
Revenue derived from sales in currency different from euro	29.00%	30.00%	31.00%
USD impact on cash and term accounts held in USD	€ 553
Rate for amount in EUR	€ 1
USD rate increase/decrease by	10.00%
Net result would be higher	€ 895
Net result would be lower	€ 780

Risks - Liquidity risk (Detail)

Risks - Liquidity risk (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total aggregated time bands [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Loan and borrowings	€ 123,453	€ 114,097	€ 107,249
Lease liabilities	10,352
Trade payables	18,517	18,667	15,670
Other current liabilities	4,063	2,267	1,390
Total	156,385	135,031	124,309
Not later than one year [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Loan and borrowings	14,300	14,491	14,331
Lease liabilities	3,685
Trade payables	18,517	18,667	15,670
Other current liabilities	4,063	2,267	1,390
Total	40,565	35,425	31,391
Later than one year and not later than three years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Loan and borrowings	33,034	42,100	37,933
Lease liabilities	4,907
Trade payables	0	0	0
Other current liabilities	0	0	0
Total	37,941	42,100	37,933
Later than three years and not later than five years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Loan and borrowings	41,672	33,636	22,286
Lease liabilities	1,040
Trade payables	0	0	0
Other current liabilities	0	0	0
Total	42,712	33,636	22,286
Later than five years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Loan and borrowings	34,447	23,870	32,699
Lease liabilities	720
Trade payables	0	0	0
Other current liabilities	0	0	0
Total	€ 35,167	€ 23,870	€ 32,699

Risks - Liquidity risk Narrativ

Risks - Liquidity risk Narrative (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Undrawn lines of credit		€ 26,040	€ 4,473
EIB Finance contract	€ 35,000
EIB finance contract max. draw first tranche	25,000
EIB finance contract draw first tranche	10,000
EIB finance contract draw second tranche	€ 25,000
EIB finance contract interest rate first tranche	2.40%
EIB finance contract interest rate second tranche	2.72%

Risks - Credit risk (Detail)

Risks - Credit risk (Detail) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total [member]
Credit risk [line items]
At end of period	€ 40,977	€ 36,891	€ 35,582
Non-due [member]
Credit risk [line items]
At end of period	31,528	26,208	21,630
Up to 30 days [member]
Credit risk [line items]
At end of period	4,924	5,395	6,920
31-60 days [member]
Credit risk [line items]
At end of period	2,094	1,479	1,765
61-90 days [member]
Credit risk [line items]
At end of period	733	931	1,526
91-180 days [member]
Credit risk [line items]
At end of period	981	1,512	1,614
More than 180 days [member]
Credit risk [line items]
At end of period	€ 717	€ 1,366	€ 2,127

Related party transactions (Det

Related party transactions (Detail)	12 Months Ended
	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)	Dec. 31, 2017EUR (€)
Related party transactions [abstract]
Short-term employee benefits	€ 2,394,000	€ 2,334,000	€ 2,190,000
Post-employment benefits	85,000	80,000	80,000
Total	€ 2,479,000	€ 2,414,000	€ 2,270,000
Warrants granted	0	0	0
Warrants outstanding	359,266	557,935	573,980

Related party transactions Narr

Related party transactions Narrative (Detail) € in Thousands	12 Months Ended
	Dec. 31, 2019EUR (€)shares	Dec. 31, 2018EUR (€)	Dec. 31, 2017EUR (€)
Details related party transactions Narrative [line items]
Share based payment expense related to key management	€ 214
Rent paid to Ailanthus (related party)	113	€ 123	€ 172
Rent paid to related party - Engimplan building	7
Convertible bond K EUR 1,000	€ 1,000
Convertible number of bonds | shares	1,000
Purchase 3D printer RSPRINT		€ 200

Transactions (Detail)

Transactions (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Non-executive directors of the group [member]
Disclosure of transactions between related parties [line items]
Sale of goods to	€ 0	€ 0	€ 0
Purchases from	128	123	96
Depreciation	0	0	0
Interest expense	37	51	50
Right-of-use assets	0	0	0
Receivables	0	0	0
Lease liabilities	0	0	0
Other liabilities	1,053	1,038	965
Shareholders of the group [member]
Disclosure of transactions between related parties [line items]
Sale of goods to	0	0	0
Purchases from	113	123	172
Depreciation	0	0	0
Interest expense	9	10	11
Right-of-use assets	0	0	0
Receivables	0	0	0
Lease liabilities	0	0	0
Other liabilities	131	261	371
Joint ventures [member]
Disclosure of transactions between related parties [line items]
Sale of goods to	1,431	1,156	714
Purchases from	0	241	23
Depreciation	0	0	0
Interest expense	0	0	0
Right-of-use assets	0	0	0
Receivables	1,279	1,281	804
Lease liabilities	0	0	0
Other liabilities	0	22	28
Non-controlling interest [Member]
Disclosure of transactions between related parties [line items]
Sale of goods to	0	0	0
Purchases from	0	0	0
Depreciation	26	0	0
Interest expense	9	0	0
Right-of-use assets	617	0	0
Receivables	0	0	0
Lease liabilities	652	0	0
Other liabilities	€ 0	€ 0	€ 0

Events subsequent to the stat_2

Events subsequent to the statement of financial position date (Detail) € in Thousands	12 Months Ended
	Dec. 31, 2019EUR (€)
Disclosure of events subsequent to the statement of financial position date [abstract]
Raise share capital	€ 1
Raise share premium	140
Raise exercise of Warrants	140
Convertible loan to Fluidda NV	0
Exercise of warrant	€ 21,750
Software segment total sales	24.00%
Medical segment total sales	34.00%
Manufacturing segment total sales	42.00%